WO2023143347A1 - 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 - Google Patents

一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 Download PDF

Info

Publication number
WO2023143347A1
WO2023143347A1 PCT/CN2023/073047 CN2023073047W WO2023143347A1 WO 2023143347 A1 WO2023143347 A1 WO 2023143347A1 CN 2023073047 W CN2023073047 W CN 2023073047W WO 2023143347 A1 WO2023143347 A1 WO 2023143347A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
ligand
histidine
buffer
drug conjugate
Prior art date
Application number
PCT/CN2023/073047
Other languages
English (en)
French (fr)
Inventor
沈立君
赵志龙
汤辰翔
李磊
Original Assignee
上海迈晋生物医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海迈晋生物医药科技有限公司 filed Critical 上海迈晋生物医药科技有限公司
Publication of WO2023143347A1 publication Critical patent/WO2023143347A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Definitions

  • the disclosure belongs to the field of pharmaceutical preparations, and in particular relates to a pharmaceutical composition comprising an anti-CD79b antibody drug conjugate and its use as a medicine.
  • B cell antigen receptor (B cell receptor, BCR) complex is the most important molecule on the surface of B cells.
  • the BCR complex consists of membrane immunoglobulin (mIg) that recognizes and binds antigens and heterodimers of Ig ⁇ (CD79a) and Ig ⁇ (CD79b) that transmit antigen-stimulatory signals.
  • Ig ⁇ and Ig ⁇ are 47kDa and 37kDa glycoproteins, respectively, and belong to the members of the immunoglobulin superfamily.
  • the genes encoding Ig ⁇ and Ig ⁇ are called mb-1 and B29, respectively. Both Ig ⁇ and Ig ⁇ have an Ig-like domain at the amino-terminus of the extracellular domain.
  • Ig ⁇ and Ig ⁇ can serve as substrates of protein tyrosine kinases and participate in BCR signal transduction.
  • BCR is widely expressed on B-cell lymphomas as well as on normal B-cells.
  • the development of therapeutic methods targeting BCR should also have good efficacy and safety.
  • CD79b antibody-drug conjugates To address the unmet medical needs related to CD79b, many international pharmaceutical companies including Roche Pharmaceuticals are actively developing CD79b antibodies and related products, such as CD79b antibody-drug conjugates.
  • Antibody drug conjugates connect monoclonal antibodies or antibody fragments to biologically active cytotoxins through stable chemical linker compounds, making full use of the specificity of antibodies to tumor cell-specific or highly expressed antigens And the high efficiency of cytotoxin, avoiding the toxic and side effects on normal cells. This means that, compared with traditional chemotherapy drugs in the past, antibody drug conjugates can precisely bind tumor cells and reduce the impact on normal cells.
  • ADC drugs are composed of three parts: antibody (targeting part), linker and toxin. Among them, a good targeting part determines the specificity of ADC drugs, which includes not only specific targeting binding, but also effective endocytosis.
  • antibody drugs especially ADCs
  • ADCs have larger molecular weights and more complex structures, and are prone to degradation, polymerization, or undesired chemical modifications and become unstable.
  • the present disclosure provides a pharmaceutical composition comprising a CD79b ADC that is sufficiently stable and more suitable for administration.
  • the present disclosure provides a pharmaceutical composition comprising a ligand-drug conjugate (eg, an anti-CD79b antibody drug conjugate). And a method for preparing the pharmaceutical composition, and a method for treating or preventing diseases or related pharmaceutical applications thereof are provided.
  • a ligand-drug conjugate eg, an anti-CD79b antibody drug conjugate
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a ligand-drug conjugate and a buffer, wherein the ligand is an anti-CD79b antibody or an antigen-binding fragment thereof; the drug is selected from MMAE or its derivatives, exinotecan or its derivatives, Ari Bollinger or its derivatives.
  • the buffer is selected from acetate buffer, histidine buffer, Tris-HCl buffer, Tris-citrate buffer, phosphate buffer or succinate buffer agent.
  • the buffer is a histidine buffer or a succinate buffer.
  • the buffer is a histidine-hydrochloride buffer or a succinic acid-sodium succinate buffer.
  • the composition has the activity of treating or preventing diseases.
  • the composition can also have the characteristics of good stability and the like.
  • the ligand-drug conjugate is at a concentration of 10 mg/mL to 30 mg/mL. In some embodiments, the ligand-drug conjugate is at a concentration of 15 mg/mL to 25 mg/mL.
  • the ligand-drug conjugate concentration is about 0.1 mg/mL, about 0.5 mg/mL, about 1 mg/mL, about 2 mg/mL, about 5 mg/mL, about 8 mg/mL mL, about 10mg/mL, about 11mg/mL, about 12mg/mL, about 13mg/mL, about 14mg/mL, about 15mg/mL, about 16mg/mL, about 17mg/mL, about 18mg/mL, about 19mg/mL mL, about 20mg/mL, about 21mg/mL, about 22mg/mL, about 23mg/mL, about 24mg/mL, about 25mg/mL, about 26mg/mL, about 27mg/mL, about 28mg/mL, about 29mg/mL mL, about 30mg/mL, about 35mg/mL, about 40mg/mL, about 35mg/m
  • the pharmaceutical composition of any one of the above, wherein the concentration of the buffer is 1 mM to 30 mM.
  • the pharmaceutical composition of any one of the above, wherein the concentration of the buffer is 5 mM to 15 mM.
  • the buffer concentration is about 0.5 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, for example about 10 mM .
  • the pH value of the pharmaceutical composition according to any one of the above is 4.0 to 8.5, such as 4.0 to 8.0, 4.5 to 7.5, 5.0 to 7.0, 5.6 to 6.5, 6.0 to 7.5, 4.5 to 6.5, 5.0 to 6.5, 5.0 to 6.0, 5.0 to 5.5, 5.6 to 6.0, 5.35 to 5.75 (eg about 5.6), 5.2 to 5.8, 5.5 to 6.5, 4.5 to 6.5, 4.5 to 6.0, 4.5 to 5.5, 4.0 to 6.0, 3.5 to 5.8, or any range between these point values.
  • the pH of any of the pharmaceutical compositions above is 5.0 to 6.5.
  • the pH of any of the pharmaceutical compositions above is 5.5 to 6.0.
  • the pH of the pharmaceutical composition is about 4.0, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 4.95, about 5.0, about 5.05, about 5.1, about 5.15 , about 5.2, about 5.25, about 5.3, about 5.35, about 5.4, about 5.45, about 5.5, about 5.55, about 5.6, about 5.65, about 5.7, about 5.75, About 5.8, about 5.85, about 5.9, about 5.95, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 7.0, about 7.5, about 8.0, about 8.5.
  • the pH of the pharmaceutical composition obtained by exchanging the buffer almost coincides with the pH of the buffer.
  • the pH drift of pharmaceutical preparations is generally small (within the range of ⁇ 0.3). In some embodiments, the pH of the pharmaceutical formulation drifts within ⁇ 0.1.
  • the surfactant is a nonionic surfactant.
  • the surfactant is selected from the group consisting of poloxamers (eg, poloxamer 188), polysorbates (eg, polysorbate 20 (ie, PS20), polysorbate 80 (ie, PS80)), Polyhydroxyalkylene, Triton, Sodium Lauryl Sulfonate, Sodium Lauryl Sulfonate, Sodium Octyl Glycoside, Lauryl-Sultaine, Myristyl-Sultaine, Linoleyl-Sultaine Betaine, Stearyl-Sultaine, Lauryl-Sarcosine, Myristyl-Sarcosine, Linoleyl-Sarcosine, Stearyl-Sarcosine, Linoleyl-Betaine, Myristyl-Betaine, Cetyl-Betaine, Laurylamidopropyl-
  • the surfactant is a polysorbate or a poloxamer. In some embodiments, the surfactant is polysorbate 80, polysorbate 20, or poloxamer 188. In some embodiments, the surfactant is polysorbate 80.
  • the concentration of the surfactant is 0.01 mg/mL to 1 mg/mL, such as 0.01 mg/mL to 0.8 mg/mL, 0.05 mg/mL to 0.6 mg/mL, 0.08 mg/mL to 0.5 mg/mL, 0.1mg/mL to 0.4mg/mL, 0.1mg/mL to 0.3mg/mL, 0.15mg/mL to 0.25mg/mL, 0.2mg/mL to 0.3mg/mL, 0.1mg/mL to 0.2 mg/mL, or any range between these point values.
  • the surfactant is present at a concentration of 0.1 mg/mL to 0.3 mg/mL.
  • the concentration of the surfactant is about 0.01 mg/mL, about 0.02 mg/mL, about 0.03 mg/mL, about 0.04 mg/mL, about 0.05 mg/mL, about 0.06 mg /mL, about 0.07mg/mL, about 0.08mg/mL, about 0.09mg/mL, about 0.1mg/mL, about 0.11mg/mL, about 0.12mg/mL, about 0.13mg/mL, about 0.14mg/mL , about 0.15mg/mL, about 0.16mg/mL, about 0.17mg/mL, about 0.18mg/mL, about 0.19mg/mL, about 0.2mg/mL, about 0.21mg/mL, about 0.22mg/mL, about 0.23mg/mL, about 0.24mg/mL, about 0.25mg/mL, about 0.3mg/mL, about 0.4mg/mL, about
  • the pharmaceutical composition according to any one of the above which comprises an osmotic pressure regulator.
  • the osmotic pressure regulator is a sugar (including monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, non-reducing sugars, etc.), amino acids (including arginine, glycine, semi cystine, histidine, etc.) or salts (sodium chloride, potassium chloride, calcium chloride, etc.).
  • the osmotic pressure regulator is a sugar selected from the group consisting of: glucose, sucrose, trehalose, lactose, fructose, maltose, dextran, glycerin, erythritol, glycerol, arabic Sugar alcohol, xylitol, sorbitol (also known as sorbitol), mannitol, milibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, Maltitol, lactitol and iso-maltulose.
  • the osmotic pressure regulator is selected from one or more of the group consisting of sucrose, trehalose, sorbitol, arginine, proline, glycine and sodium chloride Various.
  • the osmotic pressure regulator is a non-reducing disaccharide; in some embodiments, the osmotic pressure regulator is trehalose and/or sucrose; in some embodiments, the osmotic pressure regulator The agent is sucrose.
  • the concentration of the osmotic pressure regulator in the pharmaceutical composition according to any one of the above is 1 mg/mL to 300 mg/mL, such as 5 mg/mL to 200 mg/mL, 10 mg/mL to 150 mg/mL , 20mg/mL to 140mg/mL, 30mg/mL to 130mg/mL, 40mg/mL to 120mg/mL, 50mg/mL to 110mg/mL, 60mg/mL to 100mg/mL, 70mg/mL to 90mg/mL (for example 80 mg/mL), or any range between these points.
  • the concentration of the osmolarity regulator is about 10 mg/mL, about 20 mg/mL, about 30 mg/mL, about 40 mg/mL, about 50 mg/mL, about 60 mg/mL, about 70 mg /mL, about 80mg/mL, about 90mg/mL, about 100mg/mL, about 110mg/mL, about 120mg/mL, about 130mg/mL, about 140mg/mL, about 150mg/mL, about 160mg/mL, about 170mg /mL, about 180mg/mL, about 190mg/mL, about 200mg/mL, about 250mg/mL, about 300mg/mL.
  • the pharmaceutical composition according to any one of the above contains any of a)-o):
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 0.5 mM to 50 mM 1 mM to 30 mM
  • 5 mM to 15 mM eg about 10 mM
  • histidine buffer or succinate buffer sucrose or trehalose, and polysorbate.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 0.5mM to 50mM 1mM to 30mM
  • 5mM to 15mM eg about 10mM
  • histidine salt buffer or succinate buffer sucrose and/or trehalose, and polysorbate.
  • ligand-drug conjugate eg anti-CD79b antibody drug conjugate
  • 0.5 mM to 50 mM 1 mM to 30 mM
  • 5 mM to 15 mM eg 10 mM
  • Histidine buffer or succinate buffer sucrose and/or trehalose, and polysorbate.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 0.5mM to 50mM 1mM to 30mM
  • 5mM to 15mM eg about 10mM
  • histidine salt buffer or succinate buffer sucrose and/or trehalose, and polysorbate.
  • the pH of the pharmaceutical composition in a) to c) is 4.0 to 8.5, 5.0 to 6.5, 5.5 to 6.0 (eg about 5.0, about 5.6);
  • the concentration of sucrose or trehalose in the pharmaceutical composition in a) to c) and l) is 1 mg/mL to 300 mg/mL, 30 mg/mL to 130 mg/mL, 70 mg/mL to 90 mg/mL ( For example about 70 mg/mL, about 80 mg/mL, about 90 mg/mL, about 100 mg/mL, about 110 mg/mL, about 120 mg/mL);
  • the polysorbate in the pharmaceutical composition in a) to c) and l) is polysorbate 20 or polysorbate 80, and the concentration of the polysorbate is 0.01 mg/mL to 1 mg/mL, 0.05 mg/mL to 0.6 mg/mL, 0.1 mg/mL to 0.3 mg/mL (eg, about 0.1 mg/mL, about 0.2 mg/mL, about 0.3 mg/mL);
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 0.5mM to 50mM histidine buffer or succinate buffer 1mg/mL to 300mg /mL sucrose and/or trehalose, and 0.01 mg/mL to 1 mg/mL polysorbate 80 or polysorbate 20, pH 4.0 to 8.5.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 1mM to 30mM histidine buffer or succinate buffer 30mg/mL to 130mg/mL Sucrose and/or trehalose
  • 0.05 mg/mL to 0.6 mg/mL polysorbate 80 or polysorbate 20 pH 5.0 to 6.5.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 1mM to 30mM histidine buffer or succinate buffer 1mM to 30mM histidine buffer or succinate buffer
  • 30mg/mL to 130mg/mL Sucrose and/or trehalose 1mM to 30mM histidine buffer or succinate buffer
  • 30mg/mL to 130mg/mL Sucrose and/or trehalose 0.05 mg/mL to 0.6 mg/mL polysorbate 80 or polysorbate 20, pH 5.0 to 6.5.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 1mM to 30mM histidine salt buffer 30mg/mL to 130mg/mL sucrose, and 0.05mg/mL mL to 0.6 mg/mL polysorbate 80, pH 5.0 to 6.5.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 5mM to 15mM histidine salt buffer 70mg/mL to 90mg/mL sucrose, and 0.1mg/mL mL to 0.3 mg/mL polysorbate 80, pH 5.5 to 6.0.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM histidine salt buffer about 80mg/mL sucrose, and 0.1mg/mL to 0.3mg/mL mL Polysorbate 80, pH 5.5 to 6.0 (eg, about 5.6).
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 5mM to 15mM histidine-HCl buffer 70mg/mL to 90mg/mL sucrose, and 0.1 mg/mL to 0.3 mg/mL polysorbate 80, pH 5.5 to 6.0.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM histidine-HCl buffer about 80mg/mL sucrose, and 0.1mg/mL to 0.3 mg/mL polysorbate 80, pH 5.5 to 6.0 (eg about 5.6).
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10 mM histidine-HCl buffer about 80 mg/mL sucrose, and about 0.2 mg/mL Polysorbate 80, pH about 5.6.
  • p-1) 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate), about 10mM histidine-histidine hydrochloride, about 80mg/mL sucrose, and about 0.2mg/mL mL polysorbate 80, pH about 5.6.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride about 80mg/mL sucrose, and about 0.2mg/mL mL polysorbate 80, pH about 5.75.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride about 80mg/mL sucrose, and about 0.3mg/mL mL polysorbate 80, pH about 5.5.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride about 80mg/mL sucrose, and about 0.3mg/mL mL polysorbate 80, pH about 5.75.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride about 80mg/mL sucrose, and about 0.3mg/mL mL polysorbate 80, pH about 6.0.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 15mM histidine-histidine hydrochloride 15mM histidine-histidine hydrochloride, about 80mg/mL sucrose, and about 0.1mg/mL mL polysorbate 80, pH about 5.5.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10 mM Histidine - Histidine HCl 15 mg/mL to 25 mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10 mM Histidine - Histidine HCl 15 mg/mL to 25 mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • about 10 mM Histidine - Histidine HCl about 80 mg/mL sucrose
  • 0.1 mg/mL polysorbate 80 pH about 5.75.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride 15mg/mL to 25mg/mL ligand-drug conjugate (such as anti-CD79b antibody drug conjugate)
  • 10mM histidine-histidine hydrochloride about 80mg/mL sucrose, and about 0.1mg/mL mL polysorbate 80, pH about 6.0.
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 5 mM to 15 mM succinate buffer 70 mg/mL to 90 mg/mL sucrose
  • 0.1 mg/mL to 0.3 mg/mL polysorbate 80 at a pH of 4.5 to 6.5 (eg 5.0 to 6.5).
  • ligand-drug conjugate such as anti-CD79b antibody drug conjugate
  • 10mM succinic acid-sodium succinate buffer about 80mg/mL sucrose, and 0.1mg/mL to 0.3mg/mL polysorbate 80, pH about 5.0.
  • the above-mentioned anti-CD79b antibody drug conjugate can be ADC-3 of Example 3-1 of the present disclosure, or ADC-5 of Example 3-2, or ADC-6 of Example 3-3, or Example 3-4 ADC-7; for example, ADC-6 of Example 3-3.
  • the pharmaceutical compositions of the present disclosure also comprise a solvent.
  • the solvent in the pharmaceutical composition is selected from but not limited to non-toxic physiologically acceptable liquid carriers, such as physiological saline, water for injection, glucose solution (such as 5% glucose injection, glucose sodium chloride injection) and the like.
  • the present disclosure also provides a pharmaceutical composition, which is obtained by diluting any of the aforementioned pharmaceutical compositions with 0.9% normal saline or 5% glucose solution, or diluted with any of the aforementioned pharmaceutical compositions with 0.9% normal saline or
  • the anti-CD79b antibody-drug conjugate, histidine salt, sucrose, and polysorbate 80 can be used as intravenous injection concentration after dilution with 5% glucose solution.
  • the ligand-drug conjugate as in any one of the pharmaceutical compositions above, wherein:
  • the drug is selected from MMAE or its derivatives, exitecan or its derivatives, eribulin or its derivatives;
  • the ligand is an anti-CD79b antibody or an antigen-binding fragment thereof, and the anti-CD79b antibody or an antigen-binding fragment thereof comprises A heavy chain variable region (VH) and a light chain variable region (VL), wherein:
  • the VH comprises HCDR1, HCDR2, and HCDR3 of the amino acid sequences shown in SEQ ID NO: 11, 6, and 7, respectively, and the VL includes LCDR1, LCDR2 of the amino acid sequences shown in SEQ ID NO: 8, 9, and 10, respectively. , LCDR3;
  • the VH comprises HCDR1, HCDR2, and HCDR3 of the amino acid sequences shown in SEQ ID NO: 5, 6, and 7, respectively, and the VL includes LCDR1, LCDR2 of the amino acid sequences shown in SEQ ID NO: 8, 9, and 10, respectively. , LCDR3.
  • the anti-CD79b antibody or antigen-binding fragment thereof in the pharmaceutical composition can be selected from murine antibodies, chimeric antibodies, humanized antibodies, such as humanized antibodies.
  • the light chain and heavy chain FR sequences of the light chain and VH of the humanized anti-CD79b antibody described in the pharmaceutical composition are derived from the FRs of the light chain and heavy chain of human germline or their mutant sequences respectively .
  • the anti-CD79b antibody or antigen-binding fragment thereof in the pharmaceutical composition comprises antibody VH and VL, wherein:
  • VH sequence such as SEQ ID NO: 3 or an amino acid sequence having at least 80%, at least 85%, at least 90% identity therewith, VL sequence such as SEQ ID NO: 4 or having at least 80%, at least 85%, at least Amino acid sequences with 90% identity;
  • the anti-CD79b antibody or antigen-binding fragment thereof in the pharmaceutical composition comprises antibody VH and VL, wherein: the VH sequence is shown in SEQ ID NO: 3, and the VL sequence is shown in SEQ ID NO: 4 shown.
  • the anti-CD79b antibody or antigen-binding fragment thereof further comprises a heavy chain constant region and a light chain constant region.
  • the heavy chain constant region is selected from human IgG1, IgG2, IgG3, IgG4 constant regions and conventional variants thereof, and the light chain constant region is selected from human kappa and lambda chain constant regions and conventional variants thereof. Variants.
  • the heavy chain constant region is human IgG1, IgG4.
  • the anti-CD79b antibody or antigen-binding fragment thereof contains IgG Fc region, such as human IgG Fc region, or human IgG1, IgG2, IgG4 Fc region.
  • the anti-CD79b antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain, wherein: the heavy chain has a sequence shown in SEQ ID NO: 12 or at least 80%, at least 85% thereof , a sequence of at least 90% identity, and said light chain has the sequence shown in SEQ ID NO: 13 or a sequence with at least 80%, at least 85%, at least 90% identity thereto.
  • the "at least 90% identity” encompasses at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity.
  • the anti-CD79b antibody or antigen-binding fragment thereof in the pharmaceutical composition comprises an antibody heavy chain and a light chain, wherein: the heavy chain sequence is shown in SEQ ID NO: 12, and the light chain The sequence is shown in SEQ ID NO:13.
  • the above-mentioned anti-CD79b antibodies or fragments thereof may be variants with 1 to 10 VL variants (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid changes, and/or VH has 1 to 10 (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid changes.
  • VL variants e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 amino acid changes
  • VH has 1 to 10 (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid changes.
  • the aforementioned variants have the same or similar biological function or effect as the original anti-CD79b antibody or fragment thereof.
  • the antigen-binding fragment of the anti-CD79b antibody is a Fab, Fv, sFv, Fab', F(ab')2, linear antibody, single chain antibody, scFv, sdAb, sdFv, Nanobody, peptibody Peptibodies, domain antibodies and multispecific antibodies (bispecific antibodies, diabody, triabody and tetrabody, tandem di-scFv, tandem tri-scFv), eg specifically scFv, Fv, Fab or Fab' fragments.
  • the ligand-drug conjugate in any one of the aforementioned pharmaceutical compositions is a conjugate of ligand-Exitecan or its derivatives, which is represented by the general formula (Pc of formula (I) -LYD) shows:
  • Y is selected from -O-(CR a R b ) m -CR 1 R 2 -C(O)-, -O-CR 1 R 2 -(CR a R b ) m -, -O-CR 1 R 2 - , -NH-(CR a R b ) m -CR 1 R 2 -C(O)- and -S-(CR a R b ) m -CR 1 R 2 -C(O)-;
  • R a and R b are the same or different, and each independently selected from hydrogen atom, deuterium atom, halogen, alkyl, haloalkyl, deuterated alkyl, alkoxy, hydroxyl, amino, cyano, nitro, hydroxyalkane A group, a cycloalkyl group and a heterocyclyl group; or, R a and R b form a cycloalkyl group and a heterocyclyl group together with the carbon atoms to which they are connected;
  • R is selected from hydrogen atom, halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl and heteroaryl;
  • R is selected from hydrogen atom , halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl, and heteroaryl; or, the carbon to which R and R are attached Atoms together form a cycloalkyl or heterocyclyl;
  • Ra and R form a cycloalkyl or heterocyclic group together with the carbon atoms connected to them;
  • n is an integer from 0 to 4.
  • n 1 to 10
  • n is a decimal or an integer, preferably, n is 2 to 8 or 5 to 9;
  • Pc is the anti-CD79b antibody or antigen-binding fragment thereof described in any of the foregoing disclosures.
  • the conjugate of the ligand of the present disclosure-Exitecan or its derivatives or a pharmaceutically acceptable salt or solvate thereof wherein -Y- is -O-(CR a R b )m -CR 1 R 2 -C(O)-;
  • R a and R b are the same or different, and are each independently selected from a hydrogen atom, a deuterium atom, a halogen or an alkyl group;
  • R 1 is C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl, hydrogen atom;
  • R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 cycloalkyl group; preferably a hydrogen atom;
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • m 0 or 1.
  • the ligand-exitecan or its derivative conjugate of the present disclosure wherein the structural unit -Y- is -O-(CH 2 )m-CR 1 R 2 -C(O)- ;
  • R 1 is C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl, hydrogen atom;
  • R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 cycloalkyl group;
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • m 0 or 1.
  • the ligand-exitecan or its derivative conjugate of the present disclosure wherein the structural unit -Y- is -O-(CH 2 )m-CR 1 R 2 -C(O)- ;
  • R 1 is C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl, hydrogen atom;
  • R 2 is a hydrogen atom
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • m 0 or 1.
  • the ligand-exitecan or its derivative conjugate of the present disclosure wherein the structural unit -Y- is -O-(CH 2 )m-CR 1 R 2 -C(O)- ;
  • R 1 is C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl, hydrogen atom;
  • R 2 is a hydrogen atom
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • the ligand-exitecan or its derivative conjugate of the present disclosure wherein the structural unit -Y- is -O-(CH 2 )m-CR 1 R 2 -C(O)- ;
  • R 1 is a hydrogen atom
  • R 2 is a hydrogen atom
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • Y is selected from:
  • the present disclosure provides ligand-exitecan or its derivative conjugates, which are shown in the general formula (Pc-L-D1) of formula (II):
  • R 1 is a hydrogen atom, C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl;
  • R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 cycloalkyl group; preferably a hydrogen atom;
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • n 0 or 1
  • n is 1 to 10, can be an integer or a decimal, preferably, n is a decimal or integer of 1 to 8 or 1 to 6, more preferably, n is a decimal or integer of 1-5 or 2-4.
  • the present disclosure provides conjugates of ligand-exitecan or its derivatives, wherein n is 1 to 8, which can be an integer or a decimal; preferably 1 to 6, which can be an integer , can also be a decimal.
  • the present disclosure provides a ligand-exitecan or derivative thereof conjugate, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -,
  • L 1 is selected from -(succinimide-3-yl-N)-WC(O)-, -CH 2 -C(O)-NR 3 -WC(O)- or -C(O)-WC( (O)-, wherein W is selected from C 1-8 alkyl, C 1-8 alkyl-cycloalkyl or straight chain heteroalkyl of 1 to 8 atoms, said heteroalkyl contains 1 to 3 selected from A heteroatom of N, O or S, wherein said C 1-8 alkyl, cycloalkyl and linear heteroalkyl are each independently optionally further selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, One or more substituents of chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
  • L 2 is selected from -NR 4 (CH 2 CH 2 O)p 1 CH 2 CH 2 C(O)-, -NR 4 (CH 2 CH 2 O)p 1 CH 2 C(O)-, -S(CH 2 ) p 1 C(O)- or a chemical bond, wherein p 1 is an integer from 1 to 20;
  • L3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are selected from the group consisting of phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, aspartic acid
  • An amino acid residue formed from an amino acid in an acid and is optionally further selected from one or more of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl Replaced by multiple substituents;
  • L 4 is selected from -NR 5 (CR 6 R 7 ) t -, -C(O)NR 5 , -C(O)NR 5 (CH 2 ) t - or a chemical bond, wherein t is an integer from 1 to 6;
  • R 3 , R 4 and R 5 are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group and a hydroxyalkyl group;
  • R 6 and R 7 are the same or different, and are each independently selected from a hydrogen atom, halogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl.
  • the present disclosure provides ligand-exitecan or derivatives thereof conjugates, wherein the linker unit L 1 is selected from the group consisting of -(succinimidyl-3-yl-N)-(CH 2 )s 1 -C(O)-, -(succinimidyl-3-yl-N)-CH 2 -cyclohexyl-C(O)-, -(succinimidyl-3-yl-N)-(CH 2 CH 2 O)s 2 -CH 2 CH 2 -C(O)-, -CH 2 -C(O)-NR 3 -(CH 2 )s 3 -C(O)- or -C(O)- (CH 2 )s 4 C(O)-, wherein s 1 is an integer from 2 to 8, s 2 is an integer from 1 to 3, s 3 is an integer from 1 to 8, and s 4 is an integer from 1 to 8; s 1 is preferably 5.
  • the present disclosure provides ligand-exitecan or derivatives thereof conjugates, wherein the linker unit L 2 is selected from the group consisting of -NR 4 (CH 2 CH 2 O)p 1 CH 2 C(O) - or a chemical bond, p 1 is an integer from 6 to 12.
  • the present disclosure provides a conjugate of ligand-exitecan or its derivatives, wherein L 4 is selected from -NR 5 (CR 6 R 7 )t-, R 5 is selected from a hydrogen atom or an alkane R 6 and R 7 are the same or different, and each independently is a hydrogen atom or an alkyl group, t is 1 or 2, preferably 2; L 4 is preferably from -NR 5 CR 6 R 7 -; L 4 is more preferably -NHCH 2 -.
  • the present disclosure provides ligand-exitecan or derivatives thereof conjugates, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -,
  • L 1 is s 1 is an integer from 2 to 8;
  • L 2 is a chemical bond
  • L 3 is a tetrapeptide residue
  • L 4 is -NR 5 (CR 6 R 7 )t-, R 5 is selected from a hydrogen atom or an alkyl group, R 6 and R 7 are the same or different, and each independently is a hydrogen atom or an alkyl group, and t is 1 or 2 .
  • the present disclosure provides ligand-exitecan or derivatives thereof conjugates, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -,
  • L 1 is -(succinimide-3-yl-N)-CH 2 -cyclohexyl-C(O)-;
  • L 2 is -NR 4 (CH 2 CH 2 O) 9 CH 2 C(O)-;
  • L 3 is a tetrapeptide residue
  • L 4 is -NR 5 (CR 6 R 7 )t-, R 5 is selected from a hydrogen atom or an alkyl group, R 6 and R 7 are the same or different, and each independently is a hydrogen atom or an alkyl group, and t is 1 or 2 .
  • the present disclosure provides ligand-exitecan or its derivatives conjugates, wherein the peptide residue of L3 is composed of one, two or more selected from phenylalanine Amino acid formation in (E), glycine (G), valine (V), lysine (K), citrulline, serine (S), glutamic acid (E), aspartic acid (N) Amino acid residues; preferably amino acid residues formed by one, two or more amino acids selected from phenylalanine and glycine; more preferably tetrapeptide residues; most preferably GGFG (glycine-glycine-phenylalanine amino acid-glycine) tetrapeptide residues.
  • the present disclosure provides a conjugate of ligand-exitecan or its derivatives, wherein the linker unit -L-, the L 1 end is connected to the ligand, and the L 4 end is connected to Y.
  • the present disclosure provides a ligand-exitecan or a derivative thereof conjugate, wherein said -LY- is:
  • L 1 is selected from -(succinimide-3-yl-N)-(CH 2 )s 1 -C(O)- or -(succinimide-3-yl-N)-CH 2 -cyclohexyl -C(O)-;
  • L 2 is -NR 4 (CH 2 CH 2 O)p 1 CH 2 C(O)- or a chemical bond, and p 1 is an integer from 6 to 12;
  • L 3 is a tetrapeptide residue of GGFG
  • R is a hydrogen atom, cycloalkylalkyl or cycloalkyl; preferably C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl;
  • R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 cycloalkyl group; preferably a hydrogen atom;
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • R 5 is selected from a hydrogen atom or an alkyl group
  • R 6 and R 7 are the same or different, and each independently is a hydrogen atom or an alkyl group
  • s1 is an integer from 2 to 8; preferably 5;
  • n is an integer of 0 to 4.
  • the present disclosure provides ligand-exitecan or derivative thereof conjugates
  • L 2 is -NR 4 (CH 2 CH 2 O) 9 CH 2 C(O)-;
  • L 3 is a tetrapeptide residue of GGFG
  • R is a hydrogen atom, cycloalkylalkyl or cycloalkyl; preferably C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl;
  • R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 cycloalkyl group; preferably a hydrogen atom;
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • R 5 is selected from a hydrogen atom or an alkyl group
  • R 6 and R 7 are the same or different, and each independently is a hydrogen atom or an alkyl group
  • n is an integer of 0 to 4.
  • the present disclosure provides conjugates of ligand-Exitecan or derivatives thereof, wherein the conjugates of ligand-Exitecan or derivatives thereof comprise the compound represented by formula (III) structure:
  • L 2 is a chemical bond
  • L 3 is a tetrapeptide residue of GGFG
  • R 1 is a hydrogen atom, C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl;
  • R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 cycloalkyl group;
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • R 5 is selected from a hydrogen atom or an alkyl group
  • R 6 and R 7 are the same or different, and each independently is a hydrogen atom or an alkyl group
  • s 1 is an integer from 2 to 8;
  • n is an integer of 0 to 4.
  • the present disclosure provides a conjugate of ligand-Exitecan or a derivative thereof, wherein the conjugate of ligand-Exitecan or a derivative thereof comprises a compound represented by the formula (-LY-) The structure shown:
  • L 1 is selected from -(succinimide-3-yl-N)-(CH 2 )s 1 -C(O)- or -(succinimide-3-yl-N)-CH 2 -cyclohexyl -C(O)-;
  • L 2 is -NR 4 (CH 2 CH 2 O)p 1 CH 2 C(O)- or a chemical bond, and p 1 is an integer from 1 to 20;
  • L 3 is a tetrapeptide residue of GGFG
  • R is a hydrogen atom, cycloalkylalkyl or cycloalkyl; preferably C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl;
  • R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 cycloalkyl group; preferably a hydrogen atom;
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • R 5 , R 6 or R 7 are the same or different, and each independently is a hydrogen atom or an alkyl group
  • s 1 is an integer from 2 to 8;
  • n is an integer of 0 to 4.
  • the present disclosure provides a conjugate of ligand-Exitecan or a derivative thereof, wherein the conjugate of ligand-Exitecan or a derivative thereof comprises a compound represented by the formula (-LY-) The structure shown:
  • L 2 is a chemical bond
  • L 3 is a tetrapeptide residue of GGFG
  • R is a hydrogen atom, cycloalkylalkyl or cycloalkyl; preferably C 3-6 cycloalkylalkyl or C 3-6 cycloalkyl;
  • R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 cycloalkyl group; preferably a hydrogen atom;
  • R 1 and R 2 together form a C 3-6 cycloalkyl group with the carbon atom to which they are connected;
  • R 5 is selected from a hydrogen atom or an alkyl group
  • R 6 and R 7 are the same or different, and each independently is a hydrogen atom or an alkyl group
  • s 1 is an integer from 2 to 8;
  • n is an integer of 0 to 4.
  • the present disclosure provides ligand-exitecan or its derivative conjugates, which are ligand-exitecan represented by the general formula (Pc-L a -Y-Dr) of formula (IV).
  • W is selected from C 1-8 alkyl, C 1-8 alkyl-cycloalkyl or linear heteroalkyl of 1 to 8 atoms, the heteroalkyl contains 1 to 3 selected from N, O or S wherein said C 1-8 alkyl, cycloalkyl and linear heteroalkyl are each independently optionally further selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, Substituted by one or more substituents of deuterated alkyl, alkoxy and cycloalkyl;
  • L 2 is selected from -NR 4 (CH 2 CH 2 O)p 1 CH 2 CH 2 C(O)-, -NR 4 (CH 2 CH 2 O)p 1 CH 2 C(O)-, -S(CH 2 ) p 1 C(O)- or a chemical bond, p 1 is an integer from 1 to 20;
  • L3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are optionally further selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cyclic One or more substituents in the alkyl group are substituted;
  • R is selected from a hydrogen atom, halogen, cycloalkylalkyl, deuterated alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
  • R is selected from a hydrogen atom, halogen, haloalkyl, deuterated alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
  • R 1 and R 2 form a cycloalkyl or heterocyclic group together with the carbon atom to which they are attached;
  • R 4 and R 5 are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group and a hydroxyalkyl group;
  • R 6 and R 7 are the same or different, and each independently selected from hydrogen atom, halogen, alkyl, haloalkyl, deuterated alkyl and hydroxyl alkyl;
  • n is an integer from 0 to 4.
  • n 1 to 10, and can be an integer or a decimal
  • Pc is the anti-CD79b antibody or antigen-binding fragment thereof provided in the present disclosure.
  • the present disclosure provides a conjugate of ligand-exitecan or its derivatives, which is the ligand-exitecan represented by the general formula (Pc-L b -Y-Dr) of formula (V).
  • s1 is an integer from 2 to 8; preferably 5;
  • the linking unit -LY- of the ligand-exitecan or its derivative conjugate of the present disclosure includes, but is not limited to:
  • the present disclosure provides ligand-exitecan or its derivative conjugates including, but not limited to:
  • n 1 to 10, and can be an integer or a decimal
  • Pc is the aforementioned anti-CD79b antibody of the present disclosure or an antigen-binding fragment thereof.
  • the method for preparing a conjugate of ligand-exitecan or its derivatives as shown in the general formula (Pc-L a -YD) comprises the following steps:
  • Pc is the anti-CD79b antibody or antigen-binding fragment thereof of the present disclosure
  • W, L 2 , L 3 , R 1 , R 2 , R 5 -R 7 , m and n are as defined in formula (IV).
  • Pc is any anti-CD79b antibody or antigen-binding fragment thereof of the present disclosure; preferably an anti-CD79b antibody or an antigen-binding fragment thereof in the examples; more preferably comprising a heavy chain as shown in SEQ ID NO: 12 and An antibody to the light chain as set forth in SEQ ID NO: 13.
  • the conjugates of the ligand of the present disclosure-Exitecan or its derivatives include its tautomers, mesoforms, racemates, enantiomers, diastereomers Isomers, deuterated substances, or mixtures thereof.
  • the present disclosure provides a new MMAE analogue/derivative, which is a compound represented by the general formula (D(MMAE)):
  • R 8 -R 13 are selected from hydrogen atom, halogen, hydroxyl, cyano, alkyl, alkoxy and cycloalkyl;
  • R 14 is selected from a hydrogen atom, an alkyl group, an alkoxy group and a cycloalkyl group
  • R 15 -R 18 form a cycloalkyl group, and the remaining two groups are optionally selected from a hydrogen atom, an alkyl group and a cycloalkyl group;
  • R 19 is selected from a hydrogen atom or an alkyl group
  • R 20 -R 22 are selected from hydrogen atom, hydroxyl, alkyl, alkoxy or halogen
  • R 23 is selected from aryl or heteroaryl, and said aryl or heteroaryl is optionally further substituted by a substituent selected from hydrogen atom, halogen, hydroxyl, alkyl, alkoxy and cycloalkyl.
  • the compound represented by the general formula (D(MMAE)) is a compound represented by the general formula (D(MMAE) 1 ):
  • R 16 and R 17 form a cycloalkyl group
  • R 9 -R 15 , R 18 -R 23 are as defined in the general formula (D).
  • the compound represented by the general formula (D(MMAE)) is:
  • Another aspect of the present disclosure relates to a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, wherein the ligand-drug conjugate comprises a compound represented by the formula (-D(MMAE)) structure:
  • R 9 -R 13 are selected from hydrogen atom, halogen, hydroxyl, cyano, alkyl, alkoxy and cycloalkyl;
  • R 14 is selected from a hydrogen atom, an alkyl group, an alkoxy group and a cycloalkyl group
  • R 15 -R 18 form a cycloalkyl group, and the remaining two groups are optionally selected from a hydrogen atom, an alkyl group and a cycloalkyl group;
  • R 19 is selected from a hydrogen atom or an alkyl group
  • R 20 -R 22 are selected from hydrogen atom, hydroxyl, alkyl, alkoxy or halogen
  • R 23 is selected from aryl or heteroaryl, and the aryl or heteroaryl is optionally further substituted by a substituent selected from hydrogen atom, halogen, hydroxyl, alkyl, alkoxy and cycloalkyl;
  • Wavy lines indicate hydrogen atoms, either covalently linked to linker units or to antibodies that bind antigens expressed by target cells.
  • the conjugate of the ligand-MMAE or its derivatives or a pharmaceutically acceptable salt or solvate thereof, wherein the ligand-drug conjugate comprises the formula (- The structure shown in D(MMAE) 1 ):
  • R 16 and R 17 form a cycloalkyl group
  • R 9 -R 15 , R 18 -R 23 are as defined in the general formula (D(MMAE)).
  • the conjugate of the ligand-MMAE or a derivative thereof or a pharmaceutically acceptable salt or solvate thereof wherein the conjugate of the ligand-MMAE or a derivative thereof
  • the material contains the following structure:
  • Wavy lines indicate hydrogen atoms, either covalently linked to linker units or to antibodies that bind antigens expressed by target cells.
  • the conjugate of the ligand-MMAE or its derivatives or a pharmaceutically acceptable salt or solvate thereof is represented by the general formula (Pc-LD(MMAE)) Ligand-drug conjugates or pharmaceutically acceptable salts or solvates thereof:
  • R 9 -R 23 are as defined in the general formula (D(MMAE));
  • n 1 to 10, and can be an integer or a decimal
  • Pc is the anti-CD79B antibody of the present disclosure or an antigen-binding fragment thereof;
  • L is a linker unit.
  • the conjugate of the ligand-MMAE or its derivatives or a pharmaceutically acceptable salt or solvate thereof is represented by the general formula (Pc-L-D1) Ligand-MMAE or its derivatives conjugate or pharmaceutically acceptable salt or solvate thereof:
  • R 9 -R 23 are as defined in the general formula (-D(MMAE));
  • Pc, L, n are as defined in the general formula (Pc-L-D(MMAE)).
  • the conjugate of the ligand-MMAE or its derivatives or a pharmaceutically acceptable salt or solvate thereof is the ligand-MMAE or its derivatives shown in the general formula Conjugates of derivatives or pharmaceutically acceptable salts or solvates thereof:
  • Pc, L, n are as defined in the general formula (Pc-L-D(MMAE)).
  • the conjugate of the ligand-MMAE or its derivatives or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 to 8, can be an integer, or can be Decimal; preferably 1 to 6, can be an integer or a decimal.
  • Y is the tensile unit, selected from Or chemical key, X1 is selected from hydrogen atom, alkyl, alkoxy group, aryl or halogen, X2 is selected from alkylene, and described alkylene is optionally further selected from halogen, hydroxyl, cyano, One or more substituents of amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
  • L 5 is a stretching unit selected from -(succinimide-3-yl-N)-WC(O)-, -CH 2 -C(O)-NR 24 -WC(O)- or -C( O)-WC(O)-, wherein W is selected from C 1-8 alkyl, C 1-8 alkyl-cycloalkyl or straight-chain heteroalkyl of 1 to 8 atoms, said heteroalkyl comprising 1 to 3 heteroatoms selected from N, O or S, wherein said C 1-8 alkyl, cycloalkyl and linear heteroalkyl are each independently optionally further selected from halogen, hydroxyl, cyano, One or more substituents of amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
  • L 6 is selected from -NR 25 (CH 2 CH 2 O)p 1 CH 2 CH 2 C(O)-, -NR 25 (CH 2 CH 2 O)p 1 CH 2 C(O)-, -S(CH 2 ) p 1 C(O)- or a chemical bond, wherein p 1 is an integer from 1 to 20; preferably a chemical bond;
  • L 7 is a peptide residue consisting of 2 to 7 amino acids, the amino acid is preferably selected from valine, citrulline, methyl valine; wherein the amino acid is optionally further selected from halogen, hydroxyl, cyano, One or more substituents in amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
  • R 24 and R 25 are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group and a hydroxyalkyl group;
  • L8 is a stretching unit, preferably PAB.
  • the a-end is connected to the ligand, and the b-end is connected to the drug.
  • the conjugate of the ligand-MMAE or its derivatives or a pharmaceutically acceptable salt or solvate thereof is selected from the following structural formulas: in:
  • n 1 to 10, and can be an integer or a decimal
  • Pc is an anti-CD79B antibody or an antigen-binding fragment thereof of the present disclosure; preferably an anti-CD79B antibody or an antigen-binding fragment thereof in the examples, more preferably comprising a heavy chain as shown in SEQ ID NO: 12 and a heavy chain as shown in SEQ ID NO: Antibodies with light chains shown in 13.
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by the general formula (D(MMAE)) or its tautomer, mesoform, racemate, enantiomer, diastereomer isomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, comprising the following steps:
  • R 9 -R 23 are as defined in the general formula (D).
  • Another aspect of the present disclosure relates to a compound as shown below:
  • Another aspect of the present disclosure relates to a method for preparing Compound 2 (MMAE) or its tautomers, mesoforms, racemates, enantiomers, diastereoisomers, or mixtures thereof , or a pharmaceutically acceptable salt thereof, comprising the steps of:
  • Another aspect of the present disclosure relates to a method for preparing a ligand-drug conjugate represented by the general formula (Pc-LD(MMAE)) or a pharmaceutically acceptable salt or solvate thereof, comprising the following steps:
  • Pc, n are as defined in the general formula (Pc-L-D(MMAE)).
  • R 9 -R 23 are as defined in the general formula (D(MMAE)).
  • Reagents providing basic conditions include organic bases and inorganic bases
  • the organic bases include but not limited to triethylamine, diethylamine, N-methylmorpholine, pyridine, hexahydropyridine, N,N-di Isopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide or potassium tert-butoxide
  • the inorganic bases include but not limited to sodium hydride, potassium phosphate, sodium carbonate, Potassium carbonate, cesium carbonate, sodium hydroxide and lithium hydroxide; diethylamine is preferred.
  • the preparation method of compound 2 (MMAE) or its pharmaceutically acceptable salt or solvate of the present disclosure comprises:
  • Reagents providing basic conditions include organic bases and inorganic bases
  • the organic bases include but not limited to triethylamine, diethylamine, N-methylmorpholine, pyridine, hexahydropyridine, N,N-di Isopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide or potassium tert-butoxide
  • the inorganic bases include but not limited to sodium hydride, potassium phosphate, sodium carbonate, Potassium carbonate, cesium carbonate, sodium hydroxide and lithium hydroxide, preferably N,N-diisopropylethylamine.
  • the condensing agent is selected from 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholine chloride, 1-hydroxybenzotriazole and 1- (3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7-azobenzotriazole, O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, 2-(7-azobenzotriazole)-N,N,N',N'- Tetramethyluronium hexafluorophosphate, benzotriazol-1-yloxytris(di
  • the method of the ligand-drug conjugate represented by the general formula (Pc-LD) of the present disclosure or a pharmaceutically acceptable salt or solvate thereof comprises the following steps:
  • the reducing agent is preferably TCEP, in particular, the disulfide bond on the antibody is preferably reduced;
  • Pc, n are as defined in the general formula (Pc-L-D(MMAE)).
  • ligand-drug conjugates selected from:
  • Pc is any anti-CD79b antibody or antigen-binding fragment thereof of the present disclosure
  • n is 1 to 10, which can be an integer or a decimal.
  • Pc is an anti-CD79b antibody or an antigen-binding fragment thereof in the embodiments of the present disclosure, for example, comprising a heavy chain as shown in SEQ ID NO: 12 and a light chain as shown in SEQ ID NO: 13 Antibody, n is an integer or decimal between 1 and 6.
  • the average DAR value of the antibody drug conjugate of the present disclosure can be 1-10, such as 2-8, or 2-6, or 1-6, or any value between 4-6 .
  • the DAR is between about 1 and about 6, eg, about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7.0, 7.5, 8.0.
  • at least 50% of the samples are compounds having an average DAR of plus or minus 2 by weight, and in some embodiments at least 50% of the samples are conjugates having an average DAR of plus or minus 1.
  • a DAR of 'about x' means that the measured value of the DAR is within 20% of x.
  • the pharmaceutical composition of any one of the foregoing can be intravenous injection, subcutaneous injection, intraperitoneal injection or intramuscular injection.
  • the present disclosure provides a method for preparing any one of the aforementioned pharmaceutical compositions, the method comprising replacing the stock solution of a ligand-drug conjugate (such as an anti-CD79b antibody drug conjugate) with a buffer step.
  • a ligand-drug conjugate such as an anti-CD79b antibody drug conjugate
  • the present disclosure also provides a liquid formulation comprising the pharmaceutical composition described in any one of the foregoing.
  • the pharmaceutical composition described in the present disclosure has sufficient pharmaceutical stability and can be placed stably for a long time.
  • the present disclosure also provides a method for preparing a lyophilized formulation of a pharmaceutical composition comprising a ligand-drug conjugate (such as an anti-CD79b antibody drug conjugate), the method comprising the step of lyophilizing the aforementioned pharmaceutical composition .
  • a ligand-drug conjugate such as an anti-CD79b antibody drug conjugate
  • the present disclosure also provides a lyophilized formulation of a pharmaceutical composition comprising a ligand-drug conjugate (such as an anti-CD79b antibody-drug conjugate), wherein the lyophilized formulation is prepared by subjecting any of the pharmaceutical compositions described above to Obtained by freeze-drying.
  • a ligand-drug conjugate such as an anti-CD79b antibody-drug conjugate
  • the lyophilized formulation is stored at 2-8° C. in the dark and is stable for at least 1 month, at least 3 months, at least 6 months, at least 12 months, at least 18 months, at least 24 months, at least 30 months.
  • the lyophilized formulation is stable at 25°C for at least 1 month, at least 3 months, at least 6 months, at least 12 months.
  • the lyophilized formulation is stable at 40°C for at least 7 days, at least 14 days, or at least 30 days.
  • the present disclosure also provides a reconstitution solution comprising a pharmaceutical composition of a ligand-drug conjugate (such as the aforementioned anti-CD79b antibody drug conjugate of the present disclosure).
  • a reconstitution solution comprising a pharmaceutical composition of a ligand-drug conjugate (such as the aforementioned anti-CD79b antibody drug conjugate of the present disclosure).
  • the dry preparation is prepared by reconstitution.
  • the present disclosure further provides a product, which includes a container filled with the pharmaceutical composition, liquid preparation, freeze-dried preparation or reconstitution solution as described in any one of the above containers.
  • the container may be, but is not limited to, a neutral borosilicate glass tubing injection bottle.
  • the present disclosure also provides the pharmaceutical composition according to any of the above, the liquid preparation according to any of the above, the freeze-dried preparation according to any of the above, the reconstitution solution according to any of the above, or the product according to any of the above in Use in the preparation of medicines for treating or preventing proliferative diseases or delaying the progress of proliferative diseases.
  • the present disclosure also provides the pharmaceutical composition according to any of the above, the liquid preparation according to any of the above, the freeze-dried preparation according to any of the above, the reconstitution solution according to any of the above, or the product according to any of the above, It is used for treating or preventing proliferative diseases or delaying the progress of proliferative diseases.
  • the proliferative disease as described in any one of the above may be a cancer or a tumor; the cancer or tumor is selected from the group consisting of lymphoma, diffuse large B-cell lymphoma, non-Hodgkin's lymphoma (NHL), aggressive relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL ), acute lymphoblastic leukemia (ALL), and/or mantle cell lymphoma.
  • NHL non-Hodgkin's lymphoma
  • NHL non-Hodgkin's lymphoma
  • aggressive relapsed aggressive NHL relapsed indolent NHL
  • refractory NHL refractory indolent NHL
  • CLL chronic lymphocytic leukemia
  • small lymphocytic lymphoma leuk
  • the present disclosure provides a method for treating or preventing a proliferative disease or delaying the progress of a proliferative disease, comprising administering to a subject in need a therapeutically or preventively effective amount of the pharmaceutical composition as described in any one of the above, any one of the above
  • the present disclosure provides a method for enhancing immune function in a subject with a B-cell proliferative disorder or an autoimmune disorder, comprising administering to a subject in need thereof an effective amount for treating or delaying a disease.
  • FIGS. 1 A-C are the curative effects of different ADCs on human diffuse large B-cell lymphoma WSU-DLCL2 subcutaneously transplanted tumors in nude mice.
  • Figure 2 Effect of different ADCs on body weight of tumor-bearing nude mice.
  • Figure 3 Efficacy of different ADCs on human diffuse large B-cell lymphoma WSU-DLCL2 subcutaneously transplanted tumors in nude mice.
  • Figure 4 Effects of different ADCs on body weight of WSU-DLCL2 tumor-bearing nude mice.
  • FIG. 5 Tumor photos of the efficacy of different ADCs on human diffuse large B-cell lymphoma WSU-DLCL2 subcutaneously transplanted tumors in nude mice.
  • Figure 6 Efficacy of different ADCs on human follicular lymphoma DOHH-2 subcutaneously transplanted tumors in nude mice.
  • Figure 7 Effects of different ADCs on body weight of DOHH-2 tumor-bearing nude mice.
  • Figure 8 Screening of the pH value of the buffer system of the ADC composition preparation.
  • Figures 8A and 8B show the trends of SEC and RCE under different pH/buffer conditions, respectively.
  • Figure 9 Screening of ADC composition excipients and surfactants
  • Figures 9A and 9B show the trends of SEC and RCE under different pH/buffer conditions, respectively.
  • Figure 10 ADC composition pH fine screening and polysorbate 80 concentration screening
  • Figures 10A and 10B respectively show the trend of SEC and RCE under different pH/buffer conditions.
  • ADC-1, ADC-2, and ADC-4 are other anti-CD79b antibody-drug conjugates obtained through screening in the present disclosure, and the specific structures are not shown.
  • Antibody drug conjugate is to link an antibody or antibody fragment with a biologically active cytotoxin or a small molecule drug with cell killing activity through a stable chemical linker compound, making full use of the antibody's ability to inhibit tumors. Cell-specific or highly expressed antigen-binding specificity and high efficiency of cytotoxicity, avoiding toxic and side effects on normal cells. Compared with traditional chemotherapy drugs in the past, antibody drug conjugates can precisely bind tumor cells and reduce the impact on normal cells.
  • Buffering agent refers to a buffering agent that is resistant to pH changes through the action of its acid-base conjugated component.
  • buffers to control pH in an appropriate range include acetate, succinate, gluconate, histidine, oxalate, lactate, phosphate, citrate, tartrate, fumarate, Glycylglycine and other organic acid buffers.
  • a “histidine buffer” is a buffer comprising histidine ions.
  • histidine salt buffers include histidine-hydrochloride, histidine-acetate, histidine-phosphate, histidine-sulfate and other buffers, preferably histidine-hydrochloride buffer.
  • Histidine-HCl buffer is formulated with histidine and hydrochloric acid or histidine and histidine hydrochloride.
  • Tris-citrate buffer is a buffer comprising citrate ions.
  • Tris-citrate buffer include Tris-hydrochloride, Tris-acetate, Tris-phosphate, Tris-sulfate, Tris-citrate and the like, preferably Tris-citrate.
  • Tris-HCl buffer is a buffer that includes hydrochloride ions.
  • Tris-hydrochloride buffer include Tris-hydrochloride, Tris-acetate, Tris-phosphate, Tris-sulfate, Tris-citrate and the like buffers and the like.
  • a preferred citrate buffer is Tris-HCl buffer.
  • a “phosphate buffer” is a buffer that includes phosphate ions.
  • phosphate buffers include disodium phosphate- Sodium dihydrogen phosphate, disodium hydrogen phosphate acid-potassium dihydrogen phosphate, etc.
  • a preferred phosphate buffer is disodium phosphate-sodium dihydrogen phosphate buffer.
  • Acetate buffer is a buffer that includes acetate ions.
  • acetate buffers include acetic acid-sodium acetate, acetic acid-histidine salt, acetic acid-potassium acetate, acetic acid-calcium acetate, acetic acid-magnesium acetate, and the like.
  • a preferred acetate buffer is acetic acid-sodium acetate buffer.
  • succinate buffer is a buffer that includes succinate ions.
  • succinate buffers include succinate-sodium succinate, succinate-succinate potassium, succinate-succinate calcium salt, and the like.
  • a preferred succinate buffer is sodium succinate-succinate.
  • the succinic acid-sodium succinate can be prepared from succinic acid and sodium hydroxide, or from succinic acid and sodium succinate.
  • “Pharmaceutical composition” means a mixture containing one or more compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components such as physiologically/pharmaceutically acceptable Carriers and Excipients.
  • the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
  • “pharmaceutical composition” and “formulation” are not mutually exclusive.
  • the solvent therein is water.
  • the term “about” means that a value is within an acceptable error range for the particular value as determined by one of ordinary skill in the art, depending in part on how it is measured or determined (ie, the limits of the measurement system). For example, “about” can mean within 1 or more than 1 standard deviation every practice in the art. Alternatively, “about” or “comprising essentially” can mean a range of up to 20%. Furthermore, particularly with respect to biological systems or processes, the term can mean up to an order of magnitude or up to 5 times a value. Unless otherwise stated, when a specific value appears in the application and claims, the meaning of "about” or “comprising essentially” should be assumed to be within an acceptable error range for the specific value.
  • the pharmaceutical composition of the present disclosure can achieve a stable effect: the antibody therein substantially retains its physical stability and/or chemical stability and/or biological activity after storage, preferably, the pharmaceutical composition Afterwards, its physical and chemical stability and its biological activity are substantially retained.
  • the shelf life is generally selected based on the intended shelf life of the pharmaceutical composition.
  • a stable pharmaceutical antibody formulation is one in which no significant changes are observed when stored at refrigerated temperatures (2-8° C.) for at least 3 months, preferably 6 months, more preferably 1 year, and even more preferably up to 2 years.
  • stable liquid formulations include liquid formulations that exhibit the desired characteristics after a period that includes storage at 25°C including 1 month, 3 months, 6 months, or 1 month at 40°C.
  • Typical acceptable criteria for stability are as follows: Usually no more than about 10%, preferably no more than about 5%, of the antibody monomer is degraded as measured by SEC-HPLC. By visual analysis, drug antibody preparations were colorless or yellow, clear to micro-opalescent. The concentration, pH and osmolality of the formulations have no more than ⁇ 10% variation. Typically not more than about 10%, preferably not more than about 5% truncation is observed, and typically not more than about 10%, preferably not more than about 5%, aggregates are formed.
  • the antibody does not show significant increased aggregation, precipitation and/or denaturation after visual inspection for color and/or clarity, or as measured by UV light scattering, size exclusion chromatography (SEC), and dynamic light scattering (DLS) , then the antibody "retains its physical stability" in the pharmaceutical formulation. Changes in protein conformation can be assessed by fluorescence spectroscopy (which determines protein tertiary structure) and by FTIR spectroscopy (which determines protein secondary structure).
  • An antibody "retains its chemical stability” in a pharmaceutical formulation if it does not exhibit significant chemical changes.
  • Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein. Degradative processes that often alter the chemical structure of proteins include hydrolysis or truncation (assessed by methods such as size exclusion chromatography and SDS-PAGE).
  • oxidation evaluationated by methods such as peptide mapping combined with mass spectrometry or MALDI/TOF/MS
  • deamidation by methods such as ion-exchange chromatography, capillary isoelectric focusing, peptide mapping, isoaspartate acid measurement, etc.
  • isomerization evaluationated by measuring isoaspartic acid content, peptide mapping, etc.
  • An antibody "retains its biological activity" in a pharmaceutical formulation if the biological activity of the antibody at a given time is within a predetermined range of biological activity exhibited at the time the pharmaceutical formulation was prepared.
  • the biological activity of an antibody can be determined, for example, by an antigen binding assay.
  • Antibodies or antigen-binding fragments engineered in the present disclosure can be prepared and purified using conventional methods.
  • cDNA sequences encoding heavy and light chains can be cloned and recombined into GS expression vectors.
  • the recombinant immunoglobulin expression vector can stably transfect CHO cells.
  • mammalian expression systems lead to glycosylation of antibodies, especially at the highly conserved N-terminal site of the Fc region.
  • Stable clones were obtained by expressing antibodies that specifically bind to human FXI. Positive clones are expanded in serum-free medium in bioreactors for antibody production.
  • the culture fluid from which the antibody has been secreted can be purified by conventional techniques.
  • an antibody refers to an immunoglobulin, which is a tetrapeptide chain structure formed by two identical heavy chains and two identical light chains connected by interchain disulfide bonds.
  • the amino acid composition and sequence of the constant region of the immunoglobulin heavy chain are different, so their antigenicity is also different.
  • immunoglobulins can be divided into five classes, or isotypes of immunoglobulins, namely IgM, IgD, IgG, IgA, and IgE, and their corresponding heavy chains are ⁇ , ⁇ , and ⁇ chains, respectively. , ⁇ chain and ⁇ chain.
  • IgG can be divided into different subclasses according to the amino acid composition of its hinge region and the number and position of heavy chain disulfide bonds.
  • IgG can be divided into IgG1, IgG2, IgG3, and IgG4.
  • Light chains are classified as either kappa chains or lambda chains by difference in the constant region.
  • Each of the five Ig classes can have either a kappa chain or a lambda chain.
  • the antibody light chain variable region described in the present application may further comprise a light chain constant region, and the light chain constant region comprises human or murine ⁇ , ⁇ chain or variants thereof.
  • the antibody heavy chain variable region described in the present application may further comprise a heavy chain constant region, and the heavy chain constant region comprises human or murine IgG1, 2, 3, 4 or variants thereof.
  • variable region The sequence of about 110 amino acids near the N-terminus of the antibody heavy and light chains varies greatly, which is the variable region (V region); the remaining amino acid sequences near the C-terminus are relatively stable, which is the constant region (C region).
  • the variable region includes 3 hypervariable regions (HVR) and 4 framework regions (FR) with relatively conserved sequences. Three hypervariable regions determine the specificity of antibodies, also known as complementarity determining regions (CDR).
  • CDR complementarity determining regions
  • Each light chain variable region (VL) and heavy chain variable region (VH) are composed of 3 CDR regions and 4 FR regions, and the sequence from the amino terminal to the carboxyl terminal is: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.
  • the number and position of the CDR amino acid residues in the VL region and VH region of the antibody or antigen-binding fragment conform to known Chothia (ABM) numbering scheme.
  • recombinant human antibody includes human antibodies prepared, expressed, created or isolated by recombinant methods, techniques and methods involved are well known in the art, such as:
  • Antibodies isolated from host cells transformed to express the antibodies such as transfectomas
  • Antibodies prepared, expressed, created or isolated by methods such as splicing human immunoglobulin gene sequences into other DNA sequences.
  • Such recombinant human antibodies comprise variable and constant regions which utilize specific human germline immunoglobulin sequences encoded by germline genes, but also include rearrangements and mutations that occur subsequently, such as during antibody maturation.
  • murine antibody in this application refers to a monoclonal antibody against human CD79b or its epitope prepared according to the knowledge and skills in the art. In preparation, test subjects are injected with the CD79b antigen, and hybridomas expressing antibodies having the desired sequence or functional properties are isolated.
  • the murine CD79b antibody or antigen-binding fragment thereof may further comprise a light chain constant region of a murine ⁇ , ⁇ chain or a variant thereof, or further comprise a murine IgG1, IgG2 , IgG3 or IgG4 or a variant thereof heavy chain constant region.
  • human antibody includes antibodies having variable and constant regions of human germline immunoglobulin sequences.
  • the human antibodies of the present application may include amino acid residues not encoded by human germline immunoglobulin sequences (eg, mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • the term “human antibody” does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences (ie, "humanized antibodies”) .
  • humanized antibody also known as CDR-grafted antibody (CDR-grafted antibody) refers to an antibody produced by grafting mouse CDR sequences into human antibody variable region frameworks. It can overcome the strong immune response induced by the chimeric antibody because it carries a large amount of mouse protein components. In order to avoid a decrease in activity while reducing immunogenicity, the human antibody variable region can be subjected to minimal reverse mutations to maintain activity.
  • chimeric antibody is an antibody formed by fusing the variable region of a murine antibody with the constant region of a human antibody, which can reduce the immune response induced by the murine antibody.
  • To establish a chimeric antibody it is necessary to select and establish a hybridoma that secretes a mouse-derived specific monoclonal antibody, then clone the variable region gene from the mouse hybridoma cell, and then clone the constant region gene of the human antibody as required, and make the mouse variable region gene
  • the region gene and the human constant region gene are connected to form a chimeric gene and then inserted into a human vector, and finally the chimeric antibody molecule is expressed in a eukaryotic industrial system or a prokaryotic industrial system.
  • the constant region of the human antibody can be selected from the heavy chain constant region of human IgG1, IgG2, IgG3 or IgG4 or variants thereof, preferably comprising a human IgG2 or IgG4 heavy chain constant region, or using amino acid mutations without ADCC (antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity) toxic IgG1.
  • ADCC antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity
  • the "antigen-binding fragments" mentioned in this application refer to Fab fragments, Fab' fragments, F(ab')2 fragments, and Fv fragments sFv fragments that bind to human CD79b with antigen-binding activity.
  • the Fv fragment contains the antibody heavy chain variable region and the light chain variable region, but has no constant region, and has the smallest antibody fragment with all antigen-binding sites.
  • Fv antibodies also contain a polypeptide linker between the VH and VL domains and are capable of forming the structures required for antigen binding. It is also possible to use different The linker connects the variable regions of two antibodies into one polypeptide chain, which is called single chain antibody (single chain antibody) or single chain Fv (sFv).
  • single-chain antibody single-chain Fv or “scFv” is meant to comprise an antibody heavy chain variable domain (or region; VH) and an antibody light chain variable domain (or region; VL) connected by a linker molecules.
  • Such scFv molecules may have the general structure: NH2 -VL-linker-VH-COOH or NH2 -VH-linker-VL-COOH.
  • Suitable prior art linkers consist of the repeated GGGGS amino acid sequence or variants thereof, for example using 1-4 repeat variants (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448) .
  • linkers useful in the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur.J. Immuno 1.31:94-106, Hu et al. (1996) , Cancer Res. 56:3055-3061, described by Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001 ), Cancer Immunol.
  • CDR refers to one of the six hypervariable regions within the variable domain of an antibody that primarily contribute to antigen binding.
  • One of the most commonly used definitions of the six CDRs is provided by Kabat E.A. et al., (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242).
  • the Kabat definition of CDRs applies only to CDR1, CDR2, and CDR3 (CDR L1, CDR L2, CDR L3 or L1, L2, L3) of the light chain variable domain, and to CDR1, CDR L2, and L3 of the heavy chain variable domain.
  • CDR2 and CDR3 CDR H2, CDR H3 or H2, H3).
  • CDR1, HCDR2, HCDR3 there are three CDRs (HCDR1, HCDR2, HCDR3) in each heavy chain variable region and three CDRs (LCDR1, LCDR2, LCDR3) in each light chain variable region.
  • Amino acid sequence boundaries for CDRs can be determined using any of a variety of well-known schemes, including the "Kabat” numbering convention (see Kabat et al.
  • VH heavy chain variable domain
  • VL light chain variable domain
  • CDR amino acids in VH are numbered 26-32 (HCDR1), 52-56 (HCDR2) and 95-102 (HCDR3)
  • amino acids in VL Residues are numbered 26-32 (LCDR1), 50-52 (LCDR2) and 91-96 (LCDR3).
  • the CDRs consist of amino acid residues 26-35 in human VH (HCDR1 ), 50-65 (HCDR2) and 95-102 (HCDR3) and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2) and 89-97 (LCDR3) in human VL constitute.
  • VH The numbering of CDR amino acid residues in VL is approximately 26-35 (CDR1), 51-57 (CDR2) and 93-102 (CDR3), and the numbering of CDR amino acid residues in VL is approximately 27-32 (CDR1), 50-52 (CDR2) and 89-97 (CDR3).
  • the CDR regions of antibodies can be determined using the program IMGT/DomainGap Align.
  • antibody framework refers to the portion of a variable domain VL or VH that serves as a scaffold for the antigen-binding loops (CDRs) of the variable domain. Essentially, it is a variable domain without CDRs.
  • binding to CD79b refers to being capable of interacting with CD79b or its epitope, which may be of human origin.
  • antigen-binding site in the present application refers to a discontinuous three-dimensional site on the antigen that is recognized by the antibody or antigen-binding fragment of the present application.
  • epitope refers to the site on an antigen to which an immunoglobulin or antibody specifically binds.
  • An epitope typically comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 contiguous or noncontiguous amino acids in a unique spatial conformation. See, eg, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996).
  • the terms “specifically bind”, “selectively bind”, “selectively bind” and “specifically bind” refer to the binding of an antibody to a predetermined epitope on an antigen. Typically, the antibody binds with an affinity (KD) of about less than 10 "7M , eg, about less than 10 "8M , 10 "9M , or 10 " 10M or less.
  • KD affinity
  • Amino acid sequence identity means that when the amino acid sequences are aligned and gaps are introduced as necessary to achieve the maximum percent sequence identity, and any conservative substitutions are not considered as part of the sequence identity, the difference between a first sequence and a second sequence is The percentage of amino acid residues that are identical to each other. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine suitable parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • cross-reactive refers to the ability of an antibody of the present application to bind to CD79b from a different species.
  • an antibody of the application that binds human CD79b may also bind CD79b of another species.
  • Cross-reactivity is measured by detecting specific reactivity with purified antigen in binding assays such as SPR and ELISA, or binding or functional interaction with cells physiologically expressing CD79b. Methods of determining cross-reactivity include standard binding assays as described herein, such as surface plasmon resonance analysis, or flow cytometry.
  • Inhibition or “blocking” are used interchangeably and encompass both partial and complete inhibition/blocking. Inhibition/blocking of CD79b preferably reduces or alters the normal level or pattern of activity that occurs when CD79b binding occurs without inhibition or blocking. Inhibition and blocking are also intended to include any measurable reduction in CD79b binding affinity when contacted with an anti-CD79b antibody compared to CD79b not contacted with an anti-CD79b antibody.
  • inhibiting growth is intended to include any measurable decrease in cell growth.
  • inducing an immune response and “enhancing an immune response” are used interchangeably and refer to the stimulation (ie, passive or adaptive) of an immune response to a particular antigen.
  • induce with respect to induction of CDC or ADCC refers to the stimulation of specific direct cell killing mechanisms.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • antibody-dependent cell-mediated cytotoxicity refers to the direct killing of cells expressing Fc receptors by recognizing the Fc segment of the antibody and being coated by the antibody target cells.
  • the ADCC effector function of the antibody can be reduced or eliminated by modifying the Fc segment of IgG.
  • the modification refers to mutations in the heavy chain constant region of the antibody, such as N297A, L234A, L235A selected from IgG1; IgG2/4 chimerism, IgG4 F235E, or L234A/E235A mutations.
  • linker refers to a chemical structural segment or bond that is connected to a ligand at one end and a drug at the other end, and can also be connected to other linkers before being connected to a drug.
  • a joint may comprise one or more joint components.
  • exemplary linker building blocks include 6-maleimidocaproyl ("MC"), maleimidopropionyl ("MP”), valine-citrulline (“val-cit” or “vc”) "), alanine-phenylalanine (“ala-phe”), p-aminobenzyloxycarbonyl (“PAB”), and that derived from coupling with linker reagents: N-succinimidyl 4- (2-pyridylthio)pentanoate (“SPP”), N-succinimidyl 4-(N-maleimidomethyl) Cyclohexane-1 carboxylate (“SMCC”, also referred to herein as "MCC”) and N-succinimidyl (4-iodo-acetyl)aminobenzoate (“SIAB”).
  • MC 6-maleimidocaproyl
  • MP maleimidopropionyl
  • val-cit valine-
  • Linkers may include stretch units, spacer units, amino acid units and extension units, and may be synthesized by methods known in the art, such as described in US2005-0238649A1.
  • the linker can be a "cleavable linker" that facilitates release of the drug in the cell.
  • acid-labile such as hydrazone
  • protease-sensitive such as peptidase-sensitive
  • photolabile linkers dimethyl linkers, or disulfide-containing linkers
  • disulfide-containing linkers can be used (Chari et al., Cancer Research 52:127-131 (1992); US Patent No. 5,208,020).
  • amino acid unit means that if there is an extension unit, the carbonyl group in the following structural formula Y R can be connected to the extension unit, and if there is no extension unit, Y R can be directly connected to the amino acid on the cytotoxic drug , in the embodiments of the present disclosure, the amino acid unit is represented as -K k -:
  • -K k is a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide or decapeptide, each of the -K-units independently has the following structural formula K a or K b , and k is An integer between 0-10:
  • R 23 in the above-mentioned amino acid unit is -H or methyl
  • R 25 is -aryl-, -alkyl-aryl-, -cycloalkyl-, -alkyl-cycloalkyl-, -cycloalkyl-alkyl-, -alkyl-cycloalkyl-alkyl -, -heterocyclyl-, -alkyl-heterocyclyl-, -heterocyclyl-alkyl-, -alkyl-heterocyclyl-alkyl-, -aryl-, -alkyl-aryl- , -aryl-alkyl-, -alkyl-aryl-alkyl-, -heteroaryl-, -alkyl-heteroaryl-, -heteroaryl-alkyl-, -alkyl-heteroaryl-, -heteroaryl-alkyl-, -alkyl-heteroaryl base-alkyl-.
  • -K k - is a dipeptide, preferably -valine-citrulline-, -phenylalanine-lysine- or -N-methylvaline-citrulline- , more preferably -valine-citrulline-.
  • stretch unit refers to a chemical structural fragment that is covalently linked to a ligand through a carbon atom at one end and to a cytotoxic drug at the other end through a sulfur atom.
  • spacer unit is a bifunctional compound structural fragment, which can be used to couple the linker unit and the cytotoxic drug to finally form a ligand-cytotoxic drug conjugate. This coupling method can selectively link the cytotoxic drug onto the connection unit.
  • extending unit refers to a chemical structure that can couple the amino acid unit to a cytotoxic drug when the amino acid unit is present, or can couple the cytotoxic drug to the carbonyl group on YR when the amino acid unit is absent.
  • the extension unit is represented as -Q q -, q is selected from 0, 1, 2.
  • the extension unit is PAB, the structure of which is like a 4-iminobenzylcarbamoyl fragment, and its structure is shown in the following formula, which is connected to D,
  • Joint components include but are not limited to:
  • MC 6-maleimidocaproyl
  • Val-Cit or "vc” valine-citrulline (an exemplary dipeptide in a protease cleavable linker)
  • PAB p-aminobenzyloxycarbonyl (exemplary of a "self-sacrificing" linker component)
  • Me-Val-Cit N-methyl-valine-citrulline (wherein the linker peptide bond has been modified to prevent its cleavage by cathepsin B)
  • MC(PEG)6-OH maleimidocaproyl-polyethylene glycol (can be attached to antibody cysteine)
  • SPDP N-succinimidyl 3-(2-pyridyldithio)propionate
  • SMCC succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
  • drug loading refers to the average amount of cytotoxic drug loaded on each ligand in the ADC, and can also be expressed as the ratio of the amount of drug to the amount of antibody, and the range of drug loading can be 1 - 20, preferably 1-10 cytotoxic drugs (D).
  • the drug loading is expressed as n or k, exemplarily 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 , 16, 17, 18, 19, 20 or any value between two values mean.
  • Conventional methods such as UV/visible light spectroscopy, mass spectrometry, ELISA test, monoclonal antibody molecular size variant assay (CE-SDS) and HPLC characterization can be used to identify the average amount of drug product per ADC molecule after the conjugation reaction.
  • the molecular size variant determination method (CE-SDS) of the disclosed monoclonal antibody can adopt the sodium dodecyl sulfate capillary electrophoresis (CE-SDS) ultraviolet detection method, under reducing and non-reducing conditions, according to the molecular weight, according to the capillary electrophoresis method (2015 edition of "Chinese Pharmacopoeia” 0542), quantitatively determine the purity of recombinant monoclonal antibody products.
  • CE-SDS sodium dodecyl sulfate capillary electrophoresis
  • the cytotoxic drug is coupled to the N-terminal amino group of the ligand and/or the ⁇ -amino group of the lysine residue through a linking unit.
  • the number of drug molecules will be less than the theoretical maximum.
  • the loading of ligand cytotoxic drug conjugates can be controlled by the following non-limiting methods, including:
  • the drug-to-antibody ratio has an exact value (e.g., n in formula (I)) for a particular conjugate molecule, it is understood that this value will often be an average when used to describe a sample containing many molecules values, due to some degree of non-uniformity typically associated with the conjugation step.
  • the average loading of an immunoconjugate sample is referred to herein as the drug-to-antibody ratio, or "DAR.”
  • the DAR is between about 1 and about 6, and typically about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7.0, 7.5, 8.0 .
  • At least 50% by weight of the samples are compounds with an average DAR of plus or minus 2, and preferably at least 50% of the samples are conjugates with an average DAR of plus or minus 1.
  • Embodiments include wherein the DAR is about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2.
  • a DAR of 'about x' means that the measured value of the DAR is within 20% of x.
  • LC/MS allows quantification of the average number of payload (drug moiety) molecules attached to the antibody in the ADC.
  • HPLC separates antibodies into light and heavy chains, and also separates heavy chains (HC) and light chains (LC) according to the number of linker-payload groups per chain.
  • Mass spectral data can identify the species of components in the mixture, such as LC, LC+1, LC+2, HC, HC+1, HC+2, etc.
  • the average DAR of the ADC can be calculated.
  • the DAR for a given immunoconjugate sample represents the average number of drug (payload) molecules attached to a tetrameric antibody containing two light chains and two heavy chains.
  • the DAR detection method in WO2018142322.
  • alkyl refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably 1 to 10 carbon atoms atom, most preferably an alkyl group containing 1 to 6 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-Dimethylpropyl, 2,2-Dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-
  • lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl group, 2,3-dimethylbutyl group, etc.
  • Alkyl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, said substituents being preferably one or more of the following groups independently selected from alkyl radical, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane Oxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo.
  • heteroalkyl refers to an alkyl group containing one or more heteroatoms selected from N, O or S, wherein alkyl is as defined above.
  • alkylene refers to a saturated straight or branched chain aliphatic hydrocarbon group having two residues derived from the same carbon atom or two different carbon atoms of a parent alkane by removing two hydrogen atoms, which are A linear or branched chain group containing 1 to 20 carbon atoms, preferably an alkylene group containing 1 to 12 carbon atoms, more preferably an alkylene group containing 1 to 6 carbon atoms.
  • Non-limiting examples of alkylene include, but are not limited to, methylene (-CH 2 -), 1,1-ethylene (-CH(CH 3 )-), 1,2-ethylene (-CH 2 CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene (-CH 2 CH 2 CH 2 -), 1,4-butylene (-CH 2 CH 2 CH 2 CH 2 -), and 1,5-butylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -) wait.
  • Alkylene groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, preferably independently optionally selected from alkyl, alkenyl, alkynyl , alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy , cycloalkylthio, heterocycloalkylthio and oxo with one or more substituents.
  • alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl or cycloalkyl is as defined above.
  • alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
  • Alkoxy may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkoxy Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably containing 3 to 12 carbon atoms, more preferably containing 3 to 10 carbon atoms, most preferably contain 3 to 8 carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene group, cyclooctyl group, etc.; polycyclic cycloalkyl group includes spiro ring, fused ring and Bridged cycloalkyl.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent comprising 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), but excluding ring portions of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
  • the cycloalkyl ring contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, the cycloalkyl ring contains 3 to 10 ring atoms.
  • Non-limiting examples of monocyclic heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like.
  • Polycyclic heterocyclyls include spiro, fused and bridged heterocyclyls.
  • spiroheterocyclyl refers to a polycyclic heterocyclic group that shares one atom (called a spiro atom) between 5 to 20-membered monocyclic rings, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O ) m (wherein m is an integer from 0 to 2), the remaining ring atoms are carbon. It may contain one or more double bonds, but none of the rings has a fully conjugated pi-electron system. For example, it is 6 to 14 yuan, and for example, it is 7 to 10 yuan.
  • the spiroheterocyclyl can be divided into single spiroheterocyclyl, double spiroheterocyclyl or polyspiroheterocyclyl, preferably single spiroheterocyclyl and double spiroheterocyclyl.
  • it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered monospiro heterocyclic group.
  • Non-limiting examples of spiroheterocyclyls include:
  • fused heterocyclyl refers to a 5 to 20 membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system, and one or more rings may contain one or more double bond, but none of the rings has a fully conjugated ⁇ -electron system, where one or more ring atoms are heteroatoms selected from nitrogen, oxygen, or S(O) m (where m is an integer from 0 to 2), and the remaining ring
  • the atom is carbon. For example, it is 6 to 14 yuan, and for example, it is 7 to 10 yuan.
  • bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups such as bicyclic or tricyclic, and for example, 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclic groups.
  • fused heterocyclic groups include:
  • bridged heterocyclyl refers to a 5 to 14 membered polycyclic heterocyclic group in which any two rings share two atoms not directly attached, which may contain one or more double bonds, but none of the rings has a complete shared bond.
  • bridged heterocyclic group is, for example, bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic.
  • bridged heterocyclyl groups include:
  • the heterocyclyl ring may be fused to an aryl, heteroaryl, or cycloalkyl ring where the ring bonded to the parent structure is a heterocyclyl, non-limiting examples of which include: wait.
  • Heterocyclic groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alk Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, oxo.
  • aryl refers to a 6 to 14 membered all-carbon monocyclic or fused polycyclic (that is, rings sharing adjacent pairs of carbon atoms) group having a conjugated pi-electron system, for example 6 to 10 members, such as benzene and naphthyl, specifically phenyl.
  • the aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, where the ring bonded to the parent structure is an aryl ring, non-limiting examples of which include:
  • Aryl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio.
  • heteroaryl refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen.
  • Heteroaryl is preferably 5 to 10 membered, more preferably 5 or 6 membered, such as furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetra Azolyl, etc.
  • the heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring bonded to the parent structure is a heteroaryl ring, non-limiting examples of which include:
  • Heteroaryl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alk Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio.
  • amino-protecting group is used to protect the amino group with a group that can be easily removed in order to keep the amino group unchanged when other parts of the molecule react.
  • Non-limiting examples include 9-fluorenylmethoxycarbonyl, tert-butoxycarbonyl, acetyl, benzyl, allyl, p-methoxybenzyl, and the like. These groups may be optionally substituted with 1 to 3 substituents selected from halogen, alkoxy or nitro.
  • the amino protecting group is preferably 9-fluorenylmethoxycarbonyl.
  • aminoheterocyclyl refers to a heterocyclyl group substituted by one or more amino groups, preferably one amino group, wherein heterocyclyl is as defined above, and wherein “amino” refers to -NH2 .
  • aminoheterocyclyl refers to a heterocyclyl group substituted by one or more amino groups, preferably one amino group, wherein heterocyclyl is as defined above, and wherein “amino” refers to -NH2 .
  • heterocyclylamino refers to an amino group substituted by one or more heterocyclyl groups, preferably by one heterocyclyl group, wherein amino is as defined above, and wherein heterocyclyl is as defined above.
  • Representative examples of the present disclosure are as follows:
  • cycloalkylamino refers to an amino group substituted by one or more cycloalkyl groups, preferably by one cycloalkyl group, wherein amino group is as defined above and wherein cycloalkyl group is as defined above.
  • Representative examples of the present disclosure are as follows:
  • cycloalkylalkyl refers to an alkyl group substituted by one or more cycloalkyl groups, preferably by one cycloalkyl group, wherein alkyl is as defined above, and wherein cycloalkyl is as defined above.
  • haloalkyl refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
  • deuteroalkyl refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
  • hydroxyl refers to a -OH group.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • amino refers to -NH2 .
  • nitro refers to -NO2 .
  • the present disclosure also includes various deuterated forms of the compounds.
  • Each available hydrogen atom attached to a carbon atom can be independently replaced by a deuterium atom.
  • Those skilled in the art can refer to the relevant literature to synthesize the deuterated form of the compound.
  • Commercially available deuterated starting materials can be used in the preparation of deuterated forms of the compounds, or they can be synthesized using conventional techniques using deuterated reagents including but not limited to deuterated borane, trideuterioborane in tetrahydrofuran , deuterated lithium aluminum hydride, deuterated ethyl iodide and deuterated methyl iodide, etc.
  • the hydrogen in the functional group of the compound described in the present disclosure is deuterated to obtain the corresponding deuterated compound, and the deuterated compound retains the selectivity and potential comparable to the hydrogen analog; the deuterium bond is more stable, so that "ADME” is " Toxic pharmacokinetics" are different, thereby providing clinically beneficial effects.
  • Toxic pharmacokinetics refers to the body's absorption, distribution, metabolism and excretion of exogenous chemicals.
  • Optional or “optionally” means that the subsequently described event or circumstance can but need not occur, and that the description includes instances where the event or circumstance occurs or does not occur.
  • a heterocyclic group optionally substituted with an alkyl group means that an alkyl group may but need not be present, and the description includes cases where the heterocycle group is substituted with an alkyl group and cases where the heterocycle group is not substituted with an alkyl group .
  • Substituted means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms are independently substituted by the corresponding number of substituents. It goes without saying that substituents are only in their possible chemical positions and that a person skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated (eg, ethylenic) bond.
  • administering and “treating” when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid refer to the interaction of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, human, or subject. contact with subjects, cells, tissues, organs or biological fluids.
  • administering can refer to, for example, therapeutic, pharmacokinetic, diagnostic, research and experimental methods.
  • Treatment of cells includes contacting the reagents with the cells, and contacting the reagents with a fluid, wherein the fluid contacts the cells.
  • administeristering” and “treating” also mean in vitro and ex vivo treatment of, for example, a cell by a reagent, diagnostic, binding composition or by another cell.
  • Treatment when applied to human, veterinary or research subjects means therapeutic treatment, prophylactic or preventive measures, research and diagnostic applications.
  • Treating means administering a therapeutic agent, internally or externally, such as a composition comprising any of the conjugated compounds of the present disclosure, to a patient having one or more symptoms of a disease for which the therapeutic agent is known to have an effect.
  • a therapeutic agent is administered in a patient or population to be treated in an amount effective to alleviate one or more symptoms of a disease, to induce regression of such symptoms or to inhibit the progression of such symptoms to any clinically measurable extent.
  • the amount of a therapeutic agent effective to alleviate the symptoms of any particular disease (also referred to as a "therapeutically effective amount”) will vary depending on factors such as the patient's disease state, age and weight, and the ability of the drug to produce the desired effect in the patient.
  • Whether disease symptoms have been alleviated can be assessed by any of the clinical tests commonly used by a physician or other professional health care practitioner to assess the severity or progression of such symptoms.
  • embodiments of the present disclosure may not be effective in alleviating each of the disease symptoms of interest, It is determined according to any statistical test method known in the art such as Student t test, chi-square test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test and Wilcoxon test, which are determined in statistics Target disease symptoms should be alleviated in a clinically significant number of patients.
  • an "effective amount” includes an amount sufficient to ameliorate or prevent a symptom or condition of a medical disease.
  • An effective amount also means an amount sufficient to permit or facilitate diagnosis.
  • Effective amounts for a particular patient or veterinary subject may vary depending on factors such as the condition being treated, the general health of the patient, the route and dose of administration and the severity of side effects.
  • An effective amount may be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.
  • Embodiment 1 anti-CD79b antibody preparation
  • the present disclosure provides an anti-CD79b antibody, which is obtained by screening mice immunized with the extracellular domain (ECD) of human CD79b.
  • ECD extracellular domain
  • the amino acid residues of the VH/VL CDRs of antibodies are determined and annotated by the Chothia numbering system.
  • the sequences of mouse hybridoma cell monoclonal antibody mAb015 and its humanized antibody hAb015-10 are as follows:
  • Embodiment the preparation of anti-CD79b antibody-drug conjugate
  • ADC stock solution is an antibody cross-linked drug.
  • the mechanism of its treatment of diseases is to rely on the targeting of antibodies to transport toxin molecules into cells, and then kill the cells.
  • Drug loading plays a decisive role in drug efficacy.
  • the drug loading capacity of the ADC stock solution was determined using the UV method.
  • UV spectrophotometry instrument used: Thermo nanodrop2000 UV spectrophotometer
  • the principle is that the total absorbance of ADC stock solution at a certain wavelength is equal to that of cytotoxic drugs and monoclonal antibodies at this wavelength.
  • the sum of the absorbance values that is:
  • a 280nm ⁇ mab-280 bC mab + ⁇ Drug-280 bC Drug
  • ⁇ Drug-280 The average molar extinction coefficient of the drug at 280nm is 5100;
  • ⁇ mab-280 The average molar extinction coefficient of single antigen solution at 280nm is 214600;
  • C mab the concentration of the single antigen solution
  • the optical path length is 1 cm.
  • a 370nm ⁇ mab-370 bC mab + ⁇ Drug-370 bC Drug
  • ⁇ Drug-370 The average molar extinction coefficient of the drug at 370nm is 19000;
  • ⁇ mab-370 The extinction coefficient of single antigen solution is 0 at 370nm;
  • C mab the concentration of the single antigen solution
  • the optical path length is 1 cm.
  • the loading capacity of the drug can be calculated by the two equations (1) and (2) combined with the extinction coefficient and concentration data of the monoclonal antibody and the drug at two detection wavelengths.
  • the compound MC-vc-PAB-MMAE (4.45 mg, 3.380 umol) was dissolved in 250 uL dimethyl sulfoxide, added to the above reaction solution, placed in a water bath shaker, and shaken at 25°C for 3 hours to stop the reaction.
  • the reaction solution was desalted and purified with Sephadex G25 gel column (elution phase: 0.05M PBS buffered aqueous solution with pH 6.5, containing 0.001M EDTA), to obtain the title product ADC-3 of this embodiment (i.e. hAb015-10-cys -MC-vc-PAB-MMAE) in PBS buffer (2.79 mg/mL, 17.4 mL), stored frozen at 4°C.
  • Example 2 Compound D (1.09mg, 1.015umol) in Example 2 was dissolved in 45uL dimethyl sulfoxide, added to the above reaction solution, placed in a water bath shaker, and shaken at 25°C for 3 hours to stop the reaction.
  • the reaction solution was desalted and purified with Sephadex G25 gel column (elution phase: 0.05M PBS buffered aqueous solution with pH 6.5, containing 0.001M EDTA), to obtain the title product ADC-6 of this embodiment (i.e. hAb015-10-cys -D, PBS buffer solution (0.71 mg/mL, 14.0 mL) with a DAR value of about 4), stored frozen at 4°C.
  • Example 2 Compound D (1.63mg, 1.518umol) in Example 2 was dissolved in 68uL dimethyl sulfoxide, added to the above reaction solution, placed in a water bath shaker, and shaken at 25°C for 3 hours to stop the reaction.
  • the reaction solution was desalted and purified with a Sephadex G25 gel column (elution phase: 0.05M PBS buffered aqueous solution with a pH of 6.5, containing 0.001M EDTA), to obtain the title product ADC-7 of this example (i.e. hAb015-10-cys -D, PBS buffer (0.81mg/mL, 13.5mL) with a DAR value of about 6), stored frozen at 4°C.
  • the compound MC-VC-PAB-MMAE (70.3mg, 53.40umol) was dissolved in 3.5mL dimethyl sulfoxide, added to the above reaction solution, placed in a water bath shaker, and shaken at 25°C for 3 hours to stop the reaction .
  • the reaction solution was desalted and purified with Sephadex G25 gel column (elution phase: 0.05M PBS buffered aqueous solution with a pH of 6.5, containing 0.001M EDTA), to obtain the title product ADC-8 of this embodiment (i.e. SN8-cys-MC - PAB-MMAE, DAR value about 4) in PBS buffer (5.83 mg/mL, 132 mL), stored frozen at 4°C.
  • CD79b antibodies hAb015-10 and SN8
  • ADCs ADCs to CD79b protein
  • Biacore BIAevaluation version 4.1
  • GE software fitted the data with the (1:1) Langmuir model to obtain the affinity value.
  • sequence of SN8 (that is, the antibody in Polivy) is:
  • DOHH-2 cells (DSMZ, ACC 47) highly expressing human CD79b protein were used to perform endocytosis experiments to evaluate the endocytic ability of different ADCs.
  • DOHH2 was purchased from DSMZ
  • WSU-DLCL-2 cells were purchased from American Type Culture Collection (ATCC)
  • Raji cells were purchased from American Type Culture Collection (ATCC).
  • Inhibition rate (control well OD570nm-OD690nm - drug administration well OD570nm-OD690nm ) / control well OD570nm-OD690nm ⁇ 100%
  • Example 4-4 The curative effect of ADC on human diffuse large B-cell lymphoma WSU-DLCL2 nude mice subcutaneously transplanted tumor
  • ADC-3, ADC-6, ADC-8 are the same as in Example 4-3.
  • each nude mouse was subcutaneously inoculated with 2.1 ⁇ 10 7 WSU-DLCL2 cells, and after the tumor grew to 100-150 mm 3 , the animals were divided into groups according to the tumor volume (D0). Mice were administered intravenously (IV), with an administration volume of 10 mL/kg; see Table 5 for specific administration doses and regimens. The tumor volume was measured twice a week, the body weight of the mice was weighed, and the data were recorded.
  • V tumor volume
  • T/C (%) (TT 0 )/(CC 0 ) ⁇ 100
  • T, C are the tumor volumes at the end of the experiment; T0, C0 are the tumor volumes at the beginning of the experiment.
  • T is the tumor volume administered with ADC
  • C is the tumor volume administered with IgG1 as the control group.
  • Tumor growth inhibition rate % 100-T/C (%)
  • T ⁇ T 0 or C ⁇ C 0 it is defined as partial tumor regression (PR); if the tumor completely disappears, it is defined as complete tumor regression (CR).
  • the tumor inhibition rate of ADC-3 (3mg/kg, IV, D0) on WSU-DLCL2 was 76%, and 1/6 of the tumor partially regressed; the inhibition rate of ADC-6 (3mg/kg, IV, D0) on WSU-DLCL2 The tumor rate was 86%, and 2/6 tumors partially regressed; the tumor inhibition rates of ADC-8 (3mg/kg, 10mg/kg, IV, D0) on WSU-DLCL2 were 39% and 93%, respectively, and the dose of 10mg/kg In the group, 4/6 of the tumors partially regressed; the tumor-bearing mice were well tolerated by the above drugs, and no obvious symptoms such as weight loss occurred. IgG1 was used as a negative control.
  • a single intravenous injection of 3 mg/kg or 10 mg/kg of ADC-3, ADC-6 and ADC-8 has a significant effect on human diffuse large B-cell lymphoma WSU-DLCL2 subcutaneously transplanted tumor in nude mice, causing partial tumor regression ;
  • the drug has obvious dose dependence, and the drug efficacy of each hAb015-10-conjugated ADC is better than that of the positive drug ADC-8 (ie Polivy) at the same dose.
  • Tumor-bearing mice were well tolerated to the above drugs.
  • Example 4-5 The curative effect of ADC on human diffuse large B-cell lymphoma WSU-DLCL2 nude mice subcutaneously transplanted tumor
  • the two-tailed Student’s t test was used to compare the tumor volumes of the two groups, and P ⁇ 0.05 was defined as a statistically significant difference.
  • the tumor inhibition rates of ADC-5 (3mg/kg, 6mg/kg, 12mg/kg, IV, D0) on human diffuse large B-cell lymphoma WSU-DLCL2 subcutaneously transplanted tumors in nude mice were 69%, 86% and 88%, of which 1/6 and 1/6 of the 6mg/kg and 12mg/kg dose groups had partial regression of the tumor respectively;
  • the tumor inhibition rates of DLCL2 subcutaneously transplanted tumors were 66%, 108% and 125%, respectively, and 5/6 and 6/6 of the 3mg/kg and 6mg/kg dose groups had partial tumor regression respectively;
  • Example 4-6 The curative effect of ADC on human B-cell lymphoma DoHH2 nude mice subcutaneously transplanted tumor
  • DOHH-2 cells Human follicular lymphoma DOHH-2 cells were purchased from DSMZ, Germany. Nude mice, BALB/c-nu, 4-5 weeks old, ⁇ , were purchased from Shanghai Lingchang Biotechnology Co., Ltd.
  • each nude mouse was subcutaneously inoculated with 3 ⁇ 10 7 DOHH-2 cells, and after the tumor grew to 100-150 mm 3 , the animals were divided into groups according to the tumor volume (D0). Mice were administered intravenously (IV), with an administration volume of 10 mL/kg; see Table 7 for specific administration doses and regimens. The tumor volume was measured twice a week, the body weight of the mice was weighed, and the data were recorded.
  • ADC-1, ADC-6, ADC-8 (1mg/kg, IV, D0) subcutaneously transplanted into nude mice with human follicular lymphoma DOHH-2
  • the tumor inhibition rates were 82% (1/6PR), 127% (5/6PR), and 41% respectively; tumor-bearing mice were well tolerated by the above drugs, and no obvious symptoms such as weight loss occurred.
  • a single intravenous injection of 1 mg/kg of ADC-6 has a significant effect on human follicular lymphoma
  • DoHH2 subcutaneously transplanted tumors in nude mice causing partial regression of the tumors; the drug efficacy is better than the positive drug ADC-8 (ie Polivy).
  • ADC-8 ie Polivy
  • the CD79b antibody-drug conjugate used in Examples 5 to 8 is ADC-6, which was prepared in the aforementioned Examples 3-3.
  • the following buffer solution was prepared to prepare an antibody preparation of CD79b antibody drug conjugate (ADC-6) with a concentration of 20 mg/mL, and samples were taken for high temperature 40°C and freeze-thaw stability studies.
  • ADC-6 CD79b antibody drug conjugate
  • Embodiment 6 ADC composition auxiliary material and surfactant screening
  • ADC composition preparations containing 20mg/mL antibody drug conjugate (ADC-6), different types and different concentrations of excipients and different concentrations of surfactants, and the samples are placed- Freeze and thaw 5 times at 35°C/room temperature, shake 1W (25°C, 300rpm), 40°C 1W, 40°C 2W and 40°C 1M to check the stability:
  • Appearance results show that there is no significant difference in the appearance of freeze-thawing five times compared with T0; the prescription with polysorbate 80 added, after shaking for 1W (25°C, 300rpm), there is no particle in the preparation, indicating that the addition of polysorbate 80 There was a significant change in the generation of particles in the formulation after shaking; all formulations at 40°C 2W had particles, but the formulation with polysorbate 80 did not produce flocs.
  • the sugar type and concentration had no significant difference on protein appearance, SEC, RCE, Free mAb and DAR values.
  • the target excipients It is 8% sucrose; in the 10mM succinic acid-sodium succinate pH 5.0 system, the concentration of polysorbate 80 is better for the purity of the SEC and RCE of the antibody-drug conjugate at a high temperature of 40°C.
  • Example 7 ADC composition pH fine sieve and polysorbate 80 concentration screening
  • the 10mM histidine-histidine hydrochloride system can be selected for pH fine screening and polysorbate 80 concentration screening.
  • ADC-6 20mg/mL protein
  • polysorbate 80 0.4-0.6mg/mL polysorbate 80
  • 80mg/mL sucrose as excipient
  • the target pH was determined to be 5.6; at the same time, the polysorbate 80 concentration had no significant effect on protein SEC and RCE.
  • the concentration of pearate 80 was better for the SEC and reduced CE of the antibody-drug conjugate at 40°C, and the target concentration of polysorbate 80 was finally determined to be 0.2 mg/mL.
  • the prescription was initially determined as 10mM histidine-histidine hydrochloride, 80mg/mL sucrose, 0.2mg/mL polysorbate 80, pH 5.6.
  • the preparation is subjected to pre-freezing, primary drying and secondary drying to obtain freeze-dried products.
  • the freeze-dried product had a good cake shape, clear appearance after reconstitution, and no significant changes in pH and purity items, indicating that the freeze-drying process was good. Place the freeze-dried product at 40°C 1M to check the stability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种包含抗CD79b抗体药物偶联物的药物组合物及其用途。药物组合物包括配体-药物偶联物和缓冲剂。所述配体-药物偶联物中配体为抗CD79b抗体或其抗原结合片段，药物选自MMAE或其衍生物、依喜替康或其衍生物、艾日布林或其衍生物，缓冲剂选自醋酸盐缓冲剂、组氨酸盐缓冲剂、Tris-盐酸盐缓冲剂、Tris-柠檬酸盐缓冲剂、磷酸盐缓冲剂或琥珀酸盐缓冲剂。所述组合物用于制备治疗或预防增殖性疾病的药物。

Description

一种包含抗CD79b抗体药物偶联物的药物组合物及其用途
本公开要求如下专利申请的优先权：于2022年01月26日提交，申请号为CN202210093514.0，发明名称为“一种包含抗CD79b抗体药物偶联物的药物组合物及其用途”的中国专利申请；上述专利申请的全部内容通过引用结合在本公开中。
技术领域
本公开属于药物制剂领域，具体涉及一种包含抗CD79b抗体药物偶联物的药物组合物，以及其作为药物的用途。
背景技术
B细胞抗原受体(B cell receptor，BCR)复合物是B细胞表面最主要的分子。BCR复合物由识别和结合抗原的膜免疫球蛋白(mIg)和传递抗原刺激信号的Igα(CD79a)和Igβ(CD79b)异源二聚体组成。Igα和Igβ分别为47kDa和37kDa糖蛋白，属于免疫球蛋白超家族成员，编码Igα和Igβ的基因分别称为mb-1和B29。Igα和Igβ胞膜外区氨基端处均有一个Ig样结构域。Igα和Igβ均可作为蛋白酪氨酸激酶的底物，参与BCR信号转导。BCR广泛表达于B细胞淋巴瘤以及正常B细胞上。鉴于靶向CD20的利妥昔单抗在临床上所取得的成功以及可靠的安全性，开发靶向BCR的治疗方法也应该具有良好的疗效和安全性。
针对仍未被满足的与CD79b相关的医疗需求，目前已有包括罗氏制药的多家国际制药公司在积极研发针对CD79b抗体和相关产品，例如CD79b抗体药物偶联物。
抗体药物偶联物(antibody drug conjugate，ADC)把单克隆抗体或者抗体片段通过稳定的化学接头化合物与具有生物活性的细胞毒素相连，充分利用了抗体对肿瘤细胞特异或高表达抗原结合的特异性和细胞毒素的高效性，避免对正常细胞的毒副作用。这也就意味着，与以往传统的化疗药物相比，抗体药物偶联物能精准地结合肿瘤细胞并降低对正常细胞的影响。ADC药物由抗体(靶向部分)，接头和毒素三部分组成。其中，好的靶向部分决定了ADC药物的特异性，这不仅包括特异靶向结合，还包括有效的内吞。
但是，抗体药物，尤其是ADC与其他的化学药物相比，其分子量更大，结构更复杂，容易降解、聚合或发生不希望发生的化学修饰等而变得不稳定。为了使抗体药物偶联物适合于给药，并且在储存及随后使用过程中能保持稳定性，发挥更好的效果，抗体药物的稳定制剂研究显得尤为重要。本公开提供一种足够稳定且更适于给药的包含CD79b ADC的药物组合物。
发明内容
本公开提供一种药物组合物，其包含配体-药物偶联物(例如抗CD79b抗体药物偶联物)。以及提供制备所述药物组合物的方法，及其治疗或预防疾病的方法或相关制药用途。
本公开提供一种药物组合物，其包含配体-药物偶联物和缓冲剂，其中所述配体为抗CD79b抗体或其抗原结合片段；药物选自MMAE或其衍生物、依喜替康或其衍生物、艾日 布林或其衍生物。在一些实施方案中，所述缓冲剂选自醋酸盐缓冲剂、组氨酸盐缓冲剂、Tris-盐酸盐缓冲剂、Tris-柠檬酸盐缓冲剂、磷酸盐缓冲剂或琥珀酸盐缓冲剂。在一些实施方案中，所述缓冲剂为组氨酸盐缓冲剂或琥珀酸盐缓冲剂。在一些具体实施方案中，所述缓冲剂为组氨酸-盐酸盐缓冲剂或琥珀酸-琥珀酸钠缓冲剂。该组合物具有治疗或预防疾病的活性。此外，该组合物还可具有稳定性好等特点。
在一些实施方案中，如上任一项所述的药物组合物，其中所述配体-药物偶联物浓度为0.1mg/mL至50mg/mL，例如0.5mg/mL至50mg/mL、1mg/mL至45mg/mL、1mg/mL至30mg/mL、1mg/mL至25mg/mL、5mg/mL至50mg/mL、10mg/mL至45mg/mL、15mg/mL至40mg/mL、20mg/mL至35mg/mL、25mg/mL至30mg/mL、5mg/mL至30mg/mL、10mg/mL至15mg/mL、10mg/mL至20mg/mL、10mg/mL至25mg/mL、10mg/mL至30mg/mL、15mg/mL至45mg/mL、15mg/mL至35mg/mL、15mg/mL至25mg/mL、15mg/mL至20mg/mL、20mg/mL至25mg/mL、20mg/mL至30mg/mL，或者为这些点值之间的任意范围。在一些实施方案中，所述配体-药物偶联物浓度为10mg/mL至30mg/mL。在一些实施方案中，所述配体-药物偶联物浓度为15mg/mL至25mg/mL。在一些非限制性实施例中，所述配体-药物偶联物浓度为约0.1mg/mL、约0.5mg/mL、约1mg/mL、约2mg/mL、约5mg/mL、约8mg/mL、约10mg/mL、约11mg/mL、约12mg/mL、约13mg/mL、约14mg/mL、约15mg/mL、约16mg/mL、约17mg/mL、约18mg/mL、约19mg/mL、约20mg/mL、约21mg/mL、约22mg/mL、约23mg/mL、约24mg/mL、约25mg/mL、约26mg/mL、约27mg/mL、约28mg/mL、约29mg/mL、约30mg/mL、约35mg/mL、约40mg/mL、约45mg/mL、约50mg/mL。
在一些实施方案中，如上任一项所述的药物组合物，其中所述缓冲剂浓度为0.5mM至50mM，例如1mM至40mM、1mM至30mM、1mM至20mM、1mM至15mM、1mM至10mM、5mM至45mM、5mM至35mM、5mM至25mM、5mM至15mM、5mM至10mM、10mM至15mM、10mM至20mM、10mM至30mM，或者为这些点值之间的任意范围。在一些实施方案中，如上任一项所述的药物组合物，其中所述缓冲剂浓度为1mM至30mM。在一些实施方案中，如上任一项所述的药物组合物，其中所述缓冲剂浓度为5mM至15mM。在一些非限制性实施例中，所述缓冲剂浓度为约0.5mM、约1mM、约2mM、约3mM、约4mM、约5mM、约6mM、约7mM、约8mM、约9mM、约10mM、约11mM、约12mM、约13mM、约14mM、约15mM、约16mM、约17mM、约18mM、约19mM、约20mM、约25mM、约30mM、约35mM、约40mM、约45mM、约50mM，例如约10mM。
在一些实施方案中，如上任一项所述的药物组合物的pH值为4.0至8.5，例如为4.0至8.0、4.5至7.5、5.0至7.0、5.6至6.5、6.0至7.5、4.5至6.5、5.0至6.5、5.0至6.0、5.0至5.5、5.6至6.0、5.35至5.75(例如约5.6)、5.2至5.8、5.5至6.5、4.5至6.5、4.5至6.0、4.5至5.5、4.0至6.0、3.5至5.8，或者为这些点值之间的任意范围。在一些实施方案中，如上任一项所述的药物组合物的pH值为5.0至6.5。在一些实施方案中，如上任一项所述的药物组合物的pH值为5.5至6.0。在一些非限制性实施例中，所述药物组合物的pH值为约4.0、约4.5、约4.6、约4.7、约4.8、约4.9、约4.95、约5.0、约5.05、约5.1、约5.15、约5.2、约5.25、约5.3、约5.35、约5.4、约5.45、约5.5、约5.55、约5.6、约5.65、约5.7、约5.75、 约5.8、约5.85、约5.9、约5.95、约6.0、约6.1、约6.2、约6.3、约6.4、约6.5、约7.0、约7.5、约8.0、约8.5。
通常，通过置换缓冲剂获得的药物组合物的pH与缓冲剂pH几乎一致。同时，本领域技术人员公知，在药物制剂的过程中，有时可能会存在pH飘移，但药物制剂的pH的飘移一般很小(±0.3范围内)。在一些实施方案中，药物制剂的pH的飘移在±0.1范围内。
在一些实施方案中，如上任一项所述的药物组合物，其包含表面活性剂。在一些实施方案中，所述表面活性剂是非离子表面活性剂。在一些实施方案中，所述表面活性剂选自泊洛沙姆(例如泊洛沙姆188)、聚山梨酯(例如聚山梨酯20(即PS20)、聚山梨酯80(即PS80))、聚羟亚烃、Triton、十二烷基磺酸钠、月桂基磺酸钠、辛基糖甙钠、月桂基-磺基甜菜碱、肉豆蔻基-磺基甜菜碱、亚油基-磺基甜菜碱、硬脂基-磺基甜菜碱、月桂基-肌氨酸、肉豆蔻基-肌氨酸、亚油基-肌氨酸、硬脂基-肌氨酸、亚油基-甜菜碱、肉豆蔻基-甜菜碱、鲸蜡基-甜菜碱、月桂酰胺基丙基-甜菜碱、柯卡酰胺基丙基-甜菜碱、亚油酰胺基丙基-甜菜碱、肉豆蔻酰胺基丙基-甜菜碱、棕榈酰胺基丙基-甜菜碱、异硬脂酰胺基丙基-甜菜碱、肉豆蔻酰胺基丙基-二甲基胺、棕榈酰胺基丙基-二甲基胺、异硬脂酰胺基丙基-二甲基胺、甲基可可酰基钠、甲基油基牛磺酸钠、聚乙二醇、聚丙二醇、乙烯与丙烯二醇的共聚物等，或其任意组合。在一些实施方案中，所述表面活性剂为聚山梨酯或泊洛沙姆。在一些实施方案中，所述表面活性剂为聚山梨酯80、聚山梨酯20或泊洛沙姆188。在一些实施方案中，所述表面活性剂为聚山梨酯80。
在一些实施方案中，所述表面活性剂的浓度为0.01mg/mL至1mg/mL，例如0.01mg/mL至0.8mg/mL、0.05mg/mL至0.6mg/mL、0.08mg/mL至0.5mg/mL、0.1mg/mL至0.4mg/mL、0.1mg/mL至0.3mg/mL、0.15mg/mL至0.25mg/mL、0.2mg/mL至0.3mg/mL、0.1mg/mL至0.2mg/mL，或者为这些点值之间的任意范围。在一些实施方案中，所述表面活性剂的浓度为0.1mg/mL至0.3mg/mL。在一些非限制性实施例中，所述表面活性剂的浓度为约0.01mg/mL、约0.02mg/mL、约0.03mg/mL、约0.04mg/mL、约0.05mg/mL、约0.06mg/mL、约0.07mg/mL、约0.08mg/mL、约0.09mg/mL、约0.1mg/mL、约0.11mg/mL、约0.12mg/mL、约0.13mg/mL、约0.14mg/mL、约0.15mg/mL、约0.16mg/mL、约0.17mg/mL、约0.18mg/mL、约0.19mg/mL、约0.2mg/mL、约0.21mg/mL、约0.22mg/mL、约0.23mg/mL、约0.24mg/mL、约0.25mg/mL、约0.3mg/mL、约0.4mg/mL、约0.5mg/mL、约0.6mg/mL、约0.7mg/mL、约0.8mg/mL、约0.9mg/mL、约1mg/mL。
在一些实施方案中，如上任一项所述的药物组合物，其包含渗透压调节剂。在一些实施方案中，渗透压调节剂为糖(包括单糖，二糖，三糖，多糖，糖醇，还原性糖，非还原性糖等等)、氨基酸(包括精氨酸、甘氨酸、半胱氨酸、组氨酸等等)或盐类(氯化钠、氯化钾、氯化钙等)。在一些实施方案中，所述渗透压调节剂为糖，所述糖选自：葡萄糖，蔗糖，海藻糖，乳糖，果糖，麦芽糖，右旋糖苷，甘油，赤藻糖醇，丙三醇，阿拉伯糖醇，木糖醇，山梨糖醇(也称山梨醇)，甘露醇，密里二糖，松三糖，蜜三糖，甘露三糖，水苏糖，麦芽糖，乳果糖，麦芽酮糖，麦芽糖醇，乳糖醇和异-麦芽酮糖。在一些实施方案中，所述渗透压调节剂选自由蔗糖、海藻糖、山梨糖醇、精氨酸、脯氨酸、甘氨酸和氯化钠组成的组中的一种或 多种。在一些实施方案中，所述渗透压调节剂为非还原性二糖；在一些实施方案中，所述渗透压调节剂为海藻糖和/或蔗糖；在一些实施方案中，所述渗透压调节剂为蔗糖。
在一些实施方案中，如上任一项所述的药物组合物中所述渗透压调节剂的浓度为1mg/mL至300mg/mL，例如5mg/mL至200mg/mL、10mg/mL至150mg/mL、20mg/mL至140mg/mL、30mg/mL至130mg/mL、40mg/mL至120mg/mL、50mg/mL至110mg/mL、60mg/mL至100mg/mL、70mg/mL至90mg/mL(例如约80mg/mL)，或者为这些点值之间的任意范围。在一些非限制性实施方案中，所述渗透压调节剂的浓度为约10mg/mL、约20mg/mL、约30mg/mL、约40mg/mL、约50mg/mL、约60mg/mL、约70mg/mL、约80mg/mL、约90mg/mL、约100mg/mL、约110mg/mL、约120mg/mL、约130mg/mL、约140mg/mL、约150mg/mL、约160mg/mL、约170mg/mL、约180mg/mL、约190mg/mL、约200mg/mL、约250mg/mL、约300mg/mL。
一些实施方案中，如上任一项所述的药物组合物含有a)-o)中任一：
a)0.1mg/mL至50mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，0.5mM至50mM、1mM至30mM、5mM至15mM(例如约10mM)组氨酸盐缓冲剂或琥珀酸盐缓冲剂，蔗糖或海藻糖，和聚山梨酯。
b)10mg/mL至30mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，0.5mM至50mM、1mM至30mM、5mM至15mM(例如约10mM)的组氨酸盐缓冲剂或琥珀酸盐缓冲剂，蔗糖和/或海藻糖，和聚山梨酯。
c)15mg/mL至25mg/mL(例如约20mg/mL)配体-药物偶联物(如抗CD79b抗体药物偶联物)，0.5mM至50mM、1mM至30mM、5mM至15mM(例如10mM)组氨酸盐缓冲剂或琥珀酸盐缓冲剂，蔗糖和/或海藻糖，和聚山梨酯。
l)10mg/mL至50mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，0.5mM至50mM、1mM至30mM、5mM至15mM(例如约10mM)的组氨酸盐缓冲剂或琥珀酸盐缓冲剂，蔗糖和/或海藻糖，和聚山梨酯。
其中，a)至c)中的药物组合物的pH为4.0至8.5、5.0至6.5、5.5至6.0(例如约5.0、约5.6)；
一些实施方案中，a)至c)、l)中的药物组合物中蔗糖或海藻糖的浓度为1mg/mL至300mg/mL、30mg/mL至130mg/mL、70mg/mL至90mg/mL(例如约70mg/mL、约80mg/mL、约90mg/mL、约100mg/mL、约110mg/mL、约120mg/mL)；
一些实施方案中，a)至c)、l)中的药物组合物中聚山梨酯为聚山梨酯20或聚山梨酯80，所述聚山梨酯的浓度为0.01mg/mL至1mg/mL、0.05mg/mL至0.6mg/mL、0.1mg/mL至0.3mg/mL(例如约0.1mg/mL、约0.2mg/mL、约0.3mg/mL)；
d)0.1mg/mL至50mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，0.5mM至50mM组氨酸盐缓冲剂或琥珀酸盐缓冲剂，1mg/mL至300mg/mL蔗糖和/或海藻糖，和0.01mg/mL至1mg/mL聚山梨酯80或聚山梨酯20，pH为4.0至8.5。
m)10mg/mL至50mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，1mM至30mM组氨酸盐缓冲剂或琥珀酸盐缓冲剂，30mg/mL至130mg/mL蔗糖和/或海藻糖，和0.05mg/mL至0.6mg/mL聚山梨酯80或聚山梨酯20，pH为5.0至6.5。
e)10mg/mL至30mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，1mM至30mM组氨酸盐缓冲剂或琥珀酸盐缓冲剂，30mg/mL至130mg/mL蔗糖和/或海藻糖，和0.05mg/mL至0.6mg/mL聚山梨酯80或聚山梨酯20，pH为5.0至6.5。
f)10mg/mL至30mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，1mM至30mM组氨酸盐缓冲剂，30mg/mL至130mg/mL蔗糖，和0.05mg/mL至0.6mg/mL聚山梨酯80，pH为5.0至6.5。
g)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，5mM至15mM组氨酸盐缓冲剂，70mg/mL至90mg/mL蔗糖，和0.1mg/mL至0.3mg/mL聚山梨酯80，pH为5.5至6.0。
h)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，10mM组氨酸盐缓冲剂，约80mg/mL蔗糖，和0.1mg/mL至0.3mg/mL聚山梨酯80，pH为5.5至6.0(例如约5.6)。
n)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，5mM至15mM组氨酸-盐酸盐缓冲剂，70mg/mL至90mg/mL蔗糖，和0.1mg/mL至0.3mg/mL聚山梨酯80，pH为5.5至6.0。
o)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，10mM组氨酸-盐酸盐缓冲剂，约80mg/mL蔗糖，和0.1mg/mL至0.3mg/mL聚山梨酯80，pH为5.5至6.0(例如约5.6)。
i)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸盐缓冲剂，约80mg/mL蔗糖，和约0.2mg/mL聚山梨酯80，pH为约5.6。
p-1)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.2mg/mL聚山梨酯80，pH为约5.6。
p-2)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.2mg/mL聚山梨酯80，pH为约5.5。
p-3)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.2mg/mL聚山梨酯80，pH为约5.75。
p-4)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.2mg/mL聚山梨酯80，pH为约6.0。
p-5)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.3mg/mL聚山梨酯80，pH为约5.5。
p-6)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.3mg/mL聚山梨酯80，pH为约5.75。
p-7)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.3mg/mL聚山梨酯80，pH为约6.0。
p-8)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.1mg/mL聚山梨酯80，pH为约5.5。
p-9)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM 组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.1mg/mL聚山梨酯80，pH为约5.75。
p-10)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM组氨酸-盐酸组氨酸，约80mg/mL蔗糖，和约0.1mg/mL聚山梨酯80，pH为约6.0。
j)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，5mM至15mM琥珀酸盐缓冲剂，70mg/mL至90mg/mL蔗糖，和0.1mg/mL至0.3mg/mL聚山梨酯80，pH为4.5至6.5(例如5.0至6.5)。
k)15mg/mL至25mg/mL配体-药物偶联物(如抗CD79b抗体药物偶联物)，约10mM琥珀酸-琥珀酸钠缓冲剂，约80mg/mL蔗糖，和0.1mg/mL至0.3mg/mL聚山梨酯80，pH为约5.0。
上述抗CD79b抗体药物偶联物可为本公开实施例3-1的ADC-3，或实施例3-2的ADC-5，或实施例3-3的ADC-6，或实施例3-4的ADC-7；例如为实施例3-3的ADC-6。
本公开的药物组合物还包含溶剂。药物组合物中溶剂选自但不限于无毒性的生理学可接受的液体载体，如生理盐水、注射用水、葡萄糖溶液(如5％葡萄糖注射液、葡萄糖氯化钠注射液)等。
本公开还提供一种药物组合物，其是前述任一项的药物组合物经0.9％生理盐水或5％葡萄糖溶液稀释获得的，或含有前述任一项的药物组合物经0.9％生理盐水或5％葡萄糖溶液稀释后的可作为静脉注射剂浓度的抗CD79b抗体药物偶联物、组氨酸盐、蔗糖、聚山梨酯80。
配体-药物偶联物
在一些实施方案中，如上述任一项药物组合物中的配体-药物偶联物，其中：
药物选自MMAE或其衍生物、依喜替康或其衍生物、艾日布林或其衍生物；配体为抗CD79b抗体或其抗原结合片段，所述抗CD79b抗体或其抗原结合片段包含重链可变区(VH)和轻链可变区(VL)，其中：
所述VH包含分别如SEQ ID NO：11、6、7所示氨基酸序列的HCDR1、HCDR2、HCDR3，和所述VL包含分别如SEQ ID NO：8、9、10所示氨基酸序列的LCDR1、LCDR2、LCDR3；
所述VH包含分别如SEQ ID NO：5、6、7所示氨基酸序列的HCDR1、HCDR2、HCDR3，和所述VL包含分别如SEQ ID NO：8、9、10所示氨基酸序列的LCDR1、LCDR2、LCDR3。
在一些实施方案中，药物组合物中所述抗CD79b抗体或其抗原结合片段可选自鼠源抗体、嵌合抗体、人源化抗体，例如人源化抗体。
在可选实施方案中，药物组合物中所述的人源化抗CD79b抗体轻链和VH上的轻链和重链FR序列分别来源于人种系轻链和重链的FR或其突变序列。
在一些实施方案中，药物组合物中所述抗CD79b抗体或其抗原结合片段包含抗体VH和VL，其中：
VH序列如SEQ ID NO：3或与之具有至少80％、至少85％、至少90％同一性的氨基酸序列，VL序列如SEQ ID NO：4或与之具有至少80％、至少85％、至少90％同一性的氨基酸序列；
在一些具体实施方案中，药物组合物中所述抗CD79b抗体或其抗原结合片段包含抗体VH和VL，其中：所述VH序列如SEQ ID NO：3所示，和所述VL序列如SEQ ID NO：4所示。
在一些实施方案中，所述抗CD79b抗体或其抗原结合片段进一步包含重链恒定区和轻链恒定区。在可选的实施方案中，所述重链恒定区选自人IgG1、IgG2、IgG3、IgG4恒定区及其常规变体，所述轻链恒定区选自人κ和λ链恒定区及其常规变体。在一些具体实施方案中，所述重链恒定区为人IgG1、IgG4。
在一些实施方案中，所述抗CD79b抗体或其抗原结合片段含有IgG的Fc区，例如人IgG的Fc区，又例如人IgG1、IgG2、IgG4的Fc区。
在一些实施方案中，所述抗CD79b抗体或其抗原结合片段包含重链和轻链，其中：所述重链具有SEQ ID NO：12所示的序列或与之具有至少80％、至少85％、至少90％同一性的序列，和所述轻链具有SEQ ID NO：13所示的序列或与之具有至少80％、至少85％、至少90％同一性的序列。
本公开中，所述“至少90％同一性”涵盖至少90％、至少95％、至少96％、至少97％、至少98％、至少99％同一性。
在一些具体实施方案中，药物组合物中所述抗CD79b抗体或其抗原结合片段包含抗体重链和轻链，其中：所述重链序列如SEQ ID NO：12所示，和所述轻链序列如SEQ ID NO：13所示。
在一些具体实施方案中，上述抗CD79b抗体或其片段可以为变体，所述变体在VL有1至10个(例如1、2、3、4、5、6、7、8、9、10个)氨基酸变化，和/或VH有1至10个(例如1、2、3、4、5、6、7、8、9、10个)氨基酸变化。
在一些具体实施方案中，上述变体具有与原抗CD79b抗体或其片段相同或相似的生物学功能或效果。
在一些实施方案中，所述抗CD79b抗体的抗原结合片段为Fab、Fv、sFv、Fab’、F(ab’)2、线性抗体、单链抗体、scFv、sdAb、sdFv、纳米抗体、肽抗体peptibody、结构域抗体和多特异性抗体(双特异性抗体、diabody、triabody和tetrabody、串联二-scFv、串联三-scFv)，例如具体为scFv、Fv、Fab或Fab’片段。
配体-药物(依喜替康或其衍生物)的偶联物
在一些实施方案中，前述任一项药物组合物中的配体-药物偶联物为配体-依喜替康或其衍生物的偶联物，其如式(I)的通式(Pc-L-Y-D)所示：
其中：
Y选自-O-(CRaRb)m-CR1R2-C(O)-、-O-CR1R2-(CRaRb)m-、-O-CR1R2-、-NH-(CRaRb)m-CR1R2-C(O)-和-S-(CRaRb)m-CR1R2-C(O)-；
Ra和Rb相同或不同，且各自独立地选自氢原子、氘原子、卤素、烷基、卤代烷基、氘代烷基、烷氧基、羟基、氨基、氰基、硝基、羟烷基、环烷基和杂环基；或者，Ra和Rb与其相连接的碳原子一起形成环烷基和杂环基；
R1选自氢原子、卤素、卤代烷基、氘代烷基、环烷基、环烷基烷基、烷氧基烷基、杂环基、芳基和杂芳基；R2选自氢原子、卤素、卤代烷基、氘代烷基、环烷基、环烷基烷基、烷氧基烷基、杂环基、芳基和杂芳基；或者，R1和R2与其相连接的碳原子一起形成环烷基或杂环基；
或者，Ra和R2与其相连的碳原子一起形成环烷基或杂环基；
m为0至4的整数；
n为1至10，n是小数或整数，优选地，n为2至8或5至9；
L为接头单元；
Pc为前述本公开任意所述的抗CD79b抗体或其抗原结合片段。
一些实施方案中，本公开的配体-依喜替康或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其中-Y-为-O-(CRaRb)m-CR1R2-C(O)-；
Ra和Rb相同或不同，且各自独立地选自氢原子、氘原子、卤素或烷基；
R1为C3-6环烷基烷基或C3-6环烷基、氢原子；
R2选自氢原子、卤代烷基或C3-6环烷基；优选氢原子；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
m为0或1。
一些实施方案中，本公开的配体-依喜替康或其衍生物的偶联物，其中结构单元-Y-为-O-(CH2)m-CR1R2-C(O)-；
R1为C3-6环烷基烷基或C3-6环烷基、氢原子；
R2选自氢原子、卤代烷基或C3-6环烷基；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
m为0或1。
一些实施方案中，本公开的配体-依喜替康或其衍生物的偶联物，其中结构单元-Y-为-O-(CH2)m-CR1R2-C(O)-；
R1为C3-6环烷基烷基或C3-6环烷基、氢原子；
R2为氢原子；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
m为0或1。
一些实施方案中，本公开的配体-依喜替康或其衍生物的偶联物，其中结构单元-Y-为-O-(CH2)m-CR1R2-C(O)-；
R1为C3-6环烷基烷基或C3-6环烷基、氢原子；
R2为氢原子；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
m为0。
一些实施方案中，本公开的配体-依喜替康或其衍生物的偶联物，其中结构单元-Y-为-O-(CH2)m-CR1R2-C(O)-；
R1为氢原子；
R2为氢原子；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
m为0。
一些实施方案中，本公开的配体-依喜替康或其衍生物的偶联物，Y选自：
其中Y的O端与接头单元L相连。
另一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其如式(II)的通式(Pc-L-D1)所示：
其中：
R1为氢原子、C3-6环烷基烷基或C3-6环烷基；
R2选自氢原子、卤代烷基或C3-6环烷基；优选氢原子；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
m为0或1；
n为1至10，可以为整数，也可以为小数，优选地，n为1至8或1至6的小数或整数，更优选地，n为1-5或2-4的小数或整数。
一些具体实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中n为1至8，可以为整数，也可以为小数；优选为1至6，可以为整数，也可以为小数。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中接头单元-L-为-L1-L2-L3-L4-，
L1选自-(琥珀酰亚胺-3-基-N)-W-C(O)-、-CH2-C(O)-NR3-W-C(O)-或-C(O)-W-C(O)-，其中W选自C1-8烷基、C1-8烷基-环烷基或1至8个原子的直链杂烷基，所述杂烷基包含1至3个选自N、O或S的杂原子，其中所述的C1-8烷基、环烷基和直链杂烷基各自独立地任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基的一个或多个取代基所取代；
L2选自-NR4(CH2CH2O)p1CH2CH2C(O)-、-NR4(CH2CH2O)p1CH2C(O)-、-S(CH2)p1C(O)-或化学键，其中p1为1至20的整数；
L3为由2至7个氨基酸构成的肽残基，其中所述的氨基酸选自苯丙氨酸、甘氨酸、缬氨酸、赖氨酸、瓜氨酸、丝氨酸、谷氨酸、天冬氨酸中的氨基酸形成的氨基酸残基，并任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基中的一个或多个取代基所取代；
L4选自-NR5(CR6R7)t-、-C(O)NR5、-C(O)NR5(CH2)t-或化学键，其中t为1至6的整数；
R3、R4和R5相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、氘代烷基和羟烷基；
R6和R7相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、氘代烷基和羟烷基。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中接头单元L1选自-(琥珀酰亚胺-3-基-N)-(CH2)s1-C(O)-、-(琥珀酰亚胺-3-基-N)-CH2-环己基-C(O)-、-(琥珀酰亚胺-3-基-N)-(CH2CH2O)s2-CH2CH2-C(O)-、-CH2-C(O)-NR3-(CH2)s3-C(O)-或-C(O)-(CH2)s4C(O)-，其中s1为2至8的整数，s2为1至3的整数，s3为1至8的整数，s4为1至8的整数；s1优选为5。
一些具体实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中接头单元L2选自-NR4(CH2CH2O)p1CH2C(O)-或化学键，p1为6至12的整数。
一些具体实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中L4选自-NR5(CR6R7)t-，R5选自氢原子或烷基，R6和R7相同或不同，且各自独立地为氢原子或烷基，t为1或2，优选为2；L4优选为自-NR5CR6R7-；L4更优选-NHCH2-。
一些具体实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中接头单元-L-为-L1-L2-L3-L4-，
L1为s1为2至8的整数；
L2为化学键；
L3为四肽残基；
L4为-NR5(CR6R7)t-，R5选自氢原子或烷基，R6和R7相同或不同，且各自独立地为氢原子或烷基，t为1或2。
一些具体实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中接头单元-L-为-L1-L2-L3-L4-，
L1为-(琥珀酰亚胺-3-基-N)-CH2-环己基-C(O)-；
L2为-NR4(CH2CH2O)9CH2C(O)-；
L3为四肽残基；
L4为-NR5(CR6R7)t-，R5选自氢原子或烷基，R6和R7相同或不同，且各自独立地为氢原子或烷基，t为1或2。
一些具体实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中所述的L3的肽残基为由一个、两个或多个选自苯丙氨酸(E)、甘氨酸(G)、缬氨酸(V)、赖氨酸(K)、瓜氨酸、丝氨酸(S)、谷氨酸(E)、天冬氨酸(N)中的氨基酸形成的氨基酸残基；优选为由一个、两个或多个选自苯丙氨酸和甘氨酸的氨基酸形成的氨基酸残基；更优选为四肽残基；最优选为GGFG(甘氨酸-甘氨酸-苯丙氨酸-甘氨酸)的四肽残基。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中所述的接头单元-L-，其L1端与配体相连，L4端与Y相连。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中所述-L-Y-为：
L1选自-(琥珀酰亚胺-3-基-N)-(CH2)s1-C(O)-或-(琥珀酰亚胺-3-基-N)-CH2-环己基-C(O)-；
L2为-NR4(CH2CH2O)p1CH2C(O)-或化学键，p1为6至12的整数；
L3为GGFG的四肽残基；
R1为氢原子、环烷基烷基或环烷基；优选C3-6环烷基烷基或C3-6环烷基；
R2选自氢原子、卤代烷基或C3-6环烷基；优选氢原子；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
R5选自氢原子或烷基，R6和R7相同或不同，且各自独立地为氢原子或烷基；
s1为2至8的整数；优选5；
m为0至4的整数。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，
其中所述-L-Y-为：
优选为：
L2为-NR4(CH2CH2O)9CH2C(O)-；
L3为GGFG的四肽残基；
R1为氢原子、环烷基烷基或环烷基；优选C3-6环烷基烷基或C3-6环烷基；
R2选自氢原子、卤代烷基或C3-6环烷基；优选氢原子；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
R5选自氢原子或烷基，R6和R7相同或不同，且各自独立地为氢原子或烷基；
m为0至4的整数。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中所述配体-依喜替康或其衍生物的偶联物包含式(III)所示的结构：
其中：
L2为化学键；
L3为GGFG的四肽残基；
R1为氢原子、C3-6环烷基烷基或C3-6环烷基；
R2选自氢原子、卤代烷基或C3-6环烷基；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
R5选自氢原子或烷基，R6和R7相同或不同，且各自独立地为氢原子或烷基；
s1为2至8的整数；
m为0至4的整数。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中所述配体-依喜替康或其衍生物的偶联物包含式(-L-Y-)所示的结构：
其可用于得到经由连接片段将药物与配体连接而成配体-药物偶联物；
其中：
L1选自-(琥珀酰亚胺-3-基-N)-(CH2)s1-C(O)-或-(琥珀酰亚胺-3-基-N)-CH2-环己基-C(O)-；
L2为-NR4(CH2CH2O)p1CH2C(O)-或化学键，p1为1至20的整数；
L3为GGFG的四肽残基；
R1为氢原子、环烷基烷基或环烷基；优选C3-6环烷基烷基或C3-6环烷基；
R2选自氢原子、卤代烷基或C3-6环烷基；优选氢原子；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
R5、R6或R7相同或不同，且各自独立地为氢原子或烷基；
s1为2至8的整数；
m为0至4的整数。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其中所述配体-依喜替康或其衍生物的偶联物包含式(-L-Y-)所示的结构：
其中：
L2为化学键；
L3为GGFG的四肽残基；
R1为氢原子、环烷基烷基或环烷基；优选C3-6环烷基烷基或C3-6环烷基；
R2选自氢原子、卤代烷基或C3-6环烷基；优选氢原子；
或者，R1和R2与其相连接的碳原子一起形成C3-6环烷基；
R5选自氢原子或烷基，R6和R7相同或不同，且各自独立地为氢原子或烷基；
s1为2至8的整数；
m为0至4的整数。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其为式(IV)的通式(Pc-La-Y-Dr)所示的配体-依喜替康或其衍生物的偶联物：
其中：
W选自C1-8烷基、C1-8烷基-环烷基或1至8个原子的直链杂烷基，所述杂烷基包含1至3个选自N、O或S的杂原子，其中所述的C1-8烷基、环烷基和直链杂烷基各自独立地任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基的一个或多个取代基所取代；
L2选自-NR4(CH2CH2O)p1CH2CH2C(O)-、-NR4(CH2CH2O)p1CH2C(O)-、-S(CH2)p1C(O)-或化学键，p1为1至20的整数；
L3为由2至7个氨基酸构成的肽残基，其中氨基酸任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基中的一个或多个取代基所取代；
R1选自氢原子、卤素、环烷基烷基、氘代烷基、环烷基、杂环基、芳基或杂芳基；
R2选自氢原子、卤素、卤代烷基、氘代烷基、环烷基、杂环基、芳基或杂芳基；
或者，R1和R2与其相连接的碳原子一起形成环烷基或杂环基；
R4和R5相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、氘代烷基和羟烷基；
R6和R7相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、氘代烷基和羟 烷基；
m为0至4的整数；
n为1至10，可以为整数，也可以为小数；
Pc为本公开提供的抗CD79b抗体或其抗原结合片段。
一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物，其为式(V)的通式(Pc-Lb-Y-Dr)所示的配体-依喜替康或其衍生物的偶联物：
其中：
s1为2至8的整数；优选5；
Pc、R1、R2、R5～R7、m和n如式(IV)中所定义。
一些实施方案中，本公开多的配体-依喜替康或其衍生物的偶联物的连接单元-L-Y-包括，但不限于：

一些实施方案中，本公开提供配体-依喜替康或其衍生物的偶联物包括，但不限于：


其中：
n为1至10，可以为整数，也可以为小数；
Pc为前述本公开的抗CD79b抗体或其抗原结合片段。
一些实施方式中，制备如通式(Pc-La-Y-D)所示的配体-依喜替康或其衍生物的偶联物的方法，其包括以下步骤：
Pc还原后，与通式(La-Y-D)偶联反应，得到通式(Pc-La-Y-D)所示的化合物；
其中，Pc为本公开的抗CD79b抗体或其抗原结合片段；W、L2、L3、R1、R2、R5～R7、m和n如式(IV)中所定义。
以上实施方式中，Pc为本公开任意的抗CD79b抗体或其抗原结合片段；优选为实施例中抗CD79b抗体或其抗原结合片段；更优选为包含如SEQ ID NO：12所示的重链和如SEQ ID NO：13所示的轻链的抗体。
一些具体实施方案中，本公开配体-依喜替康或其衍生物的偶联物包括其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、氘代物、或其混合物形式。
此处全文引入WO2020063673中化合物及其制备方法。
配体-药物(MMAE或其衍生物)的偶联物
本公开提供一种新的MMAE类似物/衍生物，其为如通式(D(MMAE))所示的化合物：
或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐，其中：
R8-R13选自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基；
R14选自氢原子、烷基、烷氧基和环烷基；
R15-R18之中的任意两个形成环烷基，余下的两个基团任选自氢原子、烷基和环烷基；
R19选自氢原子或烷基；
R20-R22选自氢原子、羟基、烷基、烷氧基或卤素；
R23选自芳基或杂芳基，所述的芳基或杂芳基任选进一步被选自氢原子、卤素、羟基、烷基、烷氧基和环烷基的取代基所取代。
在本公开的一些实施方案中，所述的通式(D(MMAE))所示的化合物，其为通式(D(MMAE)1)所示的化合物：
或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐，
R16与R17形成环烷基；
R9-R15，R18-R23如通式(D)中所定义。
在本公开的一些实施方案中，所述的通式(D(MMAE))所示的化合物，其为：
本公开的另一方面涉及一种配体-药物偶联物或其药学上可接受的盐或溶剂化物，其中所述配体-药物偶联物包含式(-D(MMAE))所示的结构：
或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐，其中：
R9-R13选自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基；
R14选自氢原子、烷基、烷氧基和环烷基；
R15-R18之中的任意两个形成环烷基，余下的两个基团任选自氢原子、烷基和环烷基；
R19选自氢原子或烷基；
R20-R22选自氢原子、羟基、烷基、烷氧基或卤素；
R23选自芳基或杂芳基，所述的芳基或杂芳基任选进一步被选自氢原子、卤素、羟基、烷基、烷氧基和环烷基的取代基所取代；
波浪线表示氢原子，或与接头单元或与结合靶细胞所表达抗原的抗体共价连接。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其中所述配体-药物偶联物包含式(-D(MMAE)1)所示的结构：
其中：
R16与R17形成环烷基；
波浪线，R9-R15，R18-R23如通式(D(MMAE))中所定义。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其中所述配体-MMAE或其衍生物的偶联物包含式如下所示的结构：
波浪线表示氢原子，或与接头单元或与结合靶细胞所表达抗原的抗体共价连接。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其为通式(Pc-L-D(MMAE))所示的配体-药物偶联物或其药学上可接受的盐或溶剂化物：
其中：
R9-R23如通式(D(MMAE))中所定义；
n为1至10，可以为整数，也可以为小数；
Pc为本公开的抗CD79B抗体或其抗原结合片段；L为接头单元。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其为通式(Pc-L-D1)所示的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物：
其中：
R9-R23如通式(-D(MMAE))中所定义；
Pc，L，n如通式(Pc-L-D(MMAE))中所定义。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其为通式下所示的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物：
Pc，L，n如通式(Pc-L-D(MMAE))中所定义。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其中n为1至8，可以为整数，也可以为小数；优选为1至6，可以为整数，也可以为小数。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其中接头单元-L-为-Y-L5-L6-L7-L8，
Y为拉伸单元，选自或化学健，X1选自氢原子、烷基，烷氧基，芳基或卤素，X2选自亚烷基，所述的亚烷基任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基的一个或多个取代基所取代；
L5为拉伸单元，选自-(琥珀酰亚胺-3-基-N)-W-C(O)-、-CH2-C(O)-NR24-W-C(O)-或-C(O)-W-C(O)-，其中W选自C1-8烷基、C1-8烷基-环烷基或1至8个原子的直链杂烷基，所述杂烷基包含1至3个选自N、O或S的杂原子，其中所述的C1-8烷基、环烷基和直链杂烷基各自独立地任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基的一个或多个取代基所取代；
L6选自-NR25(CH2CH2O)p1CH2CH2C(O)-、-NR25(CH2CH2O)p1CH2C(O)-、-S(CH2)p1C(O)-或化学键，其中p1为1至20的整数；优选为化学键；
L7为由2至7个氨基酸构成的肽残基，所述的氨基酸优选自缬氨酸、瓜氨酸，甲基缬氨酸；其中氨基酸任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基中的一个或多个取代基所取代；
R24和R25相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、氘代烷基和羟烷基；
L8为延伸单元，优选为PAB。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其中Y为选自
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其中L5选自-(琥珀酰亚胺-3-基-N)-(CH2)s1-C(O)-，其中s1为2至8的整数；优选为
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其中L7为二肽氨基酸单元，优选自缬氨酸-瓜氨酸。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其中接头单元-L-选自：
其中a端连着配体，b端连着药物。
在本公开的一些实施方案中，所述的配体-MMAE或其衍生物的偶联物或其药学上可接受的盐或溶剂化物，其选自以下结构式：
其中：
n为1至10，可以为整数，也可以为小数；
Pc为本公开的抗CD79B抗体或其抗原结合片段；优选为实施例中的抗CD79B抗体或其抗原结合片段，更优选为包含如SEQ ID NO：12所示的重链和如SEQ ID NO：13所示的轻链的抗体。
本公开的另一方面涉及一种制备如通式(D(MMAE))所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐的方法，其包括以下步骤：
通式(DA(MMAE))脱保护反应，得到通式(D(MMAE))所示的化合物，
其中：R9-R23如通式(D)中所定义。
本公开的另一方面涉及一种如下所示的化合物：
或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐，可做为制备本公开配体-药物偶联物的中间体。
本公开的另一方面涉及一种制备化合物2(MMAE)或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐的方法，其包括以下步骤：
化合物1(MMAE)和化合物2a(MMAE)进行缩合反应，得到化合物2(MMAE)。
本公开的另一方面涉及一种制备如通式(Pc-L-D(MMAE))所示的配体-药物偶联物或其药学上可接受的盐或溶剂化物的方法，其包括以下步骤：
还原Pc后，与化合物偶联反应，得到通式(ADC(MMAE)-1)所示的化合物；
其中，Pc，n如通式(Pc-L-D(MMAE))中所定义。
为了完成本公开的MMAE及其衍射物合成目的，本公开采用如下的合成技术方案：
方案一：
本公开通式(D(MMAE))所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐的方法，其包括以下步骤：
通式(DA(MMAE))在碱性条件下进行脱保护反应，得到通式(D(MMAE))所示的化合物，
其中：R9-R23如通式(D(MMAE))中所定义。
提供碱性条件的试剂包括有机碱和无机碱类，所述的有机碱类包括但不限于三乙胺、二乙胺、N-甲基吗啉、吡啶、六氢吡啶、N,N-二异丙基乙胺、正丁基锂、二异丙基氨基锂、醋酸钾、叔丁醇钠或叔丁醇钾，所述的无机碱类包括但不限于氢化钠、磷酸钾、碳酸钠、碳酸钾、碳酸铯、氢氧化钠和氢氧化锂；优选二乙胺。
方案二：
本公开的化合物2(MMAE)或其可药用盐或溶剂合物的制备方法，该方法包括：
化合物(1(MMAE))和化合物(2a(MMAE))在碱性条件下，加入缩合剂，进行缩合反应，得到化合物2。
提供碱性条件的试剂包括有机碱和无机碱类，所述的有机碱类包括但不限于三乙胺、二乙胺、N-甲基吗啉、吡啶、六氢吡啶、N,N-二异丙基乙胺、正丁基锂、二异丙基氨基锂、醋酸钾、叔丁醇钠或叔丁醇钾，所述的无机碱类包括但不限于氢化钠、磷酸钾、碳酸钠、碳酸钾、碳酸铯、氢氧化钠和氢氧化锂，优选N,N-二异丙基乙胺。
缩合剂选自4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐、1-羟基苯并三唑和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐、N,N'-二环己基碳化二亚胺、N,N'-二异丙基碳二酰亚胺、O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸酯、1-羟基苯并三唑、1-羟基-7-偶氮苯并三氮唑、O-苯并三氮唑-N,N,N',N'-四甲脲六氟磷酸酯、2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯、苯并三氮唑-1-基氧基三(二甲基氨基)磷鎓六氟磷酸盐或六氟磷酸苯并三唑-1-基-氧基三吡咯烷基磷，优选4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐或1-羟基苯并三唑和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐，优选1-羟基苯并三唑。
方案三：
本公开通式(Pc-L-D)所示的配体-药物偶联物或其药学上可接受的盐或溶剂化物的方法，其包括以下步骤：
还原Pc后，与化合物2(MMAE)偶联反应，得到通式(ADC(MMAE)-1)所示的化合物；还原剂优选TCEP，特别地，优选还原抗体上的二硫键；
其中，Pc，n如通式(Pc-L-D(MMAE))中所定义。
实施例化合物
本公开提供配体-药物偶联物，选自：

其中，Pc为本公开任意抗CD79b抗体或其抗原结合片段，n为1至10，可以为整数，也可以为小数。
一些具体实施方案中，Pc为本公开实施例中的抗CD79b抗体或其抗原结合片段，例如为包含如SEQ ID NO：12所示的重链和如SEQ ID NO：13所示的轻链的抗体，n为1至6之间的整数或小数。
在一些具体的实施方案中，本公开的抗体药物偶联物，平均DAR值可以为1-10，例如2-8，或2-6，或1-6，或4-6之间的任意值。在一些实施方式中，DAR在约1与约6之间，例如是约1、1.5、2、2.5、3、3.5、4、4.5、5、5.5、6、6.5、7.0、7.5、8.0。在一些实施方式中，按重量计至少50％的样品是具有平均DAR加或减2的化合物，一些具体实施方式中，至少50％的样品是含有平均DAR加或减1的缀合物。例如，包括其中DAR是约1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8、1.9、2.0、2.1、2.2、。2.3、2.4、2.5、2.6、2.7、2.8、2.9、3.0、3.1、3.2、3.3、3.4、3.5、3.6、3.7、3.8、3.9、4.0、4.1、4.2、4.3、4.4、4.5、4.6、4.7、4.8、4.9、5.0、5.1、5.2、5.4、5.4、5.5、5.6、5.7、5.8、5.9、6.0、6.1、6.2、6.3、6.4、6.5、6.6、6.7、6.8、6.9、7.0的免疫缀合物。在一些实施方式中，‘约为x’的DAR意指DAR的测量值在x的20％范围内。
在一些实施方案中，前述任一项的药物组合物，可以是静脉注射剂、皮下注射剂、腹腔注射剂或肌肉注射剂。
在一些实施方案中，本公开提供一种制备前述任一项药物组合物的方法，所述方法包括将配体-药物偶联物(如抗CD79b抗体药物偶联物)原液经缓冲剂置换的步骤。
本公开还提供一种液体制剂，其包含前述任一项所述的药物组合物。
本公开所述药物组合物已具有足够成药稳定性，可以长期稳定放置。
本公开还提供一种制备包含配体-药物偶联物(如抗CD79b抗体药物偶联物)的药物组合物的冻干制剂的方法，所述方法包括将前述药物组合物经冷冻干燥的步骤。
本公开还提供一种包含配体-药物偶联物(如抗CD79b抗体药物偶联物)的药物组合物的冻干制剂，所述冻干制剂通过将前面任一所述的药物组合物经冷冻干燥获得。
在一些实施方案中，冻干制剂于2-8℃避光保存，稳定至少1个月，至少3个月，至少6个月，至少12个月，至少18个月，至少24个月，至少30个月。
在一些实施方案中，所述冻干制剂于25℃稳定至少1个月，至少3个月，至少6个月，至少12个月。
在一些实施方案中，所述冻干制剂于40℃稳定至少7天，至少14天或至少30天。
本公开还提供一种包含配体-药物偶联物(如前述本公开的抗CD79b抗体药物偶联物)药物组合物的复溶溶液，所述复溶溶液是通过将前述任一项的冻干制剂经复溶制备获得。
本公开进一步提供一种制品，其包括容器，该容器中装有如上任一项所述的药物组合物、液体制剂、冻干制剂或复溶溶液。在一些实施方案中，所述容器可以为但不限于中性硼硅玻璃管制注射剂瓶。
本公开还提供如上任一项所述的药物组合物、如上任一项的液体制剂、如上任一项的冻干制剂、如上任一项的复溶溶液或如上任一项所述的制品在制备用于治疗或预防增殖性疾病或延缓增殖性疾病进展的药物中的用途。
本公开还提供如上任一项所述的药物组合物、如上任一项的液体制剂、如上任一项的冻干制剂、如上任一项的复溶溶液或如上任一项所述的制品，其用作治疗或预防增殖性疾病或延缓增殖性疾病进展的用途。
在一些实施方案中，如上任一项所述增殖性疾病可以是癌症或肿瘤；所述癌症或肿瘤选自淋巴瘤、弥漫大B细胞淋巴瘤、非何杰金氏淋巴瘤(NHL)、攻击性NHL、复发性攻击性NHL、复发性无痛性NHL、顽固性NHL、顽固性无痛性NHL、慢性淋巴细胞性白血病(CLL)、小淋巴细胞性淋巴瘤、白血病、毛细胞白血病(HCL)、急性淋巴细胞性白血病(ALL)，和/或套细胞淋巴瘤。
本公开提供一种治疗或预防增殖性疾病或延缓增殖性疾病进展的方法，包括向有需要的受试者施用治疗或预防有效量的如上任一项所述的药物组合物、如上任一项的液体制剂、如上任一项的冻干制剂、如上任一项的复溶溶液或如上任一项所述的制品，其中：所述增殖性疾病可以是癌症或肿瘤；所述癌症或肿瘤选自淋巴瘤、弥漫大B细胞淋巴瘤、非何杰金氏淋巴瘤(NHL)、攻击性NHL、复发性攻击性NHL、复发性无痛性NHL、顽固性NHL、顽固性无痛性NHL、慢性淋巴细胞性白血病(CLL)、小淋巴细胞性淋巴瘤、白血病、毛细胞白血病(HCL)、急性淋巴细胞性白血病(ALL)，和/或套细胞淋巴瘤。
本公开提供一种在具有B细胞增殖性病症或自身免疫性病症的受试者中增强免疫功能的方法，包括向有需要的受试者施用治疗或延缓疾病有效量的如上任一项所述的药物组合物、如上任一项的液体制剂、如上任一项的冻干制剂、如上任一项的复溶溶液或如上任一项所述的制品，其中：所述B细胞增殖性病症为癌症或肿瘤；所述B细胞增殖性病症为淋巴瘤，非何杰金氏淋巴瘤(NHL)，攻击性NHL，复发性攻击性NHL，复发性无痛性NHL，顽固性NHL，顽固性无痛性NHL，慢性淋巴细胞性白血病(CLL)，小淋巴细胞性淋巴瘤，白血病，毛细胞白血病(HCL)，急性淋巴细胞性白血病(ALL)，和/或套细胞淋巴瘤。
附图说明
图1:A-C为不同ADC对人弥漫性大B细胞淋巴瘤WSU-DLCL2裸小鼠皮下移植瘤的疗效。
图2：不同ADC对荷瘤裸小鼠体重的影响结果图。
图3：不同ADC对人弥漫性大B细胞淋巴瘤WSU-DLCL2裸小鼠皮下移植瘤的疗效。
图4：不同ADC对WSU-DLCL2荷瘤裸小鼠体重的影响。
图5：不同ADC对人弥漫性大B细胞淋巴瘤WSU-DLCL2裸小鼠皮下移植瘤的疗效的肿瘤照片。
图6：不同ADC对人滤泡性淋巴瘤DOHH-2裸小鼠皮下移植瘤的疗效。
图7：不同ADC对DOHH-2荷瘤裸小鼠体重的影响。
图8：ADC组合物制剂缓冲体系pH值的筛选，图8A、8B分别为不同pH/缓冲液条件下SEC、RCE变化趋势。
图9：ADC组合物辅料和表面活性剂筛选，图9A、9B分别为不同pH/缓冲液条件下SEC、RCE变化趋势。
图10：ADC组合物pH细筛和聚山梨酯80浓度筛选，图10A、10B分别为不同pH/缓冲液条件下SEC、RCE变化趋势。
其中，ADC-1、ADC-2、ADC-4均为本公开筛选获得的其他抗CD79b抗体药物偶联物，具体结构未示出。
具体实施方式
术语
为了更容易理解本公开，以下具体定义了某些技术和科学术语。除非在本文中另有明确定义，本文使用的所有其它技术和科学术语都具有本公开所属领域的一般技术人员通常理解的含义。
“抗体药物偶联物(antibody drug conjugate，ADC)”是把抗体或者抗体片段通过稳定的化学接头化合物与具有生物活性的细胞毒素或具有细胞杀伤活性的小分子药物相连，充分利用了抗体对肿瘤细胞特异或高表达抗原结合的特异性和细胞毒素的高效性，避免对正常细胞的毒副作用。与以往传统的化疗药物相比，抗体药物偶联物能精准地结合肿瘤细胞并降低将对正常细胞的影响。
“缓冲剂”指通过其酸-碱共轭组分的作用而耐受pH变化的缓冲剂。将pH控制在适当范围中的缓冲剂的例子包括醋酸盐、琥珀酸盐、葡萄糖酸盐、组氨酸、草酸盐、乳酸盐、磷酸盐、柠檬酸盐、酒石酸盐、延胡索酸盐、甘氨酰甘氨酸和其它有机酸缓冲剂。
“组氨酸盐缓冲剂”是包含组氨酸离子的缓冲剂。组氨酸盐缓冲剂的实例包括组氨酸-盐酸盐，组氨酸-醋酸盐，组氨酸-磷酸盐，组氨酸-硫酸盐等缓冲剂，优选组氨酸-盐酸盐缓冲剂。组氨酸-盐酸盐缓冲剂是组氨酸与盐酸或组氨酸与组氨酸盐酸盐配制而成。
“Tris-柠檬酸盐缓冲剂”是包括柠檬酸根离子的缓冲剂。Tris-柠檬酸盐缓冲剂的实例包括组Tris-盐酸盐，Tris-醋酸盐，Tris-磷酸盐，Tris-硫酸盐，Tris-柠檬酸盐等缓冲剂等，优选Tris-柠檬酸盐。
“Tris-盐酸盐缓冲剂”是包括盐酸根离子的缓冲剂。Tris-盐酸盐缓冲剂的实例包括Tris-盐酸盐，Tris-醋酸盐，Tris-磷酸盐，Tris-硫酸盐，Tris-柠檬酸盐等缓冲剂等。优选的柠檬酸盐缓冲剂为Tris-盐酸盐缓冲剂。
“磷酸盐缓冲剂”是包括磷酸离子的缓冲剂。磷酸盐缓冲剂的实例包括磷酸氢二钠酸- 磷酸二氢钠、磷酸氢二钠酸-磷酸二氢钾等。优选的磷酸盐缓冲剂为磷酸氢二钠酸-磷酸二氢钠缓冲剂。
“醋酸盐缓冲剂”是包括醋酸根离子的缓冲剂。醋酸盐缓冲剂的实例包括醋酸-醋酸钠、醋酸-组氨酸盐、醋酸-醋酸钾、醋酸-醋酸钙、醋酸-醋酸镁等。优选的醋酸盐缓冲剂为醋酸-醋酸钠缓冲剂。
“琥珀酸盐缓冲剂”是包括琥珀酸根离子的缓冲剂。琥珀酸盐缓冲剂的实例包括琥珀酸-琥珀酸钠、琥珀酸-琥珀酸钾、琥珀酸-琥珀酸钙盐等。优选的琥珀酸盐缓冲剂是琥珀酸-琥珀酸钠。示例性的，所述的琥珀酸-琥珀酸钠可由琥铂酸与氢氧化钠配制而成，或由琥铂酸与琥珀酸钠配制而成。
“药物组合物”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其他化学组分的混合物，所述其他组分例如生理学/可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药，利于活性成分的吸收进而发挥生物活性。本文中，“药物组合物”和“制剂”并不互相排斥。
本公开中所述药物组合物的溶液形式，若无特殊说明，其中的溶剂均为水。
本文所用术语“约”是指数值在由本领域一般技术人员所测定的具体值的可接受误差范围内，所述数值部分取决于怎样测量或测定(即测量体系的限度)。例如，在本领域每一次实行中“约”可意味着在1内或超过1的标准差。或者，“约”或“基本上包含”可意味着至多20％的范围。此外，特别对于生物学系统或过程而言，该术语可意味着至多一个数量级或数值的至多5倍。除非另外说明，否则当具体值在本申请和权利要求中出现时，“约”或“基本上包含”的含义应该假定为在该具体值的可接受误差范围内。
本公开所述的药物组合物能够达到一种稳定的效果：其中的抗体在贮藏后基本上保留其物理稳定性和/或化学稳定性和/或生物学活性，优选地，药物组合物在贮藏后基本上保留其物理和化学稳定性以及其生物学活性。贮藏期一般基于药物组合物的预定保存期来选择。目前有多种测量蛋白质稳定性的分析技术，可测量在选定温度贮藏选定时间段后的稳定性。
稳定的药物抗体制剂是在下述情况下没有观察到显著变化的制剂：在冷藏温度(2-8℃)保存至少3个月、优选6个月、更优选1年，且甚至更优选地最多达2年。另外，稳定的液体制剂包括这样的液体制剂：其在包括25℃保存包括1个月、3个月、6个月或在40℃保存1个月在内的时段后表现出期望的特征。稳定性的典型的可接受的标准如下：通过SEC-HPLC测得，通常不超过约10％、优选不超过约5％的抗体单体发生降解。通过视觉分析，药物抗体制剂是无色或黄色、澄清至微乳光。所述制剂的浓度、pH和重量克分子渗透压浓度具有不超过±10％变化。通常观察到不超过约10％、优选不超过约5％的截短，通常形成不超过约10％、优选不超过约5％的聚集。
如果在目检颜色和/或澄清度后，或者通过UV光散射、尺寸排阻色谱法(SEC)和动态光散射(DLS)测得，抗体没有显示出显著的聚集增加、沉淀和/或变性，那么所述抗体在药物制剂中“保留它的物理稳定性”。蛋白构象的变化可以通过荧光光谱法(其确定蛋白三级结构)和通过FTIR光谱法(其确定蛋白二级结构)来评价。
如果抗体没有显示出显著的化学改变，那么所述抗体在药物制剂中“保留它的化学稳 定性”。通过检测和定量化学上改变的形式的蛋白，可以评估化学稳定性。经常改变蛋白化学结构的降解过程包括水解或截短(通过诸如尺寸排阻色谱法和SDS-PAGE等方法来评价)、氧化(通过诸如与质谱法或MALDI/TOF/MS结合的肽谱法等方法来评价)、脱酰胺作用(通过诸如离子交换色谱法、毛细管等电聚焦、肽谱法、异天冬氨酸测量等方法来评价)和异构化(通过测量异天冬氨酸含量、肽谱法等来评价)。
如果抗体在给定时间的生物活性是在制备药物制剂时表现出的生物活性的预定范围内，那么所述抗体在药物制剂中“保留它的生物活性”。抗体的生物活性可以例如通过抗原结合测定来确定。
本公开工程化的抗体或抗原结合片段可用常规方法制备和纯化。比如，编码重链和轻链的cDNA序列，可以克隆并重组至GS表达载体。重组的免疫球蛋白表达载体可以稳定地转染CHO细胞。作为一种更推荐的现有技术，哺乳动物类表达系统会导致抗体的糖基化，特别是在Fc区的高度保守N端位点。通过表达与人FXI特异性结合的抗体得到稳定的克隆。阳性的克隆在生物反应器的无血清培养基中扩大培养以生产抗体。分泌了抗体的培养液可以用常规技术纯化。比如，用含调整过的缓冲剂的A或G Sepharose FF柱进行纯化。洗去非特异性结合的组分。再用pH梯度法洗脱结合的抗体，用SDS-PAGE检测抗体片段，收集。抗体可用常规方法进行过滤浓缩。可溶的混合物和多聚体，也可以用常规方法去除，比如分子筛、离子交换。得到的产物需立即冷冻，如-70℃，或者冻干。
本申请所用氨基酸三字母代码和单字母代码如J.Biol.Chem，243，p3558(1968)中所述。
本申请所述的术语“抗体”以最广义使用，涵盖各种抗体结构。示例性的，抗体指免疫球蛋白，是由两条相同的重链和两条相同的轻链通过链间二硫键连接而成的四肽链结构。免疫球蛋白重链恒定区的氨基酸组成和排列顺序不同，故其抗原性也不同。据此，可将免疫球蛋白分为五类，或称为免疫球蛋白的同种型，即IgM、IgD、IgG、IgA和IgE，其相应的重链分别为μ链、δ链、γ链、α链和ε链。同一类Ig根据其铰链区氨基酸组成和重链二硫键的数目和位置的差别，又可分为不同的亚类，如IgG可分为IgG1、IgG2、IgG3、IgG4。轻链通过恒定区的不同分为κ链或λ链。五类Ig中第每类Ig都可以有κ链或λ链。
在本申请中，本申请所述的抗体轻链可变区可进一步包含轻链恒定区，所述的轻链恒定区包含人源或鼠源的κ、λ链或其变体。
在本申请中，本申请所述的抗体重链可变区可进一步包含重链恒定区，所述的重链恒定区包含人源或鼠源的IgG1、2、3、4或其变体。
抗体重链和轻链靠近N端的约110个氨基酸的序列变化很大，为可变区(V区)；靠近C端的其余氨基酸序列相对稳定，为恒定区(C区)。可变区包括3个高变区(HVR)和4个序列相对保守的骨架区(FR)。3个高变区决定抗体的特异性，又称为互补性决定区(CDR)。每条轻链可变区(VL)和重链可变区(VH)由3个CDR区4个FR区组成，从氨基端到羧基端依次排列的顺序为：FR1，CDR1，FR2，CDR2，FR3，CDR3，FR4。轻链的3个CDR区指LCDR1，LCDR2，和LCDR3；重链的3个CDR区指HCDR1，HCDR2和HCDR3。所述的抗体或抗原结合片段的VL区和VH区的CDR氨基酸残基在数量和位置符合已知的 Chothia(ABM)编号规则。
术语“重组人抗体”包括通过重组方法制备、表达、创建或分离的人抗体，所涉及的技术和方法在本领域中是熟知的，诸如：
(1)从人免疫球蛋白基因的转基因、转染色体动物(例如小鼠)或由其制备的杂交瘤中分离的抗体；
(2)从经转化以表达抗体的宿主细胞如转染瘤中分离的抗体；
(3)从重组组合人抗体文库中分离的抗体；以及
(4)通过将人免疫球蛋白基因序列剪接到其他DNA序列等方法制备、表达、创建或分离的抗体。
此类重组人抗体包含可变区和恒定区，这些区域利用特定的由种系基因编码的人种系免疫球蛋白序列，但也包括随后诸如在抗体成熟过程中发生的重排和突变。
术语“鼠源抗体”在本申请中为根据本领域知识和技能制备的对人CD79b或其表位的单克隆抗体。制备时用CD79b抗原注射试验对象，然后分离表达具有所需序列或功能特性的抗体的杂交瘤。在本申请一个具体的实施方案中，所述的鼠源CD79b抗体或其抗原结合片段，可进一步包含鼠源κ、λ链或其变体的轻链恒定区，或进一步包含鼠源IgG1、IgG2、IgG3或IgG4或其变体的重链恒定区。
术语“人抗体”包括具有人种系免疫球蛋白序列的可变和恒定区的抗体。本申请的人抗体可包括不由人种系免疫球蛋白序列编码的氨基酸残基(如通过体外随机或位点特异性诱变或通过体内体细胞突变所引入的突变)。然而，术语“人抗体”不包括这样的抗体，即其中已将衍生自另一种哺乳动物物种(诸如小鼠)种系的CDR序列移植到人骨架序列上(即“人源化抗体”)。
术语“人源化抗体(humanized antibody)”，也称为CDR移植抗体(CDR-grafted antibody)，是指将小鼠的CDR序列移植到人的抗体可变区框架中产生的抗体。可以克服嵌合抗体由于携带大量小鼠蛋白成分，从而诱导的强烈的免疫应答反应。为避免在免疫原性下降的同时引起活性的下降，可对所述的人抗体可变区可进行最少反向突变，以保持活性。
术语“嵌合抗体(chimeric antibody)”，是将鼠源性抗体的可变区与人抗体的恒定区融合而成的抗体，可以减轻鼠源性抗体诱发的免疫应答反应。建立嵌合抗体，要选建立分泌鼠源性特异性单抗的杂交瘤，然后从小鼠杂交瘤细胞中克隆可变区基因，再要据需要克隆人抗体的恒定区基因，将小鼠可变区基因与人恒定区基因连接成嵌合基因后插入人载体中，最后在真核工业系统或原核工业系统中表达嵌合抗体分子。人抗体的恒定区可选自人源IgG1、IgG2、IgG3或IgG4或其变体的重链恒定区，优选包含人源IgG2或IgG4重链恒定区，或者使用氨基酸突变后无ADCC(antibody-dependent cell-mediated cytotoxicity，抗体依赖的细胞介导的细胞毒作用)毒性的IgG1。
本申请中所述的“抗原结合片段”，指具有抗原结合活性的Fab片段，Fab’片段，F(ab’)2片段，以及与人CD79b结合的Fv片段sFv片段。Fv片段含有抗体重链可变区和轻链可变区，但没有恒定区，并具有全部抗原结合位点的最小抗体片段。一般地，Fv抗体还包含在VH和VL结构域之间的多肽接头，且能够形成抗原结合所需的结构。也可以用不同的连 接物将两个抗体可变区连接成一条多肽链，称为单链抗体(single chain antibody)或单链Fv(sFv)。
术语“单链抗体”、“单链Fv”或“scFv”意指包含通过接头连接的抗体重链可变结构域(或区域；VH)和抗体轻链可变结构域(或区域；VL)的分子。此类scFv分子可具有一般结构：NH2-VL-接头-VH-COOH或NH2-VH-接头-VL-COOH。合适的现有技术接头由重复的GGGGS氨基酸序列或其变体组成，例如使用1-4个重复的变体(Holliger等人(1993)，Proc.Natl.Acad.Sci.USA90:6444-6448)。可用于本公开的其他接头由Alfthan等人(1995)，Protein Eng.8:725-731，Choi等人(2001)，Eur.J.Immuno l.31:94-106，Hu等人(1996)，Cancer Res.56:3055-3061，Kipriyanov等人(1999)，J.Mol.Biol.293:41-56和Roovers等人(2001)，Cancer Immunol.描述。
术语“CDR”是指抗体的可变结构域内主要促成抗原结合的6个高变区之一。所述6个CDR的最常用的定义之一由Kabat E.A.等人，(1991)Sequences of proteins of immunological interest.NIH Publication91-3242)提供。如本文中使用的，CDR的Kabat定义只应用于轻链可变结构域的CDR1、CDR2和CDR3(CDR L1、CDR L2、CDR L3或L1、L2、L3)，以及重链可变结构域的CDR2和CDR3(CDR H2、CDR H3或H2、H3)。通常，每个重链可变区中存在三个CDR(HCDR1、HCDR2、HCDR3)，每个轻链可变区中存在三个CDR(LCDR1、LCDR2、LCDR3)。可以使用各种公知方案中的任何一种来确定CDR的氨基酸序列边界，包括“Kabat”编号规则(参见Kabat等(1991)，“Sequences of Proteins of Immunological Interest”，第5版，Public Health Service，National Institutes of Health，Bethesda，MD)、“Chothia”编号规则(参见Al-Lazikani等人，(1997)JMB 273：927-948)和ImMunoGenTics(IMGT)编号规则(Lefranc M.P.，Immunologist，7，132-136(1999)；Lefranc，M.P.等，Dev.Comp.Immunol.，27，55-77(2003)等。例如，对于经典格式，遵循Kabat规则，所述重链可变域(VH)中的CDR氨基酸残基编号为31-35(HCDR1)、50-65(HCDR2)和95-102(HCDR3)；轻链可变域(VL)中的CDR氨基酸残基编号为24-34(LCDR1)、50-56(LCDR2)和89-97(LCDR3)。遵循Chothia规则，VH中的CDR氨基酸编号为26-32(HCDR1)、52-56(HCDR2)和95-102(HCDR3)；并且VL中的氨基酸残基编号为26-32(LCDR1)、50-52(LCDR2)和91-96(LCDR3)。通过组合Kabat和Chothia两者的CDR定义，CDR由人VH中的氨基酸残基26-35(HCDR1)、50-65(HCDR2)和95-102(HCDR3)和人VL中的氨基酸残基24-34(LCDR1)、50-56(LCDR2)和89-97(LCDR3)构成。遵循IMGT规则，VH中的CDR氨基酸残基编号大致为26-35(CDR1)、51-57(CDR2)和93-102(CDR3)，VL中的CDR氨基酸残基编号大致为27-32(CDR1)、50-52(CDR2)和89-97(CDR3)。遵循IMGT规则，抗体的CDR区可以使用程序IMGT/DomainGap Align确定。
术语“抗体框架”，是指可变结构域VL或VH的一部分，其用作该可变结构域的抗原结合环(CDR)的支架。从本质上讲，其是不具有CDR的可变结构域。
本申请的术语“与CD79b结合”，指能与CD79b或其表位相互作用，所述CD79b或其表位可以是人源的。本申请的术语“抗原结合位点”指抗原上不连续的，由本申请抗体或抗原结合片段识别的三维空间位点。
术语“表位”或“抗原决定簇”是指抗原上免疫球蛋白或抗体特异性结合的部位。表位通常以独特的空间构象包括至少3，4，5，6，7，8，9，10，11，12，13，14或15个连续或非连续的氨基酸。参见，例如，Epitope Mapping Protocols in Methods in Molecular B iology，第66卷，G.E.Morris，Ed.(1996)。
术语“特异性结合”、“选择性结合”、“选择性地结合”和“特异性地结合”是指抗体对预先确定的抗原上的表位的结合。通常，抗体以大约小于10-7M，例如大约小于10-8M、10-9M或10-10M或更小的亲和力(KD)结合。
氨基酸序列“同一性”指在比对氨基酸序列及必要时引入间隙，以达成最大序列同一性百分比，且不将任何保守性取代视为序列同一性的一部分，第一序列中与第二序列中的氨基酸残基同一的氨基酸残基的百分比。为测定氨基酸序列同一性百分比的目的，比对可以通过属于本领域技术的范围内的多种方式来实现，例如使用公开可得到的计算机软件，诸如BLAST、BLAST-2、ALIGN、ALIGN-2或Megalign(DNASTAR)软件。本领域技术人员可确定适用于测量比对的参数，包括在所比较的序列全长上达成最大比对所需的任何算法。
术语“交叉反应”是指本申请的抗体与来自不同物种的CD79b结合的能力。例如，结合人CD79b的本申请的抗体也可以结合另一物种的CD79b。交叉反应性是通过在结合测定(例如SPR和ELISA)中检测与纯化抗原的特异性反应性，或与生理表达CD79b的细胞的结合或功能性相互作用来测量。确定交叉反应性的方法包括如本文所述的标准结合测定，例如表面等离子体共振分析，或流式细胞术。
术语“抑制”或“阻断”可互换使用，并涵盖部分和完全抑制/阻断这两者。对CD79b的抑制/阻断优选地降低或改变无抑制或阻断的情况下发生CD79b结合时出现活性的正常水平或类型。抑制和阻断也旨在包括与抗CD79b抗体接触时，与未与抗CD79b抗体接触的CD79b相比，任何可测量的CD79b结合亲和力降低。
术语“抑制生长”(例如涉及细胞)旨在包括细胞生长任何可测量的降低。
术语“诱导免疫应答”和“增强免疫应答”可互换使用，并指免疫应答对特定抗原的剌激(即，被动或适应性的)。针对诱导CDC或ADCC的术语“诱导”是指剌激特定的直接细胞杀伤机制。
本申请中所述的“ADCC”，即antibody-dependent cell-mediated cytotoxicity，抗体依赖的细胞介导的细胞毒作用，是指表达Fc受体的细胞通过识别抗体的Fc段直接杀伤被抗体包被的靶细胞。可通过对IgG上Fc段的修饰，降低或消除抗体的ADCC效应功能。所述的修饰指在抗体的重链恒定区进行突变，如选自IgG1的N297A、L234A、L235A；IgG2/4嵌合，IgG4的F235E、或L234A/E235A突变。
术语“连接子、接头单元、接头或连接片段”是指一端与配体连接而另一端与药物相连的化学结构片段或键，也可以连接其他接头后再与药物相连。
接头可以包含一种或多种接头构件。例示性的接头构件包括6-马来酰亚氨基己酰基(“MC”)、马来酰亚氨基丙酰基(“MP”)、缬氨酸-瓜氨酸(“val-cit”或“vc”)、丙氨酸-苯丙氨酸(“ala-phe”)、对氨基苄氧羰基(“PAB”)、及那样源自与接头试剂的偶联的：N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯(“SPP”)、N-琥珀酰亚氨基4-(N-马来酰亚氨基甲基) 环己烷-1羧酸酯(“SMCC”，在本文中也称作“MCC”)和N-琥珀酰亚氨基(4-碘-乙酰基)氨基苯甲酸酯(“SIAB”)。接头可以包括拉伸单元、间隔单元、氨基酸单元和延伸单元，可以通过本领域已知方法合成，诸如US2005-0238649A1中所记载的。接头可以是便于在细胞中释放药物的“可切割接头”。例如，可使用酸不稳定接头(例如腙)、蛋白酶敏感(例如肽酶敏感)接头、光不稳定接头、二甲基接头、或含二硫化物接头(Chari等,Cancer Research 52:127-131(1992)；美国专利No.5,208,020)。
术语“氨基酸单元”是指如果存在延伸单元的情况下，可以将以下结构式YR中的羰基与延伸单元相连，如果没有延伸单元的情况下，可以将YR直接连接在细胞毒性药物上的氨基酸，在本公开实施方式中，氨基酸单元表示为-Kk-：
-Kk-是二肽、三肽、四肽、五肽、六肽、七肽、八肽、九肽或十肽，-K-单元各自独立地具有以下结构式Ka或Kb，k是0-10之间的一个整数：
其中：
上述氨基酸单元中的R23为-H或甲基；
R24为H、甲基、异丙基、异丁基、仲丁基、苄基、对羟基苄基、-CH2OH、-CH(OH)CH3、-CH2CH2SCH3、-CH2CONH2、-CH2COOH、-CH2CH2CONH2、-CH2CH2COOH、-(CH2)3NHC(＝NH)NH2、-(CH2)3NH2、-(CH2)3NHCOCH3、-(CH2)3NHCHO、-(CH2)4NHC(＝NH)NH2、-(CH2)4NH2、-(CH2)4NHCOCH3、-(CH2)4NHCHO、-(CH2)3NHCONH2、-(CH2)4NHCONH2、-CH2CH2CH(OH)CH2NH2、2-吡啶基甲基-、3-吡啶基甲基-、4-吡啶基甲基-、苯基、环己基，
R25为-芳基-、-烷基-芳基-、-环烷基-、-烷基-环烷基-、-环烷基-烷基-、-烷基-环烷基-烷基-、-杂环基-，-烷基-杂环基-、-杂环基-烷基-、-烷基-杂环基-烷基-、-芳基-、-烷基-芳基-、-芳基-烷基-、-烷基-芳基-烷基-、-杂芳基-、-烷基-杂芳基-、-杂芳基-烷基-、-烷基-杂芳基-烷基-。
在一个实施方案中，-Kk-为二肽，优选为-缬氨酸-瓜氨酸-、-苯丙氨酸-赖氨酸-或-N-甲基缬氨酸-瓜氨酸-，进一步优选为-缬氨酸-瓜氨酸-。
术语“拉伸单元”指一端通过碳原子与配体共价连接而另一端通过硫原子与细胞毒性药物相连的化学结构片段。
术语“间隔单元”是一种双功能化合结构片段，可用于偶联连接单元和细胞毒性药物最终形成配体-细胞毒性药物偶联物，这种偶联方式可以将细胞毒性药物选择性的连接到连接单元上。
术语“延伸单元”是指当氨基酸单元存在的情况下，可以将氨基酸单元与细胞毒性药物偶联，或当氨基酸单元不存在时，可通过与YR上羰基与细胞毒性药物偶联的化学结构。在本公开实施方式中，延伸单元表示为-Qq-，q选自0，1，2。
本公开中延伸单元为PAB，结构如4-亚氨基苄基氨甲酰基片段，其结构如式下式所示，连接在D上，
缩写
接头组件包括但不限于：
MC＝6-马来酰亚氨基己酰基，结构如下：
Val-Cit或“vc”＝缬氨酸-瓜氨酸(蛋白酶可切割接头中的例示二肽)
瓜氨酸＝2-氨基-5-脲基戊酸
PAB＝对氨基苄氧羰基(“自我牺牲”接头组件的例示)
Me-Val-Cit＝N-甲基-缬氨酸-瓜氨酸(其中接头肽键已经修饰以防止其受到组织蛋白酶B的切割)
MC(PEG)6-OH＝马来酰亚氨基己酰基-聚乙二醇(可附着于抗体半胱氨酸)
SPP＝N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯
SPDP＝N-琥珀酰亚氨基3-(2-吡啶基二硫代)丙酸酯
SMCC＝琥珀酰亚氨基-4-(N-马来酰亚氨基甲基)环己烷-1-羧酸酯
IT＝亚氨基硫烷
PBS＝磷酸缓冲盐溶液
术语“载药量”是指ADC中每个配体上加载的细胞毒性药物平均数量，也可以表示为药物量和抗体量的比值，药物载量的范围可以是每个抗体(Pc)连接1-20个，优选1-10个细胞毒性药物(D)。在本公开的实施方式中，载药量表示为n或k，示例性的为1，2，3，4，5，6，7，8，9，10，11，12，13，14，15，16，17，18，19，20或任意两数值之间数值的 均值。优选1-10，更优选1-8，或1-8，或1-7，或2-8，或2-7，或2-6，或2-5，或2-3，或1-2，或2-4，或1-4，或1-5，或1-6，或3-8，或3-7，或3-6，或4-7，或4-6，或4-5的均值。可用常规方法如UV/可见光光谱法，质谱，ELISA试验、单抗分子大小变异体测定法(CE-SDS)和HPLC特征鉴定偶联反应后每个ADC分子的药物品均数量。
本公开单抗分子大小变异体测定法(CE-SDS)可采用十二烷基硫酸钠毛细管电泳(CE-SDS)紫外检测方法，在还原和非还原条件下，依据分子量大小，按毛电泳法(2015年版《中国药典》0542)，定量测定重组单克隆抗体产品的纯度。
本公开的一个实施方式中，细胞毒性药物通过连接单元偶联在配体的N端氨基和/或赖氨酸残基的ε-氨基上，一般地，偶联反应中能与抗体偶联的药物分子数将小于理论上的最大值。
可以用以下非限制性方法控制配体细胞毒性药物偶联物的载量，包括：
(1)控制连接试剂和单抗的摩尔比，
(2)控制反应时间和温度，
(3)选择不同的反应试剂。
虽然对于特定缀合物分子而言，药物对抗体比率具有确切值(例如，在式(I)中为n)，但是应理解当用来描述含有许多分子的样品时，该值将经常是平均值，这归因于典型地与缀合步骤相关的某种程度的非均匀性。免疫缀合物样品的平均载量在本文中称为药物对抗体比率或“DAR”。在一些实施例中，DAR在约1与约6之间，并且典型地是约1、1.5、2、2.5、3、3.5、4、4.5、5、5.5、6、6.5、7.0、7.5、8.0。在一些实施例中，按重量计至少50％的样品是具有平均DAR加或减2的化合物，并且优选地至少50％的样品是含有平均DAR加或减1的缀合物。实施例包括其中DAR是约1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8、1.9、2.0、2.1、2.2、。2.3、2.4、2.5、2.6、2.7、2.8、2.9、3.0、3.1、3.2、3.3、3.4、3.5、3.6、3.7、3.8、3.9、4.0、4.1、4.2、4.3、4.4、4.5、4.6、4.7、4.8、4.9、5.0、5.1、5.2、5.4、5.4、5.5、5.6、5.7、5.8、5.9、6.0、6.1、6.2、6.3、6.4、6.5、6.6、6.7、6.8、6.9、7.0的免疫缀合物。在一些实施例中，‘约为x’的DAR意指DAR的测量值在x的20％内。
DAR的检测方法例如，从还原和去糖基化样品的LC-MS数据外推出DAR值。LC/MS允许定量ADC中连接至抗体的有效负载(药物部分)分子的平均数。HPLC将抗体分离成轻链和重链，并且还根据每条链的接头-有效负载基团的数量分离重链(HC)和轻链(LC)。质谱数据能够鉴定混合物中的组分种类，例如LC、LC+1、LC+2、HC、HC+1、HC+2等。根据LC和HC链的平均负载量，可以计算ADC的平均DAR。给定免疫缀合物样品的DAR表示连接至含有两条轻链和两条重链的四聚体抗体的药物(有效负载)分子的平均数。例如WO2018142322中的DAR检测方法。
术语“烷基”指饱和脂肪族烃基团，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子的烷基，更优选含有1至10个碳原子的烷基，最优选含有1至6个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、 4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基，及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基，非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基。
术语“杂烷基”指含有一个或多个选自N、O或S的杂原子的烷基，其中烷基如上所定义。
术语“亚烷基”指饱和的直链或支链脂肪族烃基，其具有2个从母体烷的相同碳原子或两个不同的碳原子上除去两个氢原子所衍生的残基，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子，更优选含有1至6个碳原子的亚烷基。亚烷基的非限制性实例包括但不限于亚甲基(-CH2-)、1,1-亚乙基(-CH(CH3)-)、1,2-亚乙基(-CH2CH2)-、1,1-亚丙基(-CH(CH2CH3)-)、1,2-亚丙基(-CH2CH(CH3)-)、1,3-亚丙基(-CH2CH2CH2-)、1,4-亚丁基(-CH2CH2CH2CH2-)和1,5-亚丁基(-CH2CH2CH2CH2CH2-)等。亚烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选独立地任选选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基和氧代基中的一个或多个取代基所取代。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基)，其中烷基或环烷基的定义如上所述。烷氧基的非限制性实例包括：甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基，环烷基环包含3至20个碳原子，优选包含3至12个碳原子，更优选包含3至10个碳原子，最优选包含3至8个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等；多环环烷基包括螺环、稠环和 桥环的环烷基。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基，其包含3至20个环原子，其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子，但不包括-O-O-、-O-S-或-S-S-的环部分，其余环原子为碳。优选包含3至12个环原子，其中1～4个是杂原子；更优选环烷基环包含3至10个环原子。单环杂环基的非限制性实例包括吡咯烷基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基等。多环杂环基包括螺环、稠环和桥环的杂环基。
术语“螺杂环基”指5至20元的单环之间共用一个原子(称螺原子)的多环杂环基团，其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子，其余环原子为碳。其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。例如为6至14元，又例如为7至10元。根据环与环之间共用螺原子的数目将螺杂环基分为单螺杂环基、双螺杂环基或多螺杂环基，优选为单螺杂环基和双螺杂环基。例如为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺杂环基。螺杂环基的非限制性实例包括：
术语“稠杂环基”指5至20元，系统中的每个环与体系中的其他环共享毗邻的一对原子的多环杂环基团，一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统，其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子，其余环原子为碳。例如为6至14元，又例如为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠杂环基，例如为双环或三环，又例如为5元/5元或5元/6元双环稠杂环基。稠杂环基的非限制性实例包括：
术语“桥杂环基”指5至14元，任意两个环共用两个不直接连接的原子的多环杂环基团，其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统，其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子，其余环原子为碳。例如为6至14元，又例如为7至10元。根据组成环的数目可以分为双环、三环、四环或多环 桥杂环基，例如为双环、三环或四环，更优选为双环或三环。桥杂环基的非限制性实例包括：
所述杂环基环可以稠合于芳基、杂芳基或环烷基环上，其中与母体结构连接在一起的环为杂环基，其非限制性实例包括：
等。
杂环基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团，例如为6至10元，例如苯基和萘基，具体例如苯基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为芳基环，其非限制性实例包括：
芳基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系，其中杂原子选自氧、硫和氮。杂芳基优选为5至10元，更优选为5元或6元，例如呋喃基、噻吩基、吡啶基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、咪唑基、四唑基等。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为杂芳基环，其非限制性实例包括：
杂芳基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“氨基保护基”是为了使分子其它部位进行反应时氨基保持不变，用易于脱去的基团对氨基进行保护。非限制性实施例包含9-芴甲氧羰基、叔丁氧羰基、乙酰基、苄基、烯丙基和对甲氧苄基等。这些基团可任选地被选自卤素、烷氧基或硝基中的1-3个取代基所取代。所述氨基保护基优选为9-芴甲氧羰基。
术语“氨基杂环基”指杂环基被一个或多个氨基取代，优选被一个氨基取代，其中杂环基如上所定义，其中“氨基”指-NH2。本公开的代表性实施例如下：
术语“杂环基氨基”指氨基被一个或多个杂环基取代，优选被一个杂环基取代，其中氨基如上所定义，其中杂环基如上所定义。本公开的代表性实施例如下：
术语“环烷基氨基”指氨基被一个或多个环烷基取代，优选被一个环烷基取代，其中氨基如上所定义，其中环烷基如上所定义。本公开的代表性实施例如下：
术语“环烷基烷基”指烷基被一个或多个环烷基取代，优选被一个环烷基取代，其中烷基如上所定义，其中环烷基如上所定义。
术语“卤代烷基”指烷基被一个或多个卤素取代，其中烷基如上所定义。
术语“氘代烷基”指烷基被一个或多个氘原子取代，其中烷基如上所定义。
术语“羟基”指-OH基团。
术语“卤素”指氟、氯、溴或碘。
术语“氨基”指-NH2。
术语“硝基”指-NO2。
化学式中简称“Me”为甲基。
本公开还包括各种氘化形式的化合物。与碳原子连接的各个可用的氢原子可独立地被氘原子替换。本领域技术人员能够参考相关文献合成氘化形式的化合物。在制备氘代形式的化合物时可使用市售的氘代起始物质，或它们可使用常规技术采用氘代试剂合成，氘代试剂包括但不限于氘代硼烷、三氘代硼烷四氢呋喃溶液、氘代氢化锂铝、氘代碘乙烷和氘代碘甲烷等。
另一方面，本公开所述化合物的官能团中氢被氘代，获得相应氘代化合物，氘代化合物保留了与氢类似物相当的选择性和潜力；氘键更稳定，使得“ADME”即“毒药物动力学”不同，从而提供临床上有益效果。毒药物动力学，指机体对外源化学物的吸收(absorption)、分布(distribution)、代谢(metabolism)及排泄(excretion)过程。
“任选”或“任选地”意味着随后所描述的事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生地场合。例如，“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在，该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
“取代的”指基团中的一个或多个氢原子，优选为最多5个，更优选为1～3个氢原子彼此独立地被相应数目的取代基取代。不言而喻，取代基仅处在它们的可能的化学位置，本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如，具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
“给予”和“处理”当应用于动物、人、实验受试者、细胞、组织、器官或生物流体时，是指外源性药物、治疗剂、诊断剂或组合物与动物、人、受试者、细胞、组织、器官或生物流体的接触。“给予”和“处理”可以指例如治疗、药物代谢动力学、诊断、研究和实验方法。细胞的处理包括试剂与细胞的接触，以及试剂与流体的接触，其中所述流体与细胞接触。“给予”和“处理”还意指通过试剂、诊断、结合组合物或通过另一种细胞体外和离体处理例如细胞。“处理”当应用于人、兽医学或研究受试者时，是指治疗处理、预防或预防性措施，研究和诊断应用。
“治疗”意指给予患者内用或外用治疗剂，例如包含本公开的任一种结合化合物的组合物，所述患者具有一种或多种疾病症状，而已知所述治疗剂对这些症状具有治疗作用。通常，在受治疗患者或群体中以有效缓解一种或多种疾病症状的量给予治疗剂，以诱导这类症状退化或抑制这类症状发展到任何临床可测量的程度。有效缓解任何具体疾病症状的治疗剂的量(也称作“治疗有效量”)可根据多种因素变化，例如患者的疾病状态、年龄和体重，以及药物在患者产生需要疗效的能力。通过医生或其它专业卫生保健人士通常用于评价该症状的严重性或进展状况的任何临床检测方法，可评价疾病症状是否已被减轻。尽管本公开的实施方案(例如治疗方法或制品)在缓解每个目标疾病症状方面可能无效，但 是根据本领域已知的任何统计学检验方法如Student t检验、卡方检验、依据Mann和Whitney的U检验、Kruskal-Wallis检验(H检验)、Jonckheere-Terpstra检验和Wilcoxon检验确定，其在统计学显著数目的患者中应当减轻目标疾病症状。
“有效量”包含足以改善或预防医学疾病的症状或病症的量。有效量还意指足以允许或促进诊断的量。用于特定患者或兽医学受试者的有效量可依据以下因素而变化：例如，待治疗的病症、患者的总体健康情况、给药的方法途径和剂量以及副作用严重性。有效量可以是避免显著副作用或毒性作用的最大剂量或给药方案。
实施例
以下结合实施例进一步描述本公开，但这些实施例并非限制着本公开的范围。本公开实施例中未注明具体条件的实验方法，通常按照常规条件，如冷泉港的抗体技术实验手册，分子克隆手册；或按照原料或商品制造厂商所建议的条件。未注明具体来源的试剂，为市场购买的常规试剂。
实施例1、抗CD79b抗体制备
本公开提供抗CD79b抗体，其是使用人CD79b细胞外区域(ECD)免疫小鼠筛选获得，筛选、功能鉴定过程具体参见WO2020156439A。抗体的VH/VL CDR的氨基酸残基由Chothia编号系统确定并注释。小鼠杂交瘤细胞单克隆抗体mAb015及其人源化抗体hAb015-10的序列如下：
>mAb015 VH：
>mAb015 VL：
>hAb015-10 VH：
>hAb015-10 VL：
表1.抗CD79b抗体的CDR序列

>hAb015-10重链：
>hAb015-10轻链：
实施例2、化合物的制备
本公开实施例中未注明具体条件的实验方法，通常按照常规条件，或按照原料或商品制造厂商所建议的条件。未注明具体来源的试剂，为市场购买的常规试剂。
本公开抗体药物偶联物的药物部分参见WO2020063676A、CN202010073671.6、US7098308、US6884869、CN201911390425.7，相关的化合物合成及测试全文引用至本公开。
化合物D的制备方法引自WO2020063676A，例如其实施例9。
实施例、抗CD79b抗体药物偶联物的制备
ADC原液药物载量分析的实验目的及原理：
ADC原液是一种抗体交联物类药物，其治疗疾病的机理是依赖抗体的靶向性将毒素分子运送到细胞中，进而将细胞杀死。药物的载量对药效起着决定性的作用。使用紫外法对ADC原液的药物载量进行了测定。
实验方法
将装有琥珀酸钠缓冲液的比色皿分别置于参比吸收池和样品测定吸收池中后，扣除溶剂空白后，再将装有供试品溶液的比色皿置于样品测定吸收池中，测定280nm和370nm处吸光度。
结果计算：采用紫外分光光度法(使用仪器：Thermo nanodrop2000紫外分光光度计)测定ADC原液载量，其原理是在某波长下ADC原液的总吸光值等于胞毒药物与单克隆抗体在该波长下吸光值的加和，即：
(1)A280nm＝εmab-280bCmab+εDrug-280bCDrug
εDrug-280：药物在280nm平均摩尔消光系数5100；
CDrug：药物的浓度；
εmab-280：单抗原液在280nm平均摩尔消光系数214600；
Cmab：单抗原液的浓度；
b：光程长度为1cm。
同理可以得到样品在370nm下的总吸光值方程：
(2)A370nm＝εmab-370bCmab+εDrug-370bCDrug
εDrug-370：药物在370nm平均摩尔消光系数19000；
CDrug：药物的浓度；
εmab-370：单抗原液在370nm消光系数为0；
Cmab：单抗原液的浓度；
b：光程长度为1cm。
由⑴和⑵两种方程结合单克隆抗体和药物在两个检测波长下的消光系数和浓度数据可以计算出药物的载量。
药物载量＝CDrug/Cmab。
实施例3-1.ADC-3
在37℃条件下，向抗体hAb017-10的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲 水溶液；10.0mg/mL，5.0mL，0.338umol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，85.0uL，0.850umol)，置于水浴振荡器，于37℃振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物MC-vc-PAB-MMAE(4.45mg，3.380umol)溶解于250uL二甲亚砜中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到本实施例标题产物ADC-3(即hAb015-10-cys-MC-vc-PAB-MMAE)的PBS缓冲液(2.79mg/mL，17.4mL)，于4℃冷冻储存。
CE-SDS计算平均值：n＝3.09。
实施例3-2.ADC-5
在37℃条件下，向抗体hAb015-10的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，1.5mL，0.101umol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，16.2uL，0.162umol)，置于水浴振荡器，于37℃振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将本实施例化合物D(0.87mg，0.810umol)溶解于37uL二甲亚砜中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到本实施例标题产物ADC-5(即HAB015-10-cys-D,DAR值约为2)的PBS缓冲液(0.90mg/mL，14.0mL)，于4℃冷冻储存。
RP-HPLC计算平均值：n＝1.81。
实施例3-3.ADC-6
在37℃条件下，向抗体hAb015-10的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，1.5mL，0.101umol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，25.3uL，0.253umol)，置于水浴振荡器，于37℃振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将实施例2中的化合物D(1.09mg，1.015umol)溶解于45uL二甲亚砜中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到本实施例标题产物ADC-6(即hAb015-10-cys-D，DAR值约为4)的PBS缓冲液(0.71mg/mL，14.0mL)，于4℃冷冻储存。
RP-HPLC计算平均值：n＝3.46。
实施例3-4.ADC-7
在37℃条件下，向抗体hAb015-10的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，1.5mL，0.101umol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，50.7uL，0.507umol)，置于水浴振荡器，于37℃振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将实施例2中的化合物D(1.63mg，1.518umol)溶解于68uL二甲亚砜中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到本实施例标题产物ADC-7(即hAb015-10-cys-D,DAR值约为6)的PBS缓冲液(0.81mg/mL，13.5mL)，于4℃冷冻储存。
RP-HPLC计算平均值：n＝5.84。
实施例3-5.ADC-8
在37℃条件下，向抗体SN8的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，79mL，5.338umol)加入配置好的的三(2-羧乙基)膦(TCEP)的水溶液(10mM，1.388mL，13.88umol)，置于水浴振荡器，于37℃振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物MC-VC-PAB-MMAE(70.3mg，53.40umol)溶解于3.5mL二甲亚砜中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH为6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到本实施例标题产物ADC-8(即SN8-cys-MC-PAB-MMAE，DAR值约为4)的PBS缓冲液(5.83mg/mL，132mL)，于4℃冷冻储存。
CE-SDS计算平均值：n＝3.59。
实施例4、生物学评价
实施例4-1.Biacore亲和力实验
采用Biacore测定CD79b抗体(hAb015-10和SN8)和ADC与CD79b蛋白的亲和力。用BIAevaluation version 4.1，GE软件以(1:1)Langmuir模型拟合数据，得出亲和力数值。
亲和力检测结果见表2。针对人CD79b蛋白，裸抗和不同ADC具有类似的结合力，且均高于阳性药Polivy。
其中，SN8(即Polivy中的抗体)序列为：
>SN8重链氨基酸序列
>SN8轻链氨基酸序列
表2.抗体及不同ADC与人CD79b蛋白的结合力
实施例4-2.体外细胞内吞实验
使用高表达人CD79b蛋白的DOHH-2细胞(DSMZ，ACC 47)进行细胞内吞实验评估不同ADC的内吞能力。
由表3数据可知，不同ADC与DoHH2细胞孵育4h的内吞率均大于65％，具有良好的内吞能力。各ADC的内吞率与阳性药Polivy相当。
表3.不同ADC在DoHH2细胞中的内吞作用
实施例4-3.细胞增殖实验
本实施例评价不同ADC对体外培养DoHH2、WSU-DLCL2和Raji细胞增殖的影响。根据文献报道(Leukemia.2015Jul；29(7):1578-86；Blood.2007 Jul 15；110(2):616-23)，DoHH2是CD79b高表达细胞，WSU-DLCL2是CD79b低表达细胞，Raji为CD79b表达阴性细胞。
药物：ADC-3(DAR＝3.59)、ADC-5(DAR＝1.81)、ADC-6(DAR＝3.46)、ADC-7(DAR＝5.84)、ADC-8(DAR＝3.59)；均遮光，4℃密闭保存。
细胞株：DOHH2购自DSMZ，WSU-DLCL-2细胞购自American Type Culture Collection(ATCC)，Raji细胞购自American Type Culture Collection(ATCC)。
接种一定数量的对数生长期细胞于96孔培养板，加入不同浓度的药物作用72小时。药物作用结束后，加入MTT工作液作用4小时，然后加入三联液溶解蓝紫色结晶甲瓒。酶标仪570nm和690nm波长下测定OD值，以下列公式计算细胞生长抑制率：
抑制率＝(对照孔OD570nm-OD690nm－给药孔OD570nm-OD690nm)/对照孔OD570nm-OD690nm×100％
根据各浓度抑制率，用PrismGraph 8计算半数抑制浓度IC50。结果如表4所示。
表4.不同ADC的体外增值抑制活性
实施例4-4.ADC对人弥漫性大B细胞淋巴瘤WSU-DLCL2裸小鼠皮下移植瘤的疗效
药物：ADC-3、ADC-6、ADC-8同实施例4-3。
细胞和小鼠：人弥漫性大B细胞淋巴瘤WSU-DLCL2细胞购自American Type Culture Collection。裸小鼠，BALB/c-nu，35日，♀，购自北京华阜康生物科技股份有限公司。
实验步骤：每只裸小鼠皮下接种2.1×107WSU-DLCL2细胞，待肿瘤生长至100-150mm3后，根据肿瘤体积将动物分组(D0)。小鼠静脉注射(IV)给药，给药体积10mL/kg；具体给药剂量和给药方案见表5。每周测2次肿瘤体积，称小鼠体重，记录数据。
实验指标及统计学分析：
肿瘤体积(V)计算公式为：V＝1/2×a×b2 其中a、b分别表示长、宽。
T/C(％)＝(T-T0)/(C-C0)×100 其中T、C为实验结束时的肿瘤体积；T0、C0为实验开始时的肿瘤体积。其中，T为给药ADC的肿瘤体积，C为给药IgG1作为对照组的肿瘤体积。
肿瘤生长抑制率％(TGI％)＝100-T/C(％)
当肿瘤出现消退时，肿瘤生长抑制率％(TGI％)＝100-(T-T0)/T0×100
如果肿瘤比起始体积缩小，即T<T0或C<C0时，即定义为肿瘤部分消退(PR)；如果肿瘤完全消失，即定义为肿瘤完全消退(CR)。
除非特别说明，二组肿瘤体积之间比较采用two way ANOVA检验，P<0.05定义为有统计学显著性差异。
ADC-3(3mg/kg,IV,D0)对WSU-DLCL2的抑瘤率为76％，有1/6肿瘤部分消退；ADC-6(3mg/kg,IV,D0)对WSU-DLCL2的抑瘤率为86％，有2/6肿瘤部分消退；ADC-8(3mg/kg、10mg/kg,IV,D0)对WSU-DLCL2的抑瘤率分别为39％和93％,10mg/kg剂量组有4/6肿瘤部分消退；荷瘤小鼠对以上药物均能较好耐受，没有明显体重减轻等症状发生。使用IgG1作为阴性对照。
结果请参见表5以及图1、图2。
表5.ADC对人弥漫性大B细胞淋巴瘤WSU-DLCL2裸小鼠皮下移植瘤的疗效

D0:第一次给药时间；P值指与溶剂相比；IV：静脉注射；部分消退：D21肿瘤体积小于D0。
ADC-3、ADC-6和ADC-8的3mg/kg或10mg/kg单次静脉注射均对人弥漫性大B细胞淋巴瘤WSU-DLCL2裸小鼠皮下移植瘤有明显疗效，引起肿瘤部分消退；药物有明显的剂量依赖性，且同等剂量下各hAb015-10偶联ADC药效均优于阳性药ADC-8(即Polivy)。荷瘤小鼠对以上药物均能较好耐受。
实施例4-5.ADC对人弥漫性大B细胞淋巴瘤WSU-DLCL2裸小鼠皮下移植瘤的疗效
药物：ADC-5、ADC-6、ADC-7、ADC-8浓度同实施例4-3。
实验材料、步骤、指标同实施例4-4，统计学分析为：
除非特别说明，二组肿瘤体积之间比较采用双尾Student’s t检验，P<0.05定义为有统计学显著性差异。
ADC-5(3mg/kg、6mg/kg、12mg/kg,IV,D0)对人弥漫性大B细胞淋巴瘤WSU-DLCL2裸小鼠皮下移植瘤的抑瘤率分别为69％、86％和88％，其中6mg/kg和12mg/kg剂量组分别有1/6和1/6肿瘤部分消退；ADC-6(1.5mg/kg、3mg/kg、6mg/kg,IV,D0)对WSU-DLCL2皮下移植瘤的抑瘤率分别为66％、108％和125％，其中3mg/kg和6mg/kg剂量组分别有5/6和6/6肿瘤部分消退；ADC-7(1mg/kg,IV,D0)对WSU-DLCL2皮下移植瘤的抑瘤率为91％,有1/6肿瘤部分消退；ADC-8(3mg/kg,IV,D0)对WSU-DLCL2皮下移植瘤的抑瘤率为10％；荷瘤小鼠对以上药物均能很好耐受，没有体重减轻等症状发生。
具体结果请参见表6和图3至图5。
表6.给药方案和实验结果

其中，D0：第一次给药时间；P值指与溶剂相比；IV：静脉注射。
实施例4-6.ADC对人B细胞淋巴瘤DoHH2裸小鼠皮下移植瘤的疗效
药物：ADC-6、ADC-8浓度同实施例4-3。
细胞和小鼠：人滤泡性淋巴瘤DOHH-2细胞购自德国DSMZ。裸小鼠，BALB/c-nu，4-5周，♀，购自上海灵畅生物科技有限公司。
实验步骤：每只裸小鼠皮下接种3×107DOHH-2细胞，待肿瘤生长至100-150mm3后，根据肿瘤体积将动物分组(D0)。小鼠静脉注射(IV)给药，给药体积10mL/kg；具体给药剂量和给药方案见表7。每周测2次肿瘤体积，称小鼠体重，记录数据。
实验指标及统计学分析同实施例4-3。
ADC-1、ADC-6、ADC-8(1mg/kg,IV,D0)对人滤泡性淋巴瘤DOHH-2裸小鼠皮下移植 瘤的抑瘤率分别为82％(1/6PR)、127％(5/6PR)、41％；荷瘤小鼠对以上药物均能很好耐受，没有明显体重减轻等症状发生。
结果请参见表7以及图6、图7。
表7.不同ADC对人滤泡性淋巴瘤DOHH-2裸小鼠皮下移植瘤的疗效

D0:第一次给药时间；P值指与溶剂相比；IV：静脉注射；部分消退：D21肿瘤体积小于D0。
ADC-6的1mg/kg单次静脉注射均对人滤泡型淋巴瘤DoHH2裸小鼠皮下移植瘤有明显疗效，引起肿瘤部分消退；药效均优于阳性药ADC-8(即Polivy)。荷瘤小鼠对以上药物均能较好耐受。
实施例5至实施例8使用的CD79b抗体药物偶联物为ADC-6，由前述实施例3-3制备获得。
实施例5、ADC组合物制剂缓冲体系pH值的筛选
配制下列缓冲液，制备CD79b抗体药物偶联物(ADC-6)浓度为20mg/mL的抗体制剂，取样品进行高温40℃和冻融稳定性研究。
1)10mM琥珀酸-琥珀酸钠，pH5.0
2)10mM琥珀酸-琥珀酸钠，pH5.5
3)10mM琥珀酸-琥珀酸钠，pH6.0
4)10mM柠檬酸-柠檬酸钠，pH5.0
5)10mM柠檬酸-柠檬酸钠，pH5.5
6)10mM柠檬酸-柠檬酸钠，pH6.0
7)10mM组氨酸-盐酸组氨酸，pH5.5
8)10mM组氨酸-盐酸组氨酸，pH6.0
表8.ADC组合物pH/Buffer筛选结果


注：W表示周；M表示月。
外观结果显示：冻融5次后F1-F8外观均与T0相比无变化；随着pH升高，10mM琥珀酸-琥珀酸钠(F1-F3)与10mM柠檬酸-柠檬酸钠(F4-F6)体系40℃1W样品从无颗粒到有颗粒产生，表明低pH可以抑制颗粒的产生；当pH升高至6.0时，F3、F6处方40℃1W均产生颗粒，而10mM组氨酸-盐酸组氨酸体系(F8)未见明显颗粒，表明10mM组氨酸-盐酸组氨酸体系优于另外两种体系。
SEC(图8A)结果显示：冻融后，SEC与T0相比无明显差异；40℃不同处方均有所下降，其中10mM组氨酸体系较琥珀酸-琥珀酸钠、柠檬酸-柠檬酸钠体系下降程度小。
RCE(图8B)结果显示：冻融后，RCE与T0相比无明显差异；40℃不同处方均有所下降，其中10mM组氨酸体系下降的最慢，其次是10mM琥珀酸体系。
DAR结果显示：冻融和40℃后DAR与T0相比均无明显差异。
综合外观和纯度检项结果，选择10mM琥珀酸-琥珀酸钠pH5.0和10mM组氨酸-盐酸组氨酸pH5.5-6.0体系进行后续考察。
实施例6、ADC组合物辅料和表面活性剂筛选
选择10mM琥珀酸-琥珀酸钠pH5.0体系，制备含20mg/mL抗体药物偶联物(ADC-6)，不同种类和不同浓度辅料及不同浓度表面活性剂的ADC组合物制剂，样品放置-35℃/室温冻融5次、振摇1W(25℃,300rpm)、40℃1W、40℃2W和40℃1M，考察稳定性：
1)10mM琥珀酸-琥珀酸钠pH5.0，60mg/mL蔗糖；
2)10mM琥珀酸-琥珀酸钠pH5.0，90mg/mL蔗糖；
3)10mM琥珀酸-琥珀酸钠pH5.0，60mg/mL海藻糖；
4)10mM琥珀酸-琥珀酸钠pH5.0，90mg/mL海藻糖；
5)10mM琥珀酸-琥珀酸钠pH5.0，0.2mg/mL聚山梨酯80，60mg/mL蔗糖；
6)10mM琥珀酸-琥珀酸钠pH5.0，0.4mg/mL聚山梨酯80，60mg/mL蔗糖；
7)10mM琥珀酸-琥珀酸钠pH5.0，0.6mg/mL聚山梨酯80，60mg/mL蔗糖。
表9.ADC组合物辅料和表面活性剂筛选结果


注：W表示周；M表示月；
外观结果显示：冻融5次外观和T0相比无显著差异；添加聚山梨酯80的处方，振摇1W(25℃,300rpm)后，制剂中都无颗粒产生，表明聚山梨酯80的加入对振摇后处方中颗粒产生有明显改观；40℃2W所有处方都出现颗粒，但添加聚山梨酯80的处方没有絮状物产生。
SEC(图9A)结果显示：40℃不同处方SEC纯度均有所下降，不同的糖种类和浓度(F1-F4)对SEC纯度差异不显著；随着聚山梨酯80浓度(F5-F7)的增加(0.2mg/mL，0.4mg/mL和0.6mg/mL)，SEC纯度逐渐下降。
RCE(图9B)结果显示：40℃不同处方RCE纯度均有所下降，不同的糖浓度(F1-F4)对RCE差异不显著，40℃1M加入海藻糖的处方(F3、F4)RCE略高于加蔗糖(F1、F2)的处方；随着聚山梨酯80浓度(F5-F7)的增加(0.2mg/mL，0.4mg/mL和0.6mg/mL)，RCE纯度逐渐下降。
Free mAb和DAR值结果表明：高温后不同处方Free mAb均有所上升，DAR值均略有下降，不同处方之间无显著差异。
综上所述，10mM琥珀酸-琥珀酸钠pH 5.0体系中，糖种类和浓度对蛋白的外观、SEC、RCE、Free mAb和DAR值差异不显著，考虑到经济成本及人体渗透压，目标辅料为8％蔗糖；在10mM琥珀酸-琥珀酸钠pH 5.0体系中，聚山梨酯80浓度对该抗体药物偶联物在40℃高温条件下的SEC、RCE的纯度较好。
实施例7、ADC组合物pH细筛和聚山梨酯80浓度筛选
考虑到颗粒问题，可选择10mM组氨酸-盐酸组氨酸体系进行pH细筛和聚山梨酯80浓度筛选。选择10mM组氨酸-盐酸组氨酸pH5.5-6.0缓冲体系，制备含20mg/mL蛋白(ADC-6)，0.4-0.6mg/mL聚山梨酯80，辅料为80mg/mL蔗糖的ADC组合物制剂，进行高温40℃和冻融稳定性研究：
1)10mM组氨酸-盐酸组氨酸pH5.5，0.4mg/mL聚山梨酯80，80mg/mL蔗糖；
2)10mM组氨酸-盐酸组氨酸pH5.5，0.6mg/mL聚山梨酯80，80mg/mL蔗糖；
3)10mM组氨酸-盐酸组氨酸pH5.8，0.4mg/mL聚山梨酯80，80mg/mL蔗糖；
4)10mM组氨酸-盐酸组氨酸pH5.8，0.6mg/mL聚山梨酯80，80mg/mL蔗糖；
5)10mM组氨酸-盐酸组氨酸pH6.0，0.4mg/mL聚山梨酯80，80mg/mL蔗糖；
6)10mM组氨酸-盐酸组氨酸pH6.0，0.6mg/mL聚山梨酯80，80mg/mL蔗糖。
表10.ADC组合物pH细筛和聚山梨酯80浓度筛选结果


注：W表示周。
外观结果显示：冻融5次外观无显著变化；40℃ 2W所有处方出现颗粒，不同处方的颗粒数无显著差异。
SEC(图10A)结果显示：40℃不同处方SEC纯度都有所降低，在pH 5.5～6.0范围内，随着pH的升高，40℃4W SEC纯度降低；聚山梨酯80浓度(0.4mg/mL,0.6mg/mL)对SEC纯度影响不显著。
RCE(图10B)和DAR值结果表明：40℃不同处方RCE纯度和DAR值均有所下降，不同处方之间无显著差异。
Free mAb结果表明：高温后不同处方Free mAb均有所上升，不同处方之间无显著差异。
综上所述，在10mM组氨酸-盐酸组氨酸体系，pH 5.5～6.0范围内，较低的pH对该抗体药物偶联物的SEC纯度有利。但考虑到处方的稳健性，目标pH确定为5.6；同时，聚山梨酯80浓度对蛋白SEC、RCE影响差异不显著，考虑到在10mM琥珀酸-琥珀酸钠pH 5.0体系中，聚山 梨酯80浓度对该抗体药物偶联物在40℃条件下的SEC、还原CE较好，最终确定聚山梨酯80目标浓度为0.2mg/mL。综合考虑样品的稳定性和外观，处方初步确定为10mM组氨酸-盐酸组氨酸，80mg/mL蔗糖，0.2mg/mL聚山梨酯80，pH 5.6。
实施例8、ADC组合物制剂成分综合筛选及冻干稳定性
为了进一步对抗体药物偶联物浓度、聚山梨酯80浓度、pH进行优化，运用JMP软件进行DoE设计，在10mM组氨酸-盐酸组氨酸的缓冲体系中，制备不同蛋白浓度，不同聚山梨酯80浓度，含80mg/mL蔗糖的CD79b抗体药物偶联物制剂，灌装量为3.8mL/瓶，处方设计如下：
1)0.3mg/mL聚山梨酯80，pH5.5，15mg/mL ADC-6
2)0.2mg/mL聚山梨酯80，pH6.0，25mg/mL ADC-6
3)0.1mg/mL聚山梨酯80，pH6.0，18.15mg/mL ADC-6
4)0.2mg/mL聚山梨酯80，pH5.75，15mg/mL ADC-6
5)0.3mg/mL聚山梨酯80，pH6.0，15mg/mL ADC-6
6)0.1mg/mL聚山梨酯80，pH5.5，15mg/mL ADC-6
7)0.1mg/mL聚山梨酯80，pH5.75，25mg/mL ADC-6
8)0.2mg/mL聚山梨酯80，pH5.5，20mg/mL ADC-6
9)0.3mg/mL聚山梨酯80，pH5.75，20mg/mL ADC-6
10)0.3mg/mL聚山梨酯80，pH5.5，25mg/mL ADC-6
制剂经过预冻、一次干燥和二次干燥获得冻干制品。冻干制品饼状良好，复溶后外观澄清，pH和纯度项也无明显变化，说明该冻干工艺良好。将冻干品放置40℃1M考察稳定性。
表11.ADC-6组合物制剂成分综合筛选及冻干稳定性结果


注：M表示月。
各数据显示，40℃ 1M强制降解条件下所有处方SEC单体峰面积在99％以上；RCE纯度在95％以上；中性峰面积在57％以上，DAR值稳定在4左右，不同处方与T0比较均无明显差异，即CD79b抗体药物偶联物(ADC-6)制剂在15～25mg/mL、pH 5.5～6.0、聚山梨酯80 0.1～0.3mg/mL范围之内纯度项差异不显著，冻干制剂可稳定存在。

Claims (20)

  1. 一种药物组合物，其包含配体-药物偶联物和缓冲剂，其中所述配体为抗CD79b抗体或其抗原结合片段，药物选自MMAE或其衍生物、依喜替康或其衍生物、艾日布林或其衍生物，其中：
    所述缓冲剂选自醋酸盐缓冲剂、组氨酸盐缓冲剂、Tris-盐酸盐缓冲剂、Tris-柠檬酸盐缓冲剂、磷酸盐缓冲剂或琥珀酸盐缓冲剂；
    所述抗CD79b抗体或其抗原结合片段含有重链可变区和轻链可变区，所述重链可变区含有如SEQ ID NO：11或5所示氨基酸序列的HCDR1，SEQ ID NO：6、SEQ ID NO：7所示氨基酸序列的HCDR2、HCDR3，所述轻链可变区含有如SEQ ID NO：8、SEQ ID NO：9、SEQ ID NO：10所示氨基酸序列的LCDR1、LCDR2、LCDR3；
    优选地，所述缓冲剂为组氨酸盐缓冲剂或琥珀酸盐缓冲剂；优选地，所述缓冲剂为组氨酸-盐酸盐缓冲剂或琥珀酸-琥珀酸钠缓冲剂。
  2. 如权利要求1所述的药物组合物，其中所述缓冲剂或所述药物组合物的pH值为4.0至8.5，优选为5.0至6.5，更优选为5.5至6.0。
  3. 如权利要求1或2所述的药物组合物，所述缓冲剂的浓度为1mM至30mM，优选为5mM至15mM，更优选为约10mM。
  4. 如权利要求1至3中任一项所述的药物组合物，其中所述配体-药物偶联物的浓度为0.1mg/mL至50mg/mL，优选为10mg/mL至30mg/mL，更优选为15mg/mL至25mg/mL。
  5. 如权利要求1至4中任一项所述的药物组合物，其中还包括表面活性剂；
    优选地，所述表面活性剂选自泊洛沙姆188、聚山梨酯80或聚山梨酯20；
    更优选地，所述表面活性剂为聚山梨酯80。
  6. 如权利要求5所述的药物组合物，其中所述表面活性剂的浓度为0.01mg/mL至1mg/mL，优选为0.05mg/mL至0.6mg/mL，更优选为0.1mg/mL至0.3mg/mL。
  7. 如权利要求1至6中任一项所述的药物组合物，其中还包括渗透压调节剂；
    优选地，所述渗透压调节剂选自蔗糖、海藻糖、山梨糖醇、精氨酸、脯氨酸、甘氨酸和氯化钠中的一种或更多种的组合；
    更优选地，所述渗透压调节剂为蔗糖。
  8. 如权利要求7所述的药物组合物，其中所述渗透压调节剂的浓度为1mg/mL至300mg/mL，优选为30mg/mL至130mg/mL，更优选为约80mg/mL。
  9. 一种药物组合物，其包含：
    (a)0.1mg/mL至50mg/mL的配体-药物偶联物，
    (b)0.5mM至50mM的组氨酸盐缓冲剂或琥珀酸盐缓冲剂，
    (c)1mg/mL至300mg/mL的蔗糖或海藻糖，和
    (d)0.01mg/mL至1mg/mL的聚山梨酯，
    所述药物组合物的pH为4.0至8.5；
    或者，
    (a)10mg/mL至30mg/mL的配体-药物偶联物，
    (b)1mM至30mM的组氨酸盐缓冲剂或琥珀酸盐缓冲剂，
    (c)30mg/mL至130mg/mL的蔗糖或海藻糖，和
    (d)0.05mg/mL至0.6mg/mL聚山梨酯80，
    所述药物组合物的pH为5.0至6.5；
    或者，
    (a)10mg/mL至50mg/mL的配体-药物偶联物，
    (b)1mM至30mM的组氨酸盐缓冲剂或琥珀酸盐缓冲剂，
    (c)30mg/mL至130mg/mL的蔗糖或海藻糖，和
    (d)0.05mg/mL至0.6mg/mL聚山梨酯80，
    所述药物组合物的pH为5.0至6.5；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)5mM至15mM的组氨酸盐缓冲剂或琥珀酸盐缓冲剂，
    (c)70mg/mL至90mg/mL的蔗糖，和
    (d)0.1mg/mL至0.3mg/mL的聚山梨酯80，
    所述药物组合物的pH为5.0至6.5；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸盐缓冲剂，
    (c)约80mg/mL的蔗糖，和
    (d)0.1mg/mL至0.3mg/mL的聚山梨酯80，
    所述药物组合物的pH为5.5至6.0；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的琥珀酸盐缓冲剂，
    (c)约80mg/mL的蔗糖，和
    (d)0.1mg/mL至0.3mg/mL的聚山梨酯80，
    所述药物组合物的pH为5.0至6.0；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸盐缓冲剂，
    (c)约80mg/mL的蔗糖，和
    (d)0.1mg/mL至0.3mg/mL的聚山梨酯80，
    所述药物组合物的pH为5.5至6.0；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的琥珀酸-琥珀酸钠缓冲剂，
    (c)约80mg/mL的蔗糖，和
    (d)0.1mg/mL至0.3mg/mL的聚山梨酯80，
    所述药物组合物的pH为5.0至6.0；
    优选地，所述药物组合物包含：
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.2mg/mL的聚山梨酯80，
    所述药物组合物的pH为5.6；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.2mg/mL的聚山梨酯80，
    所述药物组合物的pH为约5.5；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.2mg/mL的聚山梨酯80，
    所述药物组合物的pH为约5.75；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.2mg/mL的聚山梨酯80，
    所述药物组合物的pH为约6.0；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.3mg/mL的聚山梨酯80，
    所述药物组合物的pH为约5.5；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.3mg/mL的聚山梨酯80，
    所述药物组合物的pH为约5.75；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.3mg/mL的聚山梨酯80，
    所述药物组合物的pH为约6.0；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.1mg/mL的聚山梨酯80，
    所述药物组合物的pH为约5.5；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.1mg/mL的聚山梨酯80，
    所述药物组合物的pH为约5.75；
    或者，
    (a)15mg/mL至25mg/mL的配体-药物偶联物，
    (b)约10mM的组氨酸-盐酸组氨酸，
    (c)约80mg/mL的蔗糖，和
    (d)约0.1mg/mL的聚山梨酯80，
    所述药物组合物的pH为约6.0；
    所述配体为抗CD79b抗体或其抗原结合片段，所述抗CD79b抗体或其抗原结合片段含有重链可变区和轻链可变区，所述重链可变区包含如SEQ ID NO：11或5所示氨基酸序列的HCDR1，SEQ ID NO：6、SEQ ID NO：7所示氨基酸序列的HCDR2、HCDR3，所述轻链可变区包含如SEQ ID NO：8、SEQ ID NO：9、SEQ ID NO：10所示氨基酸序列的LCDR1、 LCDR2、LCDR3；
    所述药物选自MMAE或其衍生物、依喜替康或其衍生物、艾日布林或其衍生物，优选为依喜替康或其衍生物。
  10. 如权利要求1至9中任一项所述的药物组合物，其中所述抗CD79b抗体或其抗原结合片段包含抗体重链可变区和轻链可变区，其中：重链可变区序列包含如SEQ ID NO：3或与之具有至少90％同一性的氨基酸序列，轻链可变区序列包含如SEQ ID NO：4或与之具有至少90％同一性的氨基酸序列。
  11. 如权利要求1至10中任一项所述的药物组合物，其中所述抗CD79b抗体或其抗原结合片段包含重链和轻链，其中：所述重链序列包含SEQ ID NO：12或与之具有至少80％同一性的氨基酸序列，和所述轻链序列包含SEQ ID NO：13或与之具有至少80％同一性的氨基酸序列。
  12. 如权利要求1至11中任一项所述的药物组合物，其中所述的配体-药物偶联物如式(I)的通式(Pc-L-Y-D)所示：
    其中：
    Y选自-O-(CRaRb)m-CR1R2-C(O)-、-O-CR1R2-(CRaRb)m-、-O-CR1R2-、-NH-(CRaRb)m-CR1R2-C(O)-和-S-(CRaRb)m-CR1R2-C(O)-；
    Ra和Rb相同或不同，且各自独立地选自氢原子、氘原子、卤素、烷基、卤代烷基、氘代烷基、烷氧基、羟基、氨基、氰基、硝基、羟烷基、环烷基和杂环基；或者，Ra和Rb与其相连接的碳原子一起形成环烷基和杂环基；
    R1选自氢原子、卤素、卤代烷基、氘代烷基、环烷基、环烷基烷基、烷氧基烷基、杂环基、芳基和杂芳基；R2选自氢原子、卤素、卤代烷基、氘代烷基、环烷基、环烷基烷基、烷氧基烷基、杂环基、芳基和杂芳基；或者，R1和R2与其相连接的碳原子一起形成环烷基或杂环基；
    或者，Ra和R2与其相连的碳原子一起形成环烷基或杂环基；
    m为0至4的整数；
    n为1至10，n是小数或整数，优选地，n为2至8或5至9；
    L为接头单元；
    Pc为抗CD79b抗体或其抗原结合片段；
    优选地，所述配体-药物偶联物具有如下式所示的结构：
    n为1至10，n是小数或整数；
    更优选地，n为1至6，n是小数或整数。
  13. 一种冻干制剂，所述冻干制剂通过将权利要求1至12任一项所述的药物组合物经冷冻干燥获得，或所述冻干制剂复溶后可形成权利要求1至12任一项所述的药物组合物。
  14. 一种制备冻干制剂的方法，其中包括将权利要求1至12中任一项所述的药物组合物进行冷冻干燥的步骤。
  15. 一种复溶溶液，其是通过将权利要求13所述的冻干制剂经复溶制备获得。
  16. 如权利要求1至12任一项所述的药物组合物或权利要求15所述的复溶溶液，其为静脉注射剂、皮下注射剂、腹腔注射剂或肌肉注射剂；优选为静脉注射剂。
  17. 一种制品，其包括容器，该容器中装有如权利要求1至12中任一项所述的药物组合物、权利要求13所述的冻干制剂或权利要求15所述的复溶溶液。
  18. 如权利要求1至12中任一项所述的药物组合物、权利要求13所述的冻干制剂、权利要求15所述的复溶溶液或权利要求17所述的制品在制备用于治疗或预防增殖性疾病或延缓增殖性疾病进展的药物中的用途，其中：
    优选地，所述增殖性病症是癌症或肿瘤；
    更优选地，所述癌症或肿瘤选自淋巴瘤、弥漫大B细胞淋巴瘤、非何杰金氏淋巴瘤(NHL)、攻击性NHL、复发性攻击性NHL、复发性无痛性NHL、顽固性NHL、顽固性无痛性NHL、慢性淋巴细胞性白血病(CLL)、小淋巴细胞性淋巴瘤、白血病、毛细胞白血病(HCL)、急性淋巴细胞性白血病(ALL)，和/或套细胞淋巴瘤。
  19. 一种治疗或预防增殖性疾病或延缓增殖性疾病进展的方法，包括向有需要的受试者施用治疗或预防有效量的如权利要求1至12中任一项所述的药物组合物、权利要求13所述的冻干制剂、权利要求15所述的复溶溶液或权利要求17所述的制品，其中：
    优选地，所述增殖性病症是癌症或肿瘤；
    更优选地，所述癌症或肿瘤选自淋巴瘤、弥漫大B细胞淋巴瘤、非何杰金氏淋巴瘤(NHL)、攻击性NHL、复发性攻击性NHL、复发性无痛性NHL、顽固性NHL、顽固性无痛性NHL、慢性淋巴细胞性白血病(CLL)、小淋巴细胞性淋巴瘤、白血病、毛细胞白血病(HCL)、急性淋巴细胞性白血病(ALL)，和/或套细胞淋巴瘤。
  20. 一种在具有B细胞增殖性病症或自身免疫性病症的受试者中增强免疫功能的方法，包括向受试者施用治疗或延缓疾病有效量的如权利要求1至12中任一项所述的药物组合物、权利要求13所述的冻干制剂、权利要求15所述的复溶溶液或权利要求17所述的制品，其中：
    优选地，所述B细胞增殖性病症为癌症或肿瘤；
    更优选地，所述B细胞增殖性病症为淋巴瘤，非何杰金氏淋巴瘤(NHL)，攻击性NHL，复发性攻击性NHL，复发性无痛性NHL，顽固性NHL，顽固性无痛性NHL，慢性淋巴细胞性白血病(CLL)，小淋巴细胞性淋巴瘤，白血病，毛细胞白血病(HCL)，急性淋巴细胞性白血病(ALL)，和/或套细胞淋巴瘤。
PCT/CN2023/073047 2022-01-26 2023-01-19 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 WO2023143347A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210093514 2022-01-26
CN202210093514.0 2022-01-26

Publications (1)

Publication Number Publication Date
WO2023143347A1 true WO2023143347A1 (zh) 2023-08-03

Family

ID=87470785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/073047 WO2023143347A1 (zh) 2022-01-26 2023-01-19 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途

Country Status (2)

Country Link
TW (1) TW202334207A (zh)
WO (1) WO2023143347A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020156439A1 (zh) * 2019-01-28 2020-08-06 上海拓界生物医药科技有限公司 抗cd79b抗体、其抗原结合片段及其医药用途
WO2020233534A1 (zh) * 2019-05-17 2020-11-26 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
WO2021148003A1 (zh) * 2020-01-22 2021-07-29 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
WO2021190581A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
WO2022022508A1 (zh) * 2020-07-27 2022-02-03 上海拓界生物医药科技有限公司 抗cd79b抗体药物偶联物、其制备方法及其医药用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020156439A1 (zh) * 2019-01-28 2020-08-06 上海拓界生物医药科技有限公司 抗cd79b抗体、其抗原结合片段及其医药用途
WO2020233534A1 (zh) * 2019-05-17 2020-11-26 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
WO2021148003A1 (zh) * 2020-01-22 2021-07-29 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
WO2021190581A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
WO2022022508A1 (zh) * 2020-07-27 2022-02-03 上海拓界生物医药科技有限公司 抗cd79b抗体药物偶联物、其制备方法及其医药用途

Also Published As

Publication number Publication date
TW202334207A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
US20240091373A1 (en) Antibody-drug conjugate lyophilised formulation
JP6333882B2 (ja) 抗体−薬剤コンジュゲート
WO2022022508A1 (zh) 抗cd79b抗体药物偶联物、其制备方法及其医药用途
US20190381172A1 (en) Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
US11584801B2 (en) Anti-5T4 antibodies and antibody-drug conjugates
WO2022068914A1 (zh) 一种含抗体药物偶联物的药物组合物及其用途
EP4095158A1 (en) Pharmaceutical composition containing anti-btla antibody and use thereof
JP2019505520A (ja) 抗体およびその薬物コンジュゲートの製剤
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
US20180133337A1 (en) Calicheamicin constructs and methods of use
WO2018223958A1 (zh) 一种含c-Met抗体药物偶联物的药物组合物及其用途
WO2023143347A1 (zh) 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途
WO2022117060A1 (zh) 一种含抗结缔组织生长因子抗体的药物组合物
WO2021121204A1 (zh) 抗cea抗体-依喜替康类似物偶联物及其医药用途
TW202021620A (zh) 一種cd40抗體藥物組合物及其用途
WO2023222108A1 (zh) 抗体-药物偶联物的制备方法
WO2023040935A1 (zh) 一种含抗pvrig/tigit双特异性抗体的药物组合物
CN115501347A (zh) 抗her2抗体药物偶联物和parp抑制剂联合在制备治疗肿瘤的药物中的用途
JP2024012314A (ja) 抗ＨＥＲ２ ＭＡＢと組み合わせたＨＥＲ２ｘＣＤ３二重特異性抗体によるがんの処置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23746228

Country of ref document: EP

Kind code of ref document: A1